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'Why sometimes I've believed as many as six impossible things 
before breakfast.' 
The White Queen in "Through the Looking Glass", Lewis Carroll . 
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ABSTRACT 
The text begins vith a review of the mi tomycin antibiotics 
focused on their structure elucidation, chemistry, mechanism of 
action, biosynthesis and synthesis. The synthetic vork described in 
subsequent chapters is concerned vith a biomimetic approach to the 
synthesis of the mitomycin antibiotics. 
The mitomycins (1) are an important group of biologically active 
natural products isolated from Streptomyces species. They possess 
potent antitumour and antibacterial properties and mitomycin C is 
currently used in cancer chemotherapy. 
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Biosynthetic studies of the mitomycins have identified 3-amino-5-
hydroxybenzoic acid (36) and Q-glucosamine (10) as the primary 
precursors. Three key bond formations viz., the N-4--C-3 bond, the 
C-8a--C-9 bond and the N-4--C-9a bond are mandatory in the 
construction of the framevork of the antibiotics from these 
precursors. A postulated biosynthetic pathvay involves imine 
formation, oxidation of the phenol to a quinone, intramolecular 
Michael addition and transannular reaction as the crucial steps in 
the formation of the carbon-oxygen-nitrogen skeleton. 
Consideration of these probable biosynthetic processes in 
conjunction with optimized synthetic substrates has led to a 
biomimetic synthesis of a mitomycin analogue, the indoloquinone 
(337). More significant than this indoloquinone (337) itself is the 
fact that its precursor, the carbinolamine (315) carries the C-9a 
oxygen functionality typical of the mitomycins, and thus this route 
has the potential to introduce the C-9a oxygen function into the 
mitomycins. 
The sequence of the formation of the three key bonds forms the 
basis of our biomimetic approach to the synthesis of the mitomycins. 
Chapter 3 describes a short and efficient synthesis of the 
indoloquinone (337) based on this approach. The key ~keto ester 
intermediate (313) was prepared stepwise from 2-amino-6-methylphenol 
)&S 
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O CDzMe 0 
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(314) (315) (337) 
by ~-alkylation with !-butyl 4-bromobutyrate, forming the first 
crucial bond, followed by a two-carbon extension. Concomitant 
oxidation and cyclization upon treatment of the phenol (313) with 
Fremy's salt in aqueous buffer pH 6.8 yielded the desired 
benzazocinone (314) by the second key bond formation. Spontaneous 
transannular cyclization to the tricyclic carbinolamine (315) on 
catalytic hydrogenation of the benzazocinone (314) formed the third 
key bond. Facile dehydration and reoxidation then afforded the 
indoloquinone (337). 
The acylaminoquinone (266), corresponding to the 
alkylaminoquinone ~keto ester (307) and obtained by ~-acylation of 
2-amino-6-methylphenol, failed to cyclize under various reaction 
conditions. It was postulated that the acylaminoquinone (266) exists 
mainly in the ~-form and the~ to E interconversion required for 
cyclization was not favourable. This work is described in Chapter 2. 
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The successful formation of the three key bonds with our model 
system provides chemical support for the proposed biosynthetic 
pathway to the mitomycins. This sequence of reactions when applied 
to suitably functionalized substrates also provides an attractive 
approach to the synthesis of the mitomycins themselves . 
Previous approaches towards the introduction of the 1,2-aziridine 
function in the mitomycins and simplified synthetic analogues are 
reviewed in Chapter 4. In order to extend our biomimetic approach to 
a total synthesis of the mitomycins, an aziridino-substituted ~keto 
ester such as (435) or its synthetic equivalent is required. ~e 
proposed to carry the ~keto ester moiety through the synthesis in a 
latent form, with the ketonic function masked as the oxygen of a 
furanoid system. The aziridine function was to be fashioned from the 
double bond of a dihydrofuran. Attempts to introduce an aziridine 
moiety onto various dihydrofuranoid systems were not successful, 
however, leading to the conclusion that this strained functionality 
is probably better introduced at the acyclic stage. 
~: 
Br 
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CHAPTER 1 
THE MITOMYCIN ANTIBIOTICS: A REVIEV 
1. 
1.1. Introduction 
The mitomycins (1) are an important group of naturally occurring 
and structurally related antibiotics that exhibit potent antitumour 
and antibacterial properties. 1 Mitomycin C (2) is effective in the 
palliative treatment of colorectal, gastric and pancreatic 
adenocarcinoma, carcinoma of the breast, malignant melanoma, and 
various squamous cell carcinomata. 2 Until recently, its use has been 
confined largely to Japan due to its relatively high toxicity, 
especially leukopenia. However, with the development of improved 
dosage schedules that minimize its toxicity, mitomycin C (2) is 
gaining increasing clinical acceptance. Bristol Laboratories 
introduced mitomycin C (2), marketed as Mutamycin, into standard 
medical practice in the United States in 1974. 
0 0 
X H2N 
NZ NH 
0 0 
( 1 ) ( 2 ) 
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Porfiromycin (3) is less potent than mitomycin C (2) as an 
antitumour agent, but its toxicity is also considerably lower. In 
phase I clinical studies , it produced responses against carcinomata 
of the cervix, ovary, stomach, colon, head, and neck. 3 
0 0 
( 3 ) ( 4) 
2. 
The ?-hydroxy analogue of mitomycin C, 7-hydroxy-9a-methoxy-
mitosane (4), is currently undergoing clinical tests in Japan. This 
analogue is promising as a potential anticancer agent because it 
appears to have better tissue distribution and to cause less 
leukopenia than mitomycin C (2). 4 
Structural elucidation5 of the mitomycins revealed a novel 
structure in which three different carcinostatic functions, namely 
aziridine, carbamate, and quinone, are all arranged about a 
pyrrolo[l,2-~]indole nucleus. The trivial name 'mitosane' has been 
advocated for the skeleton common to this family of antibiotics, 
while 'mitosene' denotes the unsaturated derivatives which also lack 
the aziridine moiety (Figure 1). 6 The mitomycins were the first 
family of natural products shown to contain an aziridine ring, a 
feature now held in common with the antibiotic carzinophilin A 
0 
Mitosane 
Figure 1 
0 
Mitosene 
7 
The unique structure of the mitomycins, coupled with their great 
medicinal value, offers a formidable challenge to synthetic 
chemists.a-to Numerous efforts have also been directed towards the 
study of their mode of action, their structure-activity 
relationships, and their biosynthesis in the quest of mitomycins 
themselves as well as analogues with better therapeutic index. 
3. 
1.2. Isolation and Structure Determination 
Mitomycins A (5) and B (6) were firs t isolated in Japan in 1956 
by Hata and coworkers 11 at the Kitasato Institute from the culture 
broth of Streptomyces caespitosus. Two years later, Vakaki and 
coworkers 12 isolated mitomycin C (2), a close relative with superior 
antitumour activity, from the same Actinomyces species. In 1960, a 
group at the Upjohn Company 13 in the United States reported the 
isolation of porfiromycin (3) from Streptomyces ardus. Lefemine and 
collaborators14 at the Lederle Laboratories isolated mitiromycin (7) 
(vide infra), a related compound with no biological activity, 
together with the above four antibiotics from Streptomyces 
verticillatus in 1962. 
0 
;=820CONH2 0 
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In the same year, Vebb and coworkers 5a reported the elegant 
structural elucidation of mitomycin A (5) and its gross structural 
relationship with mitomycin C (2) and porfiromycin (3) by chemical 
interconversions (Scheme 1). Mitomycin A (5) was converted into 
mitomycin C (2) by treatment with methanolic ammonia.sa ,i s 
NMe 
Similarly, ~-methylmitomycin A (8), obtained by treatment of 
mitomycin A (5} with methyl iodide and sodium hydrogen carbonate, 
reacted with methanolic a~monia to give porfiromycin (3). 54 
Mitomycin C (2) was converted into porfiromycin (3) by methylation. 16 
0 
Mitomycin A ( 5 ) l M,C N>HCO, 
0 
N-Methylmitomycin A ( 8 ) 
NHyMeOH 
NHyMeOH 
Scheme 1 
Note: only two dimensional structures are depicted in this scbc:me. 
4. 
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Mitomycin C ( 2 ) 
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Porfiromycin ( 3 ) 
Although chemical conversions of mitomycins A (5) and C (2) and 
porfiromycin (3) into mitomycin B (6), or vice~, had not been 
demonstrated, it was observed that mitomycin B (6) and 
~-methylmitomycin A (8) were degraded to the same aziridinomitosene 
(9) (Scheme 2). On the basis of chemical and spectroscopic studies, 
Me 
0 
N-methylrnitomycin A ( 8 ) 
MeO 
Me 
0 
rnitomycin B ( 6 ) 
MeO 
Me 
Scheme 2 
Note : only two dimensional structures are depicted in this scheme. 
0 
( 9) 
they concluded that mitomycins A (5), B (6) and C (2), and 
porfiromycin (3) all have a common tetracyclic structure, trivially 
designated as 'mitosane' (see Figure 1). The minor differences lie 
5. 
in the nature of the substitutions in the positions N-la (hydrogen or 
methyl), C-7 (amino or methoxyl), and C-9a (methoxyl or hydroxyl). 
The structure of the mitomycins was confirmed by Tulinsky's X-ray 
crystallographic analysis of the E-bromobenzenesulfonyl derivative of 
mitomycin A. 174 Five years later, in 1967, the absolute 
stereochemistry of mitomycin A (5) was proposed by Tulinsky and van 
den Hende17b from X-ray analysis of the same derivative to be as 
shown below: 1~ 2~, 9~, 9a~ (Figure 2). As mitomycin C (2) and 
porfiromycin (3) can be derived from mitomycin A (5) by known 
chemical reactions as described previously, the stereochemistry of 
mitomycins A (5) and C (2) and porfiromycin (3) must be the same. 
Figure 2 
The absolute configuration of mitomycin B (6), originally 
assigned by Yahashi and Matsubara18 by X-ray analysis of the 7-
demethoxy-7E-bromoanilino derivative as shown in Figure 3a, was later 
corrected by the same authors to be the enantiomer (Figure 3b) having 
the following absolute configuration: 1~, 2~, 9~, 9a~, . Thus 
mitomycin B (6) is distinguished from the other three natural 
mitomycins by the stereochemistry at position C-9. 
Figure 3a Figure 3b 
6. 
1.2.1. Revised Stereochemistry 
Meanwhile, biosynthetic studies conducted by Hornemann's group19 
between 1971 and 1975, demonstrated that Q-glucosamine (10) is an 
efficient precursor of the mitomycins , and that it is utilized as an 
intact unit without cleavage of the C-2--N bond. Thus C-1 and C-6 of 
the aminosugar (10) become respectively C-3 and C-10 of the 
mitomycins and that the amino group gives rise to the aziridine 
(Figure 4). It inevitably follows that if biological aziridine 
formation involves a normal SN2 process, we would expect the 
configuration of C-1 and C-2 to be as shown in (1) : 1~ and 2S. 
However, from X-ray analyses, 17 ' 18 the configuration of the 
mitomycins at C-1 and C-2 was deduced to be the opposite as in (11), 
i.e. 1~ and 2~ (vide supra). This implies that an inversion of 
configuration at C-2 of the aminosugar (10) must have occurred during 
the biosynthesis of the aziridine ring. On the other hand, 
~-glucosamine and Q-mannosamine, both having the correct 
configuration at C-2 corresponding to the reported mitomycin 
. d ff' . 19b structures, were not incorporate as e 1c1ent precursors. These 
results raised serious doubt on the hitherto accepted absolute 
configurations of the mitomycins. In 1983, Gredley and Rickards 2 0 
questioned the absolute configurations of t he mitomycins based on the 
above mechanistic biogenetic grounds and reasoned that such an 
inversion was most unlikely to have occurred . 
oormal~2 
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7. 
This problem of the ambiguous stereochemistry at C-1 and C-2 of 
the mitomycins prompted Shirahata and Hirayama 2 1 to reinvestigate the 
stereochemistry of the mi tomycins by X-ray analysis of 1-~--(.e-
bromobenzoyl)mi tomycin C (12). As a result, the absolute 
configuration of mitomycin C (2), and thus that of mitomycin A (5) 
and porfiromycin (3), was revised to be as follows: 1§, 2§, 9§ and 
9a!; i.e., enantiomeric to the previously defined stereochemistry. 
0 0 
( 9 ) (12) 
By comparing the optical properties of two specimens of 7-
methoxy-1,2-(~-methylaziridino)mitosene (9), obtained separately from 
~-methylmitomycin A (8) and mitomycin B (6) (see Scheme 2), Hornemann 
and Heins 22 confirmed that mitomycin B (6) differs stereochemically 
from mitomycins A (5) and C (2) only at C-9. 
This revised stereochemistry agrees with that deduced by 
biogenetic reasoning as previously discussed and is currently 
accepted as the true stereochemistry of the mitomycins. The revised 
absolute structures of the mitomycins are shown in Figure 5 and 
throughout this thesis. 
0 0 gtiOCONH.i 
X Md:) ,: 
NZ Me NMe 
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(2) mitomycin C HzN H ( 6 ) mitomycin B 
( 3) porfiromycin HzN Me 
( 5) mitomycin A MeO H 
Figure 5 
8. 
1.2.2. Hitiromycin and Other Hitomycins 
Mitiromycin (7), the biologically inactive relation of the 
mitomycins isolated by Lefemine and coworkers 14 in 1962, was shown 23 
to contain the unusual oxazinone ring in place of the open-chain 
carbamate, but the configuration has not yet been defined. 
A new mitomycin antibiotic, 10-decarbamoyloxy-9-dehydromitomycin 
B (13) 24 was isolated in 1980 from Streptomyces caespitosus. This 
compound is related to mitomycin B (6) by elimination of carbamic 
acid across carbons 9 and 10, and represents the first example of a 
mitomycin having an exo-cyclic double bond in its structure. It 
shows antibacterial and cytotoxic activities. Related compounds 
differing in substitution pattern have also been found. 2 4 
0 
(I 3) 
1.3. Chemical Transformations 
The labile, highly functionalized tetracyclic framework of the 
mitomycins gives rise to some interesting chemistry. A large 
proportion of the in vitro chemistry of the mitomycins was discovered 
through structural elucidation studies using chemical degradation 
techniques. 5 • 15 • 25 Many of the derivatives thus obtained were 
subsequently used for the study of structure-activity relationships 
and antitumour testing. 
9. 
1.3.1. Acid Hydrolysis 
The tetracyclic system of the mitomycins is extremely sensitive 
to acid. For example, in the presence of a trace amount of acid in 
dichloromethane, mitomycin A (5) was solvolyzed to cis- and trans-2-
amino-1-hydroxy-7-methoxymitosene (14a and 15a), with the cis-isomer 
(14a) predominating (Scheme 3). The high preference for cis 
stereochemistry is in contrast to the trans stereochemistry that is 
0 0 
Ma) MoO 
Me Me 
0 0 ( 5 ) ( 9 ) 
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Me + NHR NHR 
0 0 
(14a) R=H (15a) RaH 
(14b) R=Me (15b) R=Me 
Scheme 3 
usually observed in the acid-catalyzed opening of simple 
aziridines . 26 • • , 27-30 This anomaly has spurred extensi ve 1nvest1gat1on 
in order to determine if anchimeric assistance by either the 
9a-methoxyl group or the carbamate function plays a major role in the 
stereochemistry of ring-opening. The 9a-methoxyl group was ruled out 
since 7-methoxy-1,2-(~-methylaziridino)mitosene (9), which lacks this 
substituent, gave cis- and trans-l-hydroxy-7-methoxy-2-
methylaminomitosene (14b and 15b) in a 3:1 cis-trans ratio, as 
compared to a 4:1 cis-trans ratio from acid hydrolysis of N-
10. 
methylmitomycin A (8). 28 On the other hand, Hornemann and 
k 31 cowor ers concluded that the carbamoyl group was not involved in 
the stereochemical course of aziridine ring-opening. Therefore, the 
preferred cis stereochemistry was not explainable by neighbouring 
group participation. 
On prolonged acid treatment of mitomycin C (2), the labile 7-
amino substituent also underwent hydrolysis to give the 7-
hydroxyquinone (16) as the principal product. Strong acid (6M HCl) 
cleaved the carbamate function in addition to the other labile 
moieties and yielded the decarbamoyl derivative (17). The hydroxyl 
groups thus generated behaved normally towards alkylating and 
acylating agents. 
0 0 
HO HO 
OH OH 
NHR NHR 
0 0 
(1 6) (17) 
1.3.2. Base Hydrolysis 
In contrast to the lability of the 9a-methoxyl and the aziridine 
function in acid, the mitosane structure is fairly stable under basic 
conditions. For instance, the 10-carbamoyloxy group could be 
selectively cleaved 32 when mitomycin C (2) was treated with sodium 
methoxide in benzene at room temperature yielding the alcohol (18) 
(Scheme 4). On the other hand, mild alkaline hydrolysis gave 7-
hydroxy-9a-methoxymitosane (4). 33 This 7-hydroxy derivative (4) 
could be alkylated with diazoalkanes 28 ' 34 or l-alkyl-3-E-
tolyltriazenes35 to furnish mitomycin A (5) and its 7-alkoxy 
analogues. Under prolonged exposure to alkaline solution, the 
corresponding decarbamoylmitosane (19) was formed. 5c 
11. 
0 ! (2) (18) 
0 
0 0 
( 4 ) (19) 
Scheme 4 
1.3.3. Reduction 
The chemistry associated with the reduction of the mitomycins 
may well be relevant to the mechanistic investigations of their 
antitumour action. Upon chemical or biochemical reduction of the 
quinone moiety in the mitomycins to the corresponding hydroquinone 
(20), the free electron pair on the nitrogen is able to participate 
in a number of interactions which activate the aziridine and the 
carbamate functions as alkylating agents. The biological 
consequences of these interactions will be discussed in section 1.4. 
Among the important chemical consequences of the quinone reduction 
are the facility with which the 9a-methoxyl or 9a-hydroxyl group can 
be replaced by other nucleophiles (path b), or lost along with the 
hydrogen at C-9 (path a), depending on the reaction conditions 
(Scheme 5). Thus, when sodium borohydride was used as the reducing 
agent in the reduction of mitomycin C (2), the product isolated after 
oxidation was demethoxymitomycin (22a). 3 2a Concomitant removal of 
the carbamoyl group occurred when lithium aluminium hydride was 
employed. 36 Reduction of mitomycin C (2) with sodium hydrosulfite 
followed by oxidation gave 7-aminomitosane-9a-sodium sulfonate (22b), 
12. 
the result of replacement of the 9a-methoxyl group by a sulfite 
anion. 37 The same compound (22b) was obtained by catalytic reduction 
over a palladium on carbon catalyst in the presence of sodium sulfite 
and subsequent reoxidation. This product (22b) could be converted 
back into mitomycin C (2) by carrying ou t the catalytic reduction in 
the presence of sodium methoxide. Catalytic reduction of mitomycin B 
(6) or ~-methylmitomycin A (8) followed by aerial oxidation yielded 
7-methoxy-(~-methylaziridino)mitosene (9). 38 These chemical 
transformations could be rationalized as proceeding by way of an 
iminium intermediate (21), generated by expulsion of the 
9a-substituent after reduction to the hydroquinone (20). 39 
0 OH 
X X 
-
0 / OH (20) 
OH O½OCONl½ 
X 
OH 
(21) 
;/ 
0 
( 9 ) X=OMe , Z=Me 
Scheme 5 
13. 
1.3.4. Derivatization 
Many derivatives were synthes ized from the natural mitomycins in 
a search for less toxic and more efficacious antibiotics (Scheme 6). 
Various 7-alkylaminomitosanes (23) were prepared by treating 
7-methoxymitosanes (24), e.g., mitomycin A (5), with alkylamines in 
methanol 32 b· 34 (Scheme 6). These derivatives showed strong 
antibacterial and antitumour activities. The corresponding 7-
alkoxymitosanes (25) could be sy~thesized by alcoholysis of 7-
methoxymitosanes (24) 40 directly. 7-Carbamoyl and 7-ureido 
derivatives were also obtained by trapping the anion of mitomycin C 
(2) with activated carbonates and isocyanates respectively. 41 
0 
R1R2N 
R1R2NH 
0 
yf,£) 
0 
(23) 
Me 
0 0 
(24) RO 
ROH , base 
0 
(25) 
Scheme 6 
The aziridine nitrogen of mitomycin A (5) and C (2) was acylated 
under mild conditions with acyl chlorides in triethylamine 32 b to give 
~-acylmitosanes (26). On heating with acetic anhydride, l-acetoxy-2-
acetamidomitosenes (27) were obtained. Sc , 15 The sulfonyl 
derivatives (28) were readily prepared from the corresponding 
sulfonyl chlorides. 32 b ~-Alkylation was achieved with alkyl iodide 
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in the presence of potassium carbonate32 b to yield ~-alkylmitosanes 
(29) (Scheme 7). 
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On treatment of mitomycin B (6) with sodium hydride, 10-
decarbamoyloxy-9-dehydromitomycin B (13) was obtained. 42 
A claim that the ~-methylmitomycin B derivative (30) was formed by 
treatment of mitomycin B (6) with sodium hydride and methyl iodide 
was incorrect. 36 In fact, simple etherification of the 9a-hydroxyl 
group occurred to form mitomycin B methyl ether (31) 8 (Scheme 8). 
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1.4. Mechanism of Action 
The mitomycins must be metabolically activated by 
reduction 39 ' 4 3 ' 44 before they can interact with DNA. A great deal of 
research has gone into establishing the mode of antitumour action as 
a detailed knowledge of this aspect of the antibiotics may lead to 
the design of new, superior anticancer drugs. 
The cytotoxic effects of the mitomycins have been attributed to 
the bioreductive alkylation of DNA. 45 Iyer and Szybalsky39 • 44 
proposed a hypothesis for the mode of action oft~ mitomycins in 
1964, which was later modified by Moore 46 (Scheme 9). According to 
this hypothesis, the mitomycin is reduced via a two-electon transfer 
to the hydroquinone which then loses methanol [or water in the case 
of mitomycin B (6)) to yield the reactive indole (32). The new 
unsaturation introduced on conversion from mitomycin to mitosene 
transmits electronic effects from the indolic nitrogen that renders 
both the aziridine ring and the carbamate function susceptible to 
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nucleophilic attack at C-1 and C-10 respectively, thereby cross-
linking complementary strands of DNA (path b). Monoalkylation at C-1 
is also conceivable (path a). The - isolation and structural 
0 o-
X X 
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0 O· 
OH 00 aiiOCONHi 
X X 
e .YOH 
OH OH (32) 
~ a I 2xDNA pamb 
CH 
X 
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NHZ NHZ 
CH i~ 
0 
X 
DNA DNA 
M, 
NHZ NHZ 
0 0 
Scheme 9 
elucidation47 of the adduct (33) formed by bifunctional alkylation of 
DNA by mitomycin C (2) constituted the first direct chemical proof 
for the putative formation of interstrand cross-links. Prior to this 
breakthrough, the chemical structure of the monoadduct (34) of 
mitomycin C (2) with DNA had also been characterized. 48 
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In vitro mechanistic studies by Tomasz and coworkers 49 in 1974 
showed that mitomycin C (2) semiquinone radicals are involved in the 
initial binding to DNA. Semiquinone intermediates of mitomycins B 
(6) and C (2) were detected by electron spin resonance 
spectroscopy. 50 Thus, a one-electon reduction to a semiquinone 
species appears to be sufficient to initiate the cascade of reactions 
that results in the cross-linking of DNA. Indeed, it has recently 
been shown 51 that a one-electron reduction is the major bioreductive 
mode of metabolism. A two-electon reduction activation mechanism as 
proposed in 196439 • 44 need not be invoked to account for the 
alkylating ability of the mitomycins. 
In their investigation into the sequence of changes in the 
molecular structure of the mitomycins after activatiofi, Danishefsky 
and coworkers 52 also concluded that the semiquinone oxidation state 
is the reactive species that yields mitosene. 
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The lethal effect of the drug action of mitomycins is not 
confined to the formation of cross-links between complementary DNA 
strands. It is also recognized 39 that a mitomycin molecule may also 
alkylate one strand of DNA through C-1 without cross-linking. This 
insertion may be lethal especially in organisms with deficient repair 
mechanisms. 
Lown 53 a demonstrated that reduced mitomycin C (2) in the presence 
of oxygen generates superoxide and hydroxyl radicals 54 which can 
degrade DNA by single strand scission. Banda and Sato 53 b confirmed 
that mitomycin C (2) facilitates the production of the superoxide 
radical on reduction and Tomasz 53 c found that mitomycin C (2) when 
reduced in vivo generates hydrogen peroxide. This may be a 
complementary mechanism of action of the antibiotic especially in 
neoplastic tissue where the levels of superoxide dismutase and 
catalase are suppressed. 
Acidic conditions (pH 4) have also been found to activate binding 
and cross-linking processes. 55 The alkylation of inorganic phosphate 
and the phosphate group of various nucleotides has been observed 
under these conditions. 30 • 5 6 This pathway may be operative in tumour 
cells where the average pH is lower than in normal tissue. 57 
In short, the mechanism of action of the mitomycins may not be 
unique and may well be dependent on the cell type , the physiological 
state of the cells, and their environment. The primary cytotoxic 
activity appears to be connected with inhibition of DNA synthesis. 
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1.5. Biosynthesis 
M. • b' h , 58 59 , , 1tomyc1n 1osynt es1s ' was 1nvest1gated on the basis of the 
working hypothesis that a C6N unit provided the right hand portion of 
the carbon-nitrogen ring skeleton while a C7N unit gave rise to the 
remaining framework. Precursor incorporation experiments have 
identified these two principal building blocks. However, the 
metabolic route linking these two units has not yet been defined. 
As already described in section 1.2, the contiguous chain of six 
carbons from C-10 to C-3, together with the attached aziridine 
nitrogen, is derived from Q-glucosamine (10). 19 The results of 
double-labelling studies indicated that Q-glucosamine (10) is 
utilized as an intact unit. 
Earlier biosynthetic studies by Kirsch and coworkers, 60 and by 
Bezanson and Vining61 showed that ~-[ 14 CH 3 ]methionine was 
incorporated and that the radioactivity was essentially confined to 
Q-methyl substituents in mitomycins which do not bear an ~-methyl 
group. This result was confirmed by Nishikohori and Fukui 62 who, in 
particular, studied the role of methylation in the later stages of 
the biogenetic pathway. Bornemann and coworkers 19 a ,c showed that in 
addition to providing the Q-methyl groups, L-methionine provides the 
~-methyl group of mitomycin B (6). 
Both (ureido- 14 C]citrulline and [guanidino- 1 4C]arginine labelled 
b f , ff, , l 19 a c 63a the car amate unction e 1c1ent y. ' ' A series of competitive 
feeding experiments indicated that independent pathways were 
operating in the utilization of these precursors. 
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~bile the origins of the C6N unit, the various Q- and ~-methyl 
groups, and the carbamate function were comparatively easy to 
formulate and subsequently succumbed to experimental verification, it 
proved to be more difficult to shed light on the mysterious C N unit. 7 
Investigations by Bezanson and Vining61 and Bornemann and 
k GJb C d"d "d d f" • • f • h cowor ers ' 1 not prov1 e e 1n1te 1n ormat1on on t e 
biosynthetic origin of the methylbenzoquinone moiety of the 
mitomycins. Feeding experiments with variously carbon-14-labelled 
pyruvate or pyruvic acid and Q-glucose species afforded specific 
labelling of C-6 and C-6a of mitomycin C (2). 61 •63b Q-[4-
14C]Erythrose but not [3-14C]pyruvate labelled C-7 of mitomycin C (2) 
significantly. 63 c These data defined the orientation of pyruvate and 
erythrose in the C7N unit as shown in Figure 6. These results led 
Bornemann to suggest that the C7N segment originated from an 
unidentified intermediate of the shikimic acid pathway. 61 · 63 b,c, G4 A 
similar proposal was also made by Bezanson and Vining. 61 
results with shikimic acid61 · 63 c and 3-dehydroquinic acid 
Negative 
6 3c 
indicated that the hypothetical branch point occurred earlier in the 
shikimate pathway. Hornemann 63 c postulated that 4-amino-3,4-dideoxy-
Q-arabinoheptulosonic acid 7-phosphate (4-amino-4-deoxy-DAHP) (35), 
or a close relative, may act as an intermediate in the formation of 
the C
7
N unit of these antibiotics. 
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A major breakthrough came in 1980 when Rickards and coworkers 65 
established that 3-amino-5-hydroxybenzoic acid (36) was the 
biogenetic progenitor of the methylbenzoquinone nucleus. 3-Amino-5-
hydroxybenzoic acid (36) was also identified as the key C
7
N nuclear 
precursor which initiates ansa chain format ion in ansamycin and 
maytansinoid biosynthesis. 66 - 68 Furthermore, the aromatic acid (36) 
was identified as a new, bona fide naturally occurring amino acid. 69 
The presence of endogenous 3-amino-5-hydroxybenzoic acid (36) in the 
fermentation of the mitomycin-producing Streptomyces verticillatus 
was verified using isotopic dilution analysis. 
Rickards 68 arrived at the structure of 3-amino-5-hydroxybenzoic 
acid (36) as the common C
7
N progenitor (more appropriately 
reformulated as the C
7
NO unit) after careful evaluation of the 
structures of the known ansamycins and maytansinoids which contain a 
similar C7N unit to the mitomycins.
58 
The biosynthetic relationships of the precursors of the 
mitomycins is summarized in Figure 7. 
OH 
A 
HO,CMNHl 
(36) 
CiNOunit 
-
L--Methionine 
0 
10 
( 6 ) 
Figure 7 
L--Cittulline 
L--Arginine 
! 
NMe 
t 
-
-
L--Methionine 
;~, 
0 
(10) 
C6 Nunit 
Biosynthetically, two major questions regarding the biog~nesis 
of the mitomycin antibiotics still remain. Firstly, the exact branch 
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point along the shikimate pathway from where 3-amino-5-hydroxybenzoic 
acid (36) is derived. Secondly, the sequence of processes involved 
in the formation of the tetracyclic carbon-nitrogen-oxygen skeleton . 
1.6. Previous Approaches to the Synthesis of the Kitomycins 
The unusual structural features which conspire to make the 
mitomycins such potent antibiotics also render them formidable 
synthetic targets. Indeed, despite the tremendous efforts made 
towards the synthesis of the mitomycins, to date only one total 
synthesis of racemic mitomycins A, Band C, and porfiromycin (3) has 
been accomplished. 70 
A successful total synthesis of the mitomycins must satisfy the 
following stringent requirements:-
(i) The efficient preparation of the pyrrolo[l,2-~]indole 
skeleton and subsequent transformation to the quinone. 
(ii) The procurement of the proper stereochemistry at the four 
contiguous chiral centres. 
(iii) The provision for easy elaboration to incorporate the 
aziridine function. Subsequent manipulations of the aziridino 
intermediate must take into account the sensitivity of the 
aziridine moiety. 
(iv) Especially important is the task of introducing and preserving 
the C-9a oxygen function (methoxyl or hydroxyl) as it is the most 
labile functionality in the target molecule. 
Kishi's synthesis was masterful in its planning strategy, 
recognizing the unique peculiarities of the labile functionalities. 
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1.6.1. Kishi's total synthesis of racemic mitomycins 
Though Kishi's 70 synthesis is very long (more than forty steps) 
and inefficient (less than 1% yield), its significance cannot be 
overlooked. It remains the only successful total synthesis of 
racemic mitomycins A, Band C, and porfiromycin twenty-five years 
after their structures were elucidated. 
Scheme 10 summarizes the synthesis of racemic mitomycin A. 
Commercially available 2,6-dimethoxytoluene (37) was readily 
converted to 2,4-dimethoxy-3-methylphenol (38) in three steps. 0-
Allylation and Claisen rearrangement gave a C-allyl derivative which 
was converted into the dibenzylated hydroquinone (39) by sequential 
oxidation to the corresponding quinone, reduction and benzylation. 
Ring-opening of the epoxide derived from (39) with the anion of 
acetonitrile followed by oxidation and a crossed aldol reaction with 
formaldehyde gave acetate (40) after protection of the resulting 
alcohol. A double bond was then introduced in conjugation with the 
cyano group to give the olefin (43) using selenium technology after 
conversion to the dimethyl ketal (42). cis-Hydroxylation of the 
acetate (44) with osmium tetroxide gave a diastereomeric mixture of 
diols (45a and 45b) which were separated by chromatography. The diol 
function of the diastereomer (45b) could be efficiently inverted in 
six steps to the diol (45a). 
The monomesylate of the diol (45a) was converted to the epoxide 
(46) which was opened regiospecifically with azide anion at C-2, 
generating a diol which was dimesylated. Displacement of the 
mesylate at the primary site with benzylamine followed by treatment 
of the resulting amine with benzyl bromide gave the dibenzylamine 
(47). Reduction of the azido group with trimethyl phosphite, 
followed by treatment with sodium hydride and lithium aluminium 
hydride, afforded the aziridine (48). 
OH C8n 
::y 95% ::¢ 57% MO~ Me ~ 
CMe OM,, Clln 
(37) (38) (39) 
OAc QA,: 
M£) MIO MIO 
78% 85% 
¼ CN Me CN Me 
OBn OBn OBn 
(40) (41) (42) 
51% 
77% 86% 87% 
Me 
OBn 
(43) (44) 
M..c) M,O 
87% 
+ 
Me Me 
(45a) (45b) 
(1:1 mixture of diastereomeric diols) 
Clln 
M..c) 
93% 51% >47% 
(45a) 
Me 
(46) (47) 
Scheme 10 
24. 
CN 
Scheme 10 (continued) 
(48) 
0 
0 
(52) 
(50) 
78% 
35% 
N(Clf2h0Ac 
77% 
25. 
42% 
N(Q¼OA.c 
NBot 
(49) 
0 
MO 
85% 
Me N(OIJ,OAc 
0 
(51) 
NHfMcOH 
--c mitomycin C (d,1)-mitomycin A . i. Mel, NaHCO, porfiromycm 
iiNHy'M,,OH 
The synthesis branched at this point to give either ~-methyl or 
N-unsubstituted mitosanes. For mitomycins A and C, the aziridino 
nitrogen had to be protected as i ts 3-acetoxypropyl derivative (49). 
Conjugate addition of the deprotected primary amine to the 
benzoquinone nucleus followed by aerial oxidation gave the eight-
membered quinone (SO). Treatment of quinone (50) with 
tetrafluoroboric acid allowed clean transannular cyclization to give 
exclusively decarbamoyl-~-(3-acetoxypropyl)mitomycin A (51). 
Carbamoylation with phosgene followed by ammonia treatment gave ~-(3-
acetoxypropyl)mitomycin A (52). The protecting group was removed in 
a 3-step procedure to give (i,!)-mitomycin A. Mitomycin C was 
obtained by treatment of mitomycin A with ammonia in methanol. 
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Porfiromycin was prepared by a similar route except that the 
aziridino nitrogen was methylated with methyl iodide in the presence 
of potassium carbonate, instead of having to put on the unusual 
protecting group. An alternative route involved two steps from 
mitomycin A, namely ~-methylation and ammonia treatment. 
The diol (45b) possesses the relative stereochemistry necessary 
for the synthesis of mitomycin B. A parallel synthetic route 
resulted in the eight-membered quinone (53). To avoid the undesired 
transannular cyclization reaction at the intermediate hemiketal stage 
(54) to form the 9a-methoxymitosane (55) upon hydrolysis, the free 
amino group at the N-4 position had to be protected. Accordingly, 
the dimethyl ketal (53) was reduced to the hydroquinone, 
carbobenzyloxylated, and then hydrolyzed with acid to give the 
desired ketone (58). Hydrogenolysis followed by aerial oxidation 
gave the decarbamoylmitomycin B (57) which was converted to mitomycin 
B (6) by treatment with trichloroacetylisocyanate followed by 
hydrolysis (Scheme 11). 
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Prior to the total synthesis of the racemic mitomycins, Kishi and 
coworkers 70 b demonstrated the feasibility of this approach by 
synthesizing deiminomitomycin A (59). They noted that the deimino 
derivative (59) was much less stable than the naturally occurring 
mitomycins; facile loss of methanol to give indoloquinone (60) was 
effected on contact with a catalytic amount of acid. 
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1.6.2. General Pyrrolo[l,2-~]indole Approaches 
Since the mitomycins themselves are clearly a formidable 
synthetic challenge, most synthetic approaches have been directed 
towards the mitosene system. The aziridinomitosene analogues are 
particular ly attractive goals due to their modified structure and 
high bioactivity. 7-Methoxy-1,2-(~-methylaziridino)mitosene (9), 
obtained from mitomycin B (6) or ~-methylmitomycin A (8) by 
elimination of the labile oxygen function at C-9a, retains much of 
the strong antibiotic and antitumour activities of the parent 
compounds. 32 • 39 Even 7-methoxymitosene (60), a mitomycin analogue 
lacking the 1,2-aziridine moiety, shows significant antibacterial 
activity in vitro and in mice. 7 1 
Several recent reviews have surveyed the numerous attempts at the 
synthesis of mitomycins and related compounds. 1 • 8 • 9 • 72 The majority 
of the published work are concerned with the formation of the 
tricyclic pyrrolo[l,2-~]indole system, the basic skeleton of the 
28. 
mitomycins. Kametani and Takahashi's review9 covers the literature 
on the synthesis of pyrrolo[l,2-~]indole and related systems prior to 
1978. A more recent review by Verboom and Reinhoudt 72 on approaches 
to the pyrrolo[l,2-~)indoles spans the literature from 1978 to the 
end of 1985. In the latter review, subsequent modification to 
mitomycin analogues or other transformations of the pyrrolo-
[1,2-~]indoles are not described. 
This section will review only those reports which developed 
systems that are closely related to the natural products or systems 
which possess features amenable to subsequent manipulations towards 
the target molecules. Thus, the work described herein usually has 
some relevance to the elaboration of the quinone, aziridine and 
carbamate functions. However, aziridination procedures are not dwelt 
upon in this section, as the subject will be expounded in Chapter 4 
of this thesis. 
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The different approaches to pyrrolo[l,2-~]indoles can be divided 
into five pathways as depicted in Scheme 12. Pathways a, b, and c 
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involve the formation of the rings A, B, and C respectively. In 
pathway d, the rings Band Care formed by a transannular cyclization 
between N-4 and C-9a. Route e involves the simultaneous construction 
of rings Band C. 
In this section, I wish to discuss the various synthetic 
approaches towards the mitomycins according to the above 
classification. 
method a 
The method of the formation of ring A in the last step has been 
used by Rebek's group 73 in their de novo synthesis of the 1,2-
disubstituted mitosene (74), a chemical degradation product of 
mitomycin C (Scheme 13). Their approach to the pyrrolo[l,2-~]indole 
system (65) involved Buisgen's pyrrole synthesis 74 and Dieckmann 
cyclization as the key steps. The acetylenic diester (62) was 
treated with the milnchnone (61b) derived from the succinoyl proline 
derivative (61a) to give the indole (63). Dieckmann cyclization of 
the corresponding alcohol (64), obtained by hydrolysis of the acetate 
(63), afforded the indole (65). Hydrolysis and decarboxylation of 
the indole (65) followed by mesylation furnished the mesylate (66), 
which on elimination afforded the olefin (67). Treatment of the 
diastereomeric bromohydrin (68), derived from the olefin (67), with 
sodium methoxide in methanol then gave a mixture of monomethyl ethers 
with the cis-isomer (69) predominating, presumably via an epoxide 
intermediate. Dehydrogenation with DDQ after mesylation and 
esterification afforded the phenol (70). Concomitant bromination and 
oxidation to the quinone followed by hydrogenolysis of the benzyl 
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ester and reduction of the resulting acid gave the bromoquinone (71). 
Treatment with excess sodium azide and in situ reduction of the azido 
group at C-7 of the intermediate azidoquinone afforded the 
aminoquinone (72). Conversion to the carbamate (73) was achieved by 
following Yeiss' procedure, 71 namely carboxylation with phenyl 
chloroformate and subsequent amination with ammonia (vide infra). 
The C-2 azido moiety was reduced with triphenylphosphine to give 
racemic 2,7-diamino-l-methoxymitosene (74). 
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OR 
This represents the only successful synthesis of a mitosene 
derivative using the 'method a' approach. This synthesis is very 
versatile, since with minor modifications to the synthetic scheme, 
variously substituted mitosenes can be produced. 
method b 
31. 
The second method involves bond formation between C-9--C-9a , 
C-8a--C-9, and N-4--C-4a; and has been used widely in the synthesis 
of mitosene systems, notably 7-methoxymitosene (60). 
Kametani's route to 7-methoxymitosene (60) involves the closure 
of the pyrrolo[l,2-~]indole ring system by an intramolecular 
nucleophilic aromatic substitution10 · 75 (Scheme 14). The 
arylacetonitrile (76) was prepared from commercially available E-
tolualdehyde (75) in eight steps. The pyrrolidin-2-ylideneacetonitrile 
(78) was obtained in good yield by heating the nitrile (76) with 2-
methoxy-61-pyrroline (77) in the presence of triethylamine or DBU. 
Cyclization of this derivative (78) in the presence of sodium hydride 
and cuprous bromide in ~,~-dimethylformamide gave the 9-cyanopyrrolo-
[l,2-~]indole (79). Reduction with nickel-aluminium alloy gave the 
aldehyde (80). Transformation of the aldehyde (80) to the quinone 
(82) was achieved by nitration followed by reduction and then 
oxidation of the resulting amine (81) with Fremy's salt. 76 
Elaboration of the carbamate function was again accomplished 
according to Veiss' procedure 71 (vide infra). 
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This route has been extended to the synthesis of 1,2-
disubstituted mitosene derivatives 77 (Scheme 15). Condensation of 
the thiopyrrolidone (83) with the dibromide (84) afforded the key 
intermediate (85). Cyclization gave the pyrroloindole (86) which was 
transformed to the 1,2-disubstituted mitosene (87) using known 
chemistry. 76 
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Various 1-substituted mitosenes 78 were also synthesized using the 
2,3-dihydro-1~-pyrrolo[l,2-~]indole (79) as starting material. The 
key reaction was selective acetoxylation with lead tetraacetate 
affording the 1-acetoxy indole (88). Hydrolysis gave the 
corresponding alcohol (89). Transformation t o the mitosene 
derivatives (90) and (91) were achieved as described previously. 76 
The acetoxy group of the 1-acetoxyquinone (90) could be converted 
into the chloride (92) (Scheme 16). 
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Scheme 16 
Yamada and Matsui 79 reported a one-step synthesis of the indoles 
(93) and (94) from toluquinone (95) and the enamino ester (96) using 
the Nenitzescu reaction80 (Scheme 17). A lack of regiocontrol in this 
reaction yielded the desired isomer (93) as the minor product 
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A novel variation of the Nenitzescu indole synthesis was 
developed by Coates and MacManus 81 for the expeditious synthesis of 
2,3-dihydro-l~-pyrrolo[l,2-~]indoles (Scheme 18). The problem of 
control over regioselectivity of the Nenitzescu reaction was overcome 
by using quinone monoketals instead of quinones. In this route, the 
exocyclic enamino ester (96) was condensed with the monoketal (97) to 
give the Michael adduct (98), which on exposure to a catalytic amount 
of concentrated hydrochloric acid rearranged to the indole (93). 
Oxidation of the phenol (93) with Fremy's salt afforded the 2-quinone 
(99). Lewis acid catalyzed demethylation afforded the 7-hydroxy-5,8-
indoloquinone (100) which was subsequently treated with diazomethane 
to give the methyl ether (101). This compound (101) was converted to 
7-methoxymitosene (60) by reduction of the ester function to a 
hydroxymethyl group which was then elaborated to a carbamate function 
following the procedure developed by Yeiss 71 (vide in_fra). 
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A modified Nenitzescu reaction has also been used in this 
laboratory by Gredley et al. 20 • 82 for the synthesis of the mitosene 
derivative (107) (Scheme 19). Use of the .trisubstituted quinone 
(102) ensures regiospecific addition to the unsubstituted position on 
the quinone. This route involves the add ition of the enamino ester 
(103) to the quinone (102), the resulting hydroquinone adduct being 
oxidized in situ, to give the quinone (104). Cyclization of the 
adduct (104) gives the 7-Q-benzoylmitosene (105) which is converted 
to the mitosene (106) in several simple steps. This mitosene 
derivative (106) has been elaborated to the aziridinomitosene (107) 
using selenium methodology to introduce the 1,2-double bond and 
nitrene addition onto the double bond to generate the aziridine 
function. 82 - 84 
CXX)Ph 
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Akiba's photochemical route 85 outlined in Scheme 20 constitutes a 
formal synthesis of 7-methoxymitosene (60). Regioselective Michael 
addition of thallium ethyl !-butylmalonate to the quinone (108) 
followed by oxidation of the resulting hydroquinone afforded the 
quinone adduct (109). Substitution with pyrrolidine yielded the 
aminoquinone (110) which was irradiated with a high pressure mercury 
lamp through Pyrex glass. The irradiated solutions were retained on 
36. 
a silica gel column for a few days, and were eluted to afford the 
pyrroloindole quinone (111) as a mixture of diastereoisomers. On 
treatment with trifluoroacetic acid both stereoisomers were converted 
to the same product (101), which was i dentical to Coates and 
MacHanus' 81 intermediate (vide supra). 
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This novel route has been extended to the synthesis of 
aziridinopyrrolo[l,2-~]benz[!]indoloquinone (115). 86 Using the same 
chemistry, substitution of the chloronapthoquinone (112) with the 
diazabicyclohexane (113) yielded the aminonaphthoquinone (114), which 
on photolysis furnished the aziridinonapthoquinone (115) (Scheme 21). 
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Akiba and coworkers 87 also developed a direct synthesis of the 
pyrroloindoloquinone system by a nitrene insertion reaction (Scheme 
22). Thermolysis or photolysis of the aminoquinone tosylhydrazone 
(117), derived from the quinone (116) , afforded t he pyrrolo[l,2-
~]indole (119) via the intermediate benzoxazoline (118). However, 
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attempts to apply this reaction to the aziridinoaminoquinone 
tosylhydrazone (1 20) did not yield the corresponding 
aziridinopyrroloindoloquinone (121). On the other hand, thermal 
decomposition of the hydroxyquinols (122) gave a mixture of the 1,2-
38. 
disubstituted mitosenes (124), the 2-aminomitosene (125), and the 1-
iminomitosene (126), presumably via decomposition of the desired 
product (121) under the reaction conditions. 
The first approach towards the synthesi s of 7-methoxymitosene 
(60) by Luly and Rapoport involved the closure of ring B via an 
iminium salt 88 (Scheme 23). Regioselective addition-oxidation of the 
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proline methyl ester (128) to the quinone (127) in the presence of 
cupric acetate and oxygen afforded the desired aminoquinone (129). 
Monoallylation was achieved by treatment of the lactone phenol (130) 
with allyl bromide. Lactone opening and dimethylation of the 
resulting allyl ether (131) followed by Claisen rearrangement and 
benzylation of the resulting phenol gave the protected hydroquinone 
(132). The desired aldehyde (133), obtained by a standard catalytic 
osmium tetroxide/sodium metaperiodate oxidation procedure, was 
converted to the dimethyl ketal (134) and then hydrolyzed to the 
amino acid (135). Ring closure to the indoline (137) was effected by 
heating the amino acid (135) with phosphorus oxychloride and 
quenching the intermediate hemiketal with methanol. Concomitant 
dehydrogenation and deacetalation with DDQ afforded the aldehyde 
(138). Oxidative dealkylation with eerie ammonium nitrate proceeded 
cleanly and efficiently to give the indoloquinone aldehyde (82). The 
transformation of the aldehyde (82) to 7-methoxymitosene (60) has 
been reported by ~eiss. 71 
Luly and Rapoport's second route 89 to 7-methoxymitosene (60) is 
outlined in Scheme 24. Regiospecific oxidative amination of quinone 
(139) with homoproline ethyl ester (140) gave the aminoquinone (141). 
Irradiation of the quinone (141) yielded the vinylogous carbamate 
(142) as the major product. Blocking the hydroquinone (142) as the 
dimethyl ether (143) and subsequent photochemical ring closure 
afforded the indole (144). Oxidative demethylation with nitrous acid 
gave the indoloquinone (101) whose transformation to 7-methoxymitosene 
(60) had been reported by Coates and MacManus 81 (vide supra). An 
alternative improved route to the key compound (101) involved 
oxidation of the hydroquinone (142) in the presence of palladium on 
carbon under oxygen to the quinone (145) followed by palladium-
catalyzed cyclization. 
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In a subsequent report Rapoport and coworkers 90 described the 
enantiospecific synthesis of the 1~, 2~-1,2-(~-benzylaziridino)mitosene 
derivative (150) (Scheme 25). This work was probably carried out 
before the revised absolute stereochemistry of the natural mitomycins 
was reported. 21 • 22 The configuration of the 1,2-aziridine function 
is opposite to what is currently accepted. The epimeric 
aziridinohomoproline derivatives (146) were prepared in a multi-step 
sequence from Q-vinylglycine (see Chapter 4). Following the approach 
developed previously89 , the dibromoquinone (139) was aminated with 
the amine (146) to give the quinone (147); photochemical oxidation-
41. 
reduction then yielded the hydroquinone (148) . The aziridinomitosene 
derivative (150) was obtained after oxidation of the hydroquinone 
(148) to the quinone (149), followed by palladium-catalyzed ring 
closure. 
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Reinhoudt and coworkers 91 reported the application of a modified 
Madelung reaction 92 to construct the pyrrolo[l , 2-~]indole skeleton by 
the formation of the C-9--C- 9a bond. Their approach is depicted in 
Scheme 26. The amide (153), prepared by acylation of the aniline 
derivative (151) with 4-chlorobutyryl chloride (152) , was cyclized to 
the lactam (154). Subsequent intramolecular cyclization to the 
indole (79) was achieved by treatment of the lactam (154) with 
potassium tert - butoxide in THF, via the intermediate (155). This 
compound (79) has been converted to 7-methoxymitosene (60) by 
Kametani and coworkers 75 (vide supra). 
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(79) 
The third approach focuses on Cring closure involving indole or 
indoline derivatives. 
Veiss and coworkers 7 1 at the Lederle Laboratories found early 
success with the synthesis of 7-methoxymitosene (60) from a bicyclic 
indolic precursor. Their approach is shown in Scheme 27. The indole 
ester (157), prepared by a Reissert indole synthesis 93 from 4-nitro-
2,5-xylenol (156), was condensed with methyl acrylate to give the 
diester (158). Dieckmann condensation then gave t he pyrroloindole 
ester (159) , which on acid-catalyzed decarbomethoxylation afforded 
the key intermediate (160). Volff-Kishner reduction gave the indole 
(161) which was formylated by a Vilsmeier-Haack reaction
94 to give 
the aldehyde (80), the same key intermediate used in Kametani's 
synthesis 75 (vide supra). Elaboration to the quinone functionali ty 
was achieved as follows , using a longer procedure than Kametani's. 
Cleavage of the methoxyl group and oxidation with Fremy's salt of the 
resulting phenol afforded the £-quinone (162). Thiele acetoxylation 
of the quinone (162) furnished the triacetate (163), which on 
43. 
alkaline hydrolysis followed by aerial oxidation and methylation with 
diazomethane, afforded the indoloquinone (82). They also developed 
the standard procedure for introducing the carbamate function. 
Reduction of the aldehyde (82) with sodium borohydride, followed by 
oxidation of the intermediate hydroquinone with acidic ferric 
chloride, furnished the 9-hydroxymethylquinone (164). Acylation of 
the carbinol (164) with phenyl chloroformate and subsequent 
ammonolysis yielded 7-methoxymitosene (60). 
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Using the ketone (160) as their starting material, Remers and 
coworkers 95 have prepared a series of !-substituted and 1,2-
disubstituted mitosenes exemplified by (165) and (166). The key to 
44. 
this work was reduction and derivatization of the 1-oxo function 
prior to Vilsmeier formylation 94 of the indole. The mitosene 
derivative (166) possesses quite good antibacterial activity but no 
anticancer activity. 
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In their pursuit of the synthesis of the mitomycins, Danishefsky 
and coworkers 96 devised an ingenious route to tetrahydropyrrolo-
[1,2-~]indoles involving the intramolecular opening of an activated 
cyclopropane. The synthetic route is outlined in Scheme 28. 2,4-
Dimethoxy-3-methylphenol (38), the same starting material as used in 
Kishi's synthesis 70 (see section 1.6.1), was Q-alkylated with 1,4-
dichloro-2-butene followed by treatment of the resulting ether with 
sodium acetate to give the allyl ether (167) . Claisen rearrangement 
and methylation of the intermediate phenol afforded the trimethoxy 
derivative (168). Nitration, hydrolysis of the acetate, and 
reduction of the nitro group followed by protection of the amino 
group converted the penta-substituted benzene (168) to the 
phthalimide (169). Acylation of the hydroxyl group with 
methylmalonyl chloride followed by treatment of the resulting ester 
with tosyl azide gave the diazoester (170) which on thermolysis 
yielded phthalimidocyclopropane (171) as the major insertion product. 
Acid-catalyzed methanolys i s afforded the hydroxy diester which was 
protected as its silyl ether (172). Removal of the phthaloyl 
protecting group with hydrazine in hot methanol released the amino 
intermediate which underwent spontaneous ring mutation in a spiro 
45. 
mode to give the indole (173). Cyclization to the tricyclic lactam 
(174) was effected by thermolysis of the indole (173) in the presence 
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of camphorsulfonic acid. ~ phenylseleno function was introduced~ to 
the lactam centre and hydrolysis of the ester followed by 
decarboxylation and diborane reduction of the lactam furnished the 
46. 
diastereomeric selenides (175). Oxidative elimination of the 
selenides (175) yielded the tricyclic 61 • 2 system (176). The 
compound (176) possesses features that are amenable to further 
manipulations towards the target molecule (1) . For example, 
oxidative demethylation would generate the quinone function and the 
double bond serves as a handle for aziridine elaboration. Less 
obvious though is the introduction of the 9a-oxygen function. 
In another approach97 the aniline derivative (177), obtained 
using similar chemistry as described above, was cyclized to the 
indole (178) with mercuric acetate (Scheme 29). Cleavage of the 
silyl protecting group followed by a Mitsunobu type reaction afforded 
the tricyclic pyrrolo[l,2-~]indole (179). 
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Vice's strategy98 for the synthesis of pyrrolo[l,2-~]-
indoles is based on an indirect side-chain alkylation of 2,3-
dimethylindoles, involving reaction of the anion of 3-
methylthioindolenines with carbon electrophiles and subsequent 
reductive desulfuration. The transformations are depicted in Scheme 
30. The thioindolenines (181), prepared from the corresponding 
indoles (180) by reaction with methanesulfenyl chloride, were f-
alkylated with ethyl iodoacetate to give the side-chain alkylated 
indoles (183) via the anions (182). Reductive desulfuration followed 
47. 
by base-induced cyclization of the resulting indoles (184) afforded 
the pyrrolo[l,2-~]indoles (185). Treatment of the indoles (185) with 
bromine and methanol gave the unstable bromoethers which underwent a 
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facile elimination in the presence of triethylamine to yield the 
exocyclic alkenes (186). Concomitant hydrat i on of the double bond 
and elimination of methanol yielded the alcohols (187) which were 
converted to the carbonates (188). The unsaturated lactams (189) 
were obtained from the tricyclic indole (188) by treatment with 
N-bromosuccinimide followed by elimination of the intermediate 
bromides with DBU . The compound (189, R1 =R3 =0Me, R2=Me) has 
potential value in the synthesis of mitosene analogues. Adjustment 
of the oxidation level to the quinone, reduction of the lactam 
carbonyl and elaboration of the double bond to the aziridine are 
among the chemical transformations required to prepare a target 
mitosene analogue such as (9). 
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The key reaction in the synthesis of mitosanes by Naruta and 
coworkers 99 was the stereospecific photochemical cyclization of the 
azidoquinone (190) with the ~.~-2,4-hexadien-1,6-diol derivative 
(191), presumably via a nitrene intermediate (Scheme 31). The 
9,9a-dihydroindoloquinone (192) thus obtained, possessed a trans 
configuration at the 9,9a-position and the olefinic double bond 
preserved its cis stereochemistry. It was efficiently converted to 
the indole (194) via the mesylate (193) after selective mono-
deprotection and mesylation at the allylic alcohol position. The 
presence of a 1,2-double bond in this compound (194) allows for 
further elaboration to the aziridinomitosane derivati ve (195). 
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49. 
This methodology was also employed by Moore's group 1 0 0 in the 
synthesis of the pyrrolo[l,2-~]indoloquinone (198) (Scheme 32). The 
azidoquinone (196) was smoothly ring-closed to the indoloquinone 
(197) on thermolysis or photolysis. Mesylation of the alcohol (197) 
followed by intramolecular cyclization yielded the mitosene 
derivative (198). 
0 0 0 
a a 
:% 
0 
OH 0 
(196) (197) OH 
Scheme 32 
method d 
This method involves the transannular cyclization of a 
benzazocine derivative between N-4 and C-9a, and is the most 
promis i ng approach for the synthesis of 9a-oxo-func t ionalized 
pyrrolo[l,2-~]indoles. 
(198) 
The only total synthesis of mitomycins , by Kishi ' s group, 70 was 
accomplished via a route involving transannular cyclization of 
1-benzazocin-5- one derivati ves as the key step (Figure 8) (see 
section 1.6.1). 
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Formation of the pyrrolo[l,2-~]indole ring system of the 
mitomycins by transannular cyclization was first demonstrated by Lown 
and coworkers101 (Scheme 33). Benzazocin-5-one (200) was prepared by 
a based-catalyzed Dieckmann cyclization of the diester (199). 
Cleavage of the E-toluenesulfonyl protecting group released the amino 
group which underwent transannular addition to the carbonyl group; 
dehydration then yielded the pyrrolo[l,2-~]indole (161). It was not 
possible to isolate the intermediate 9a-hydroxy compound (201) under 
the reaction conditions. 
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Ban's research group102 developed an approach starting from the 
phenylenediamine derivative (202) (Scheme 34). Treatment of the 
compound (202) with sodium hydride in dry THF at room temperature 
yielded an epimeric mixture of the 9a-hydroxy derivatives (205). The 
mechanism of this reaction involved a novel retroaldol type ring-
opening of the initially formed aminoketone (203) to give the 
intermediate benzazocinone (204) and transannular cyclization then 
afforded the alcohols (205). Reduction of the carbonyl function 
followed by removal of the ~-tosyl group yielded the 
pyrrolo[l,2-~]indole (207). 
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Kametani and coworkers 10 also recognized the importance of 
benzazocin-5-one intermediates in obtaining 9a-oxygenated mitomycin 
derivatives. In one approach, 103 they transformed the 
tetrahydrocyclopent[£]indole (208) into the 2,3-dihydro-lg-
pyrrolo[l,2-~]indole (211) via the 1-benzazocin-5-one (210) 
(Scheme 35). Dye-sensitized photo-oxygenation of indole (208) using 
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Rose Bengal as sensitizer furnished the eight-membered lactam (209) 
in good yield. Transposition of the ketone function at C-6 to the 
neighbouring position with concurrent introduction of a one-carbon 
unit at C-6 were achieved in several steps affording the enol ether 
52. 
(210), which cyclized to the pyrrolo[l,2-~]indole (211) either on 
acid treatment or on simply being left at room temperature for five 
days. 
In another approach, 9 • 1° Kametani's group investigated the 
interconversions of 2,3-dihydro-1~-pyrrolo[l,2-~]indoles and 1-
benzazocin-5-ones (Scheme 36). Avon Braun type reaction104 using 
cyanogen bromide or acetic anhydride and sodium acetate cleaved the 
C-4--C-9a bond of the indoline (212), derived from the 
pyrrolo[l,2-~]indole (161) , to give the benzazocine derivatives (213) 
which were converted to the ketones (214). However, attempted 
introduction of the quinone function to the benzazocine derivatives 
(214) to produce the quinones (215) resulted in failure. The 
benzazocine derivatives (214) could be converted back to the starting 
material (161). 
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Synthesis of the eight-membered quinone (221) was accomplished 
from the 5,8-diacetoxy-pyrrolo[l,2-~]indole (216). Heating the 
indoline (217), obtained by reduction of the indole (216), with 
trifluoroacetic anhydride afforded the ring-opened product (218). 
53. 
Selective hydrolysis of the Q-trifluoroacetyl group and subsequent 
oxidation gave the ketone (219) which was protected as the dimethyl 
ketal (220). Removal of the ~-trifluoroacetyl group and oxidation 
gave the eight-membered quinone (221) , an important intermediate in 
Kishi's synthesis 70 (Scheme 37). 
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Finally, the last method i nvolves recent approaches in which both 
rings Band Care formed in a one step reaction. 
Danishefsky and coworkers 10 5 developed a route to the mitosane 
skeleton by biscyclization of an hexenylaniline system which can be 
considered as a st ereospecific seleno-amination-alkylation-oxidation 
54. 
sequence (Scheme 38) . The aniline derivative (225) was prepared from 
the phenol (38) and the allylic alcohol (222) in several steps, among 
which were Q-alkylation and Claisen rearrangement. On treatment of 
the aniline derivative (225) with the Nicolaou reagent, 
~-phenylselenophthalimide, concurrent forma tion of rings Band C 
afforded a diastereomeric mixture of selenides (226) which on 
oxidative deselenylation produced a 4:1 mixture of olefins (227a) and 
(227b). Elaboration of the double bond to aziridine was achieved 
with a multi-step sequence akin to Kishi's procedure 70 (see section 
1.6.1). Direct oxidation of the £-methoxyphenol derivatives (228) 
with DDQ furnished the 9a-deoxymitosanes (229). 
OH 
=)Q 
Me ~ I 
Ma) 
Me 
Me() 
Me 
CMe 
(38) 
Mt.() 
Me 
CMe 
(226) 
OMe 
R - H, Me 
(228) 
1BuM~SiOCR: 
+ 
·~r:: 
(222) 
OH 
OBn 
CMe 
Q5iM~Bu' 
(224) 
MeO 
SePh 
Me 
NR 
Scheme 38 
MeO 
Me 
CM, 
(227a) 
= o)\~" 
~)Q ~. 
OBn 
(225) 
0 
CMe (223) 
OBn 
0 
x- Cr}-
MeO 
+ 
Me 
R - H, Me 
(229) 
0 
CM, 
(227b) 
NR 
55. 
Maruyama and coworkers 106 also developed a synthesis of mitosane 
derivatives. Their approach involved the pyrolytic decomposition of 
the corresponding azidoquinones derived from 2-halo-3(2,4-
pentadienyl)-l,4-benzoquinones (Scheme 39). The azidoquinone (231) 
was obtained by Lewis acid mediated 2,4-pentad i enylation of the 
bromoquinone (108) with the stannane (230), followed by oxidation and 
treatment with sodium azide. Decomposition of the azidoquinone (231) 
in the presence of copper powder afforded the pyrrolo[l,2-~]indole 
(232), presumably via a nitrene intermediate. Analogously, the 9~ 
benzyloxymethyl derivative (234) was obtained from the azidoquinone 
(233). This mitosane derivative (234) has the requisites for further 
elaboration to the 9a-deoxymitosane (195). 
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Scheme 39 
Coates and Hutchins 1 07 made use of an unusual [3,3]sigmatropic 
rearrangement to achieve the tricyclic indole ( 240) in a single step 
from ~-arylhydroxylamine (235) and ethyl 6-oxo-2-hexynoate (236) 
NR 
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under the influence of sodium cyanoborohydride (Scheme 40). The 
sequence of reactions involved reduction of the intermediate nitrone 
to the hydroxylamine (237) and intramolecular addition of the 
hydroxyl group to the acetylenic ester to afford the ~-aryl-Q-
vinylhydroxylamine derivative (238). This was followed by a hetero-
Cope rearrangement to yield the intermediate (239) which on 
subsequent aromatization, transannular cyclization and dehydration 
gave the product (240). 
,:::,-- 1 
Ma)n 
Me ~ NHOH + 
(235) 
(238) 
(236) 
(239) 
Scheme 40 
(237) 
---:xxS 
(240) 
Defoin's group 108 also reported a one-pot synthesis of the 
tricyclic mitomycin skeleton based on a sequential hetero-Diels-Alder 
cycloaddition and a hetero-Cope rearrangement, the latter reaction 
being akin to the Coates' procedure107 (vide supra). Reaction of the 
dienals (241) with nitrosobenzene (242) gave the pyrroloindoles 
(246); presumably the enol form of the cycloadducts (243~244) 
underwent a hetero-Cope rearrangement and aromatized to give the 
ketones (245). Transannular cyclization followed by dehydration and 
isomerization yielded the products (246) (Scheme 41). 
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Scheme 41 
In their research on the development of palladium-catalyzed 
approaches to heterocycles, Hegedus and coworkers 109 applied the 
palladium-catalyzed cyclization process to gain access to the 
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pyrrolo[l,2-~]indole ring system. Their synthetic route is outlined 
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in Scheme 42. Treatment of the dimethoxyquinone (247) with 
allylamine afforded the bis(allylamino)quinone (248) in good yield. 
Palladium (!!)-catalyzed cyclization followed ~y intramolecular 
olefin insertion afforded the tricyclic pyrrolo[l,2-~]indoles (250) 
and (251). Competitive 13,--hydride elimination gave the undesired N-
allylindoloquinone (252). 
1 . 6.3. Concluding Remarks 
~ith the exception of Kishi's synthesis, 70 the various synthetic 
approaches to the mitomycin antibiotics have not yet solved all the 
problems associated with such an enterprise. Briefly recapitulating, 
the formidable challenge of this undertaking arises from the need to 
deal simultaneously with the densely arrayed functionalities on a 
compact molecule, the high level of oxidation, the four contiguous 
chiral centres and above all, the chemical !ability of the target. 
Our approach to the synthesis of the mitomycins is based on 
analysis of the probable biosynthetic pathway by which the two 
primary precursors, 3-amino-5-hydroxybenzoic acid (36) and D-
glucosamine (10), are combined in nature. 
CHAPTER 2 
AN ATTEMPTED BIOMIMETIC APPROACH TO THE SYNTHESIS OF TBE MITOMYCINS 
59. 
2.1. Introduction 
Several approaches have been used in biosynthetic studies to 
unravel the biogenetic pathways used by organisms for the synthesis 
of natural products. 110 Many of these methods are designed to 
isolate the actual intermediates to provide concrete evidence about a 
biosynthetic pathway. Biosynthetic experiments involving 
supplementation of the growth medium with modified precursors which 
can specifically inhibit metabolic processes and result in increased 
levels of intermediates can be used to explore biosynthetic pathways. 
This technique requires that the precursor analogue can enter the 
cells freely and can compete with the true precursor for the 
synthetase enzymes. Alternatively, enzymatic blocks can be induced 
by mutagenic agents such as ultraviolet radiation. Cells lacking the 
necessary enzyme in a certain biosynthetic step may accumulate the 
obligatory intermediate. In favourable cases, where obligatory 
intermediates are isolated , sequential steps in a biosynthetic 
pathway can be elucidated. Also, precursor incorporation experiments 
using isotopically labelled molecules have been used extensively to 
follow metabolic pathways. More recently, these methods have been 
complemented by biomimetic or biogenetic-type syntheses. 
A biomimetic or biogenetic-type synthesis refers to a natural 
product synthesis that is designed to follow, i n at least it s major 
aspects, biosynthetic pathways proved or presumed to be operating in 
nature, by employing fundamental reactions of organic 
chemistry. 1 10 c,d The relationship of the laboratory synthesis to the 
actual biosynthesis is not necessarily very close. The organic 
chemist can resort to reagents and conditions that are not available 
to the living system to capitalize on the biosynthetic route. The 
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important criterion is to integrate the biogenetic perception with 
synthetic organic chemistry in order to devise an overall mimicry of 
the biosynthetic pathway. Genuine or more often structurally 
modified substituents (model substrates) can be used to test the 
individual steps in a biosynthetic sequence in order to help in the 
understanding of the interweaving of the precursors into the 
molecular framework. Biogenetic-type syntheses often are neater, 
shorter, and more efficient than normal synthetic routes in which no 
due respect is paid to the in vivo enzymic processes. An historical 
example is the biomimetic synthesis of tropinone (253) by 
Robinson1114 from simple starting materials regarded as reasonable 
biogenetic precursors (Scheme 43), whereas the synthesis by 
Yillstatter111 b was lengthy in comparison. Moreover, this method can 
be applied to metabolites of higher organisms where the other 
techniques mentioned above are less applicable. 
+ + 
succindialdehyde methylamine acetonedicarboxylic acid 
Scheme 43 
- ~o • 2cc, • 2H,O 
(253) 
However, it must be emphasized that the success of a biogenetic-
type synthesis per se does not constitute a proof for the operation 
of a particular chemical step in vivo . It can serve as a guide and 
impetus for more definite studies in the biosynthetic proposal. It 
can also lead to the preparation of closely related analogues by 
b . h , 110a directed 1osynt es1s. 
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2.2. Synthetic Strategy Based on Biogenetic Reasoning 
As already discussed in Chapter 1, biosynthetic studies have 
established that the contiguous six-carbon cha i n from C-10 to C-3 
together with the attached aziridine nitrogen of the mitomycin 
antibiotics arises from ~-glucosamine (10), while the 
methylbenzoquinone nucleus is derived from 3-amino-5-hydroxybenzoic 
acid (36). However, the sequence of reactions linking these two 
primary building blocks is not known. A biomimetic synthesis could 
determine the likely intermediates and the processes for the carbon 
framework formation. Moreover, this could lead to a feasible 
synthetic route to the natural products. 
Structural analysis of the mitomycins revealed that three key 
bonds, viz., the N-4--C-3 bond, the C-8a--C-9 bond, and the N-4--C-9a 
bond must be formed during their biosynthesis from the two primary 
precursors (Figure 9). 
HO,~,, CH20H OH 2 .•••• 
•••••• -··HO'" · OH 
~ I .. ---···· .?-------·· .. ,,. 
~ ••• -·· H HO,CDNR, ··----,--------- NH, 
0 
(36) (IO) 
Figure 9 
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It has been demonstrated that amine-carbonyl condensation 
constitutes a crucial step in a number of enzyme-mediated 
processes. 112 A probable biogenetic pathway could involve such an 
imine formation to effect the first key bond (Scheme 44). Reduction 
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of the intermediate imine would yield a secondary amine. The second 
critical bond formation could occur by an intramolecular Michael 
addition to a benzoquinone derived by oxidation of the phenol. This 
mechanism would also require the adjustment of the oxidation levels 
of the aminosugar-derived portion of the molecule, namely, oxidation 
at C-4 and reduction at C-5 [numbering system corresponds to 
aminosugar (10)) to provide for the Michael donor. The third key 
bond formation, involving a transannular cyclization between the C-4 
carbonyl of the oxidized side chain derived from Q-glucosamine (10) 
and the amino group of 3-amino-5-hydroxybenzoic acid (36), would also 
provide the C-9a oxygen function. The envisaged transannular 
interaction has been proposed by Lown101 a to resemble the 
biosynthesis of the pyrrolizidine alkaloids. 113 
+ 
(36) (10) 
OH 
[O]C 
( I ) 
Scheme 44 
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The functional transformation of the 2-amino-3-hydroxy system of 
the ~-glucosamine (10) into an aziridine function could have occurred 
at any stage of the biosynthesis. Likewise, the complete reduction 
of the carboxyl group of 3-amino-5-hydroxybenzoic acid (36) to form 
the C-6 methyl group of the quinone nucleus could have occurred at 
the precursor level of the amino acid (36) itself or at later stages 
of the mitomycin biosynthesis. Recently, Rickards and 
Rukachaisirikul 114 demonstrated by feeding experiments with labelled 
3-amino-5-hydroxybenzyl alcohol that the former was unlikely to have 
occurred. Of lesser importance is the timing of the secondary 
biosynthetic processes incorporating the various Q- and ~-methyl 
groups and the carbamate function into the mitomycin skeleton. 
This sequence of the three key bond formations for the 
construction of the mitomycin skeleton forms the basis of our 
biomimetic approach to the synthesis of the mitomycins. 
Our initial synthetic plan is outlined in Scheme 45. The ortho-
aminophenols (254) were to be used in the preliminary investigation 
of this biomimetic route rather than the natural meta-isomers, as the 
former with appropriate ~-protection can be oxidized efficiently to 
1,4-quinones in a subsequent step using Fremy's salt, 115 whereas the 
formation of the unwanted 1,2-quinones is a competing process in the 
latter isomers. For synthetic purposes, the methyl group on the 
aromatic ring was used in preference to the carboxyl group or other 
intermediates which would have to be reduced at a later stage. For a 
total synthesis of the mitomycins, an aziridino aliphatic fragment 
such as (255) would be required. The ~keto ester (255, Y=C0 2R) 
would provide a better Michael donor than a singly activated ~-methyl 
ketone (255, Y=H) though the latter might be sufficiently reactive 
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for the Michael reaction. From a synthetic point of view, it would 
be advantageous to form the first bond by condensation of the amine 
(254) with the appropriately functionalized acid (255) affording an 
~-protected amine in a single step. Oxidation of the phenol to a 
1,4-quinone followed by Michael addition of the activated side chain 
methylene group onto the quinone would yield an annulated eight-
membered ring. Transannular cyclization of the nitrogen attached to 
the quinone nucleus, rendered nucleophilic by reduction of the 
quinone and amide functions, would result in the mitomycin ring 
system with the relative configuration at the resulting tertiary 
hydroxyl position controlled by the chirality of the aziridine. 
+ 
(254) X = H, NHAc, OMc 
y 0 0 
X X 
NZ ( 1 ) 
Me 
Scheme 45 
Initially, the models chosen were simple, only the basic reaction 
components being included to establish the feasibility of the three 
crucial bond formations. Refinement to include the amino or methoxyl 
substituent at C-7, the 1,2-aziridine function and the correct 
chirality at the four asymmetric centres would follow later for the · 
total synthesis of the target natural products. 
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Although an aliphatic fragment with a ~keto ester function 
should be a better Michael donor, it is not as readily available as 
the corresponding singly activated counterpart, namely levulinic acid 
(256). Accordingly, the feasibility of t hese three crucial bond 
formations was first examined with the commerc i ally available 
levulinic acid (256) and 2-amino-6-methylphenol (257), obtainable in 
two steps from o-cresol. 
0 
~½OH 
0 
(256) (257) 
2.3. Results and Discussion 
2.3.1. Synthesis of 6-Hethyl-2~(4-oxo-pentanamido)-1,4-benzoquinone (262) 
Nitration of o-cresol using~ standard procedure11 6 with a 
mixture of nitric and sulfuric acids yielded 6-methyl-2-nitrophenol 
(258) in 25% yield after recrystallization; the £-isomer was not 
isolated. In a recent paper, Gaude and coworkers 1 17 reported a 
method for nitration of phenols with nitrates in a two-phase system . 
They obtained a mixture of o- and £-nitrated ~-cresols in a ratio of 
2.2:1 in 76% yield. However, in our hands, none of the desired 
product was isolated, only starting material being recovered. Since 
o-cresol is available in large quantities cheaply , no attempts were 
made to optimize the yield of the nitrophenol (258). 
Reduction of the nitrophenol (258) to 2-amino-6-methylphenol 
(257) was accomplished either by catalytic hydrogenation using a 
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palladium on carbon catalyst or by chemical reduction with sodium 
hydrosulfite in an alkaline medium. 118 ' 119 The former method was 
preferred since the work-up procedure was simpler and the yield was 
good (93%). Precaution had to be taken to minimize oxidative 
dimerization by adding acetic acid to the reaction mixture before 
filtering off the catalyst under nitrogen. The mass spectrum of the 
residue from sublimation of the aminophenol (257) shows a molecular 
ion at m/z 240, indicative of a dimer. It is well-known that o-
aminophenols dimerize under the influence of oxidizing agents. 120 
Previous work has shown that ~-aminophenol (257) in the presence of 
silver carbonate dimerized to give mainly 3-amino-1,9-
dimethylphenoxazin-2-one (259), the chromophore of the 
actinomycins. 121 
(') MeyNOz 
OH 
(258) 
(r(NYYNH2 
yo~o 
Me Me 
(259) 
2-Amino-6-methylphenol (257) was coupled with commercially 
available levulinic acid (256) by using DCC122 as the condensing 
agent. The co-product, DCU, has very low solubility in 
dichloromethane and can be separated from the product mixture by 
filtration. Optimal yields were obtained when the molar ratio of the 
reaction components was 1.0 aminophenol (257) to 1.2 DCC to 1.5 
levulinic acid (256) and the reaction allowed to proceed at 0° C for 
one to two hours in dichloromethane under argon or nitrogen. A 
different ratio of the reaction components or a longer reaction time 
or a higher temperature lowered the yield. The intermediate 
acylaminophenol (260) proved difficult to purify due to the presence 
of an equilibrium mixture of the open-chain form (260) and the ring-
closed benzazepin-2-one (261). 123 The crude product was therefore 
oxidized directly to the desired quinone (262) with Fremy's 
salt 115 ' 124 [80% overall yield from aminophenol (257) (Scheme 46)]. 
r1 
Me~NH2 
+ 
OH 0 OR 
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Scheme 46 
The feasibility of the oxidation of acylaminophenols to form 
acylaminoquinones with Fremy ' s salt was previously examined using 2-
acetylamino-6-methylphenol (263), obtainable in 90% yield by 
treatment of the aminophenol (257) with acetic anhydride. Oxidation 
with Fremy's salt proceeded smoothly and rapidly at room temperature 
to give 2-acetylamino-6-methyl-1,4-benzoquinone (264). 
('1 MeyNHAc 
OH 
(263) (264) 
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2.3.2. Attempted Cyclization of the Acylaminoquinone (262) 
Yith the acylaminoquinone (262) in hand, we attempted to form the 
second key bond by Michael addition of the anion onto the quinone 
nucleus. However, numerous attempts to cycli ze the acylaminoquinone 
(262) via a kinetic lithium enolate to the bicyclic hydroquinone 
(265) in a variety of solvent systems (THF, DME, ether, TMEDA/THF, 
DME/ether, DME/THF) were not successful. In most cases, only 
starting material was recovered. Deuteration of the anion solutions 
prepared from the acylaminoquinone (262) and LOA or LTMP indicated 
only 40% deuteration in total, with 11% deuteration at the terminal 
methyl site. Other potential sites for deprotonation are the amide 
NH and the 6-methyl group. Taking these into account, the 
acylaminoquinone (262) was treated with 2.2 or 3.2 equivalents of 
base, but no desired product was isolated. Yith an excess of base 
used, the starting material was recovered in low yields (about 40%) 
and more resinous materials were obtained. It was recognized that if 
an amide anion had been formed, the system would be deactivated 
towards cyclization in any case. Various electrophiles such as tert-
butyldimethylsilyl chloride, methyl chloroformate and ~- methyl-~-
(tert-butyldimethylsilyl)trifluoroacetamide12 5 were introduced into 
the 'anion solutions' in separate experiments in an attempt to trap 
and thus identify the anions. However, complex mixtures were 
obtained and this avenue was not pursued fur t her. 
OH 0 0 
~ ~q~ Me I OH H O 0 H 0 
~~ ~6~ 
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In order to avoid using strong bases and also to ensure specific 
deprotonation to initiate cyclization, the acidity of the protons at 
the terminal~ position of the keto functionality must be increased. 
An obvious solution was to extend the side chain by an electron-
withdrawing alkyl ester to give a 13-keto ester s uch as (266). 
2.3.3. Synthesis of 2-(5-(Methoxycarbonyl)-4-oxo-pentanamido]-6-
methyl-1,4-benzoquinone (266) 
Direct elongation of the acylaminoquinone (262) by trapping its 
lithium enolate with methyl chloroformate as described above was not 
successful. ~e therefore sought to prepare 1-methyl hydrogen 3-oxo-
hexanedioate (267) or its equivalent for use in the acylation of the 
aminophenol (257). 
0 0 
WO~OH 
0 
(267) 
>-y -COzMe 
(268) 
Reacting the dianion of levulinic acid (256) with methyl 
chloroformate was considered to be the shortest route to the acid 
(267). Attempts to generate the dianion using 2.2 equivalents of LOA 
in DMPU/THF or 2.2 equivalents of LOA in THF/ TMEDA led to a 
heterogeneous reaction mixture. The dianion might not have been 
formed under these reaction conditions. After the addition of methyl 
chloroformate to the reaction mixture, only the starting acid (256) 
and the urethane (268) were detected, the latter arising by reaction 
of LOA with the ester. 
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To reduce the problem to a monoanion preparation, the carboxyl 
group of the levulinic acid (256) was protected as its benzyl ester 
(269). 126 However, treatment of the ester (269) with LTMP in THF at 
-78° C afforded only the benzyl methyl carbonate (270) (20%) along 
with the starting material (7%). Under the react ion conditions, the 
ester moiety was cleaved and the benzyl alcoholate thus formed 
reacted with methyl chloroformate to give benzyl methyl carbonate 
(270). The benzyl alcoholate could have resulted from an 
intramolecular displacement of the anion. The lactone (271) formed 
via Q-acylation127 would be highly water-soluble and unlikely to be 
isolated (Scheme 47). Deuteration of an aliquot of the reaction 
solution indicated 29% deuteration of the recovered benzyl ester 
(269) ·although this does not necessarily reflect the efficiency of 
ionization since unionized material will be preferentially recovered. 
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Scheme 47 
The use of magnesium methyl carbonate i n regiospecific 
carboxylation of ketones to t3,-keto acids presumably via an 
intermediate magnesium chela t e (272) has been r eported. 128 
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An approach employing this reagent to synthesize the acid (267) 
starting from benzyl levulinate (269) was investigated. It was 
proposed that treatment of benzyl levulinate (269) with magnesium 
methyl carbonate followed by esterification of the resulting ~keto 
acid with dimethyl sulfate129 would give the benzyl methyl diester 
(273). Selective catalytic hydrogenation of the benzyl ester group 
would then give the desired monoacid (267). However, when benzyl 
levulinate (269) was treated with magnesium methyl carbonate, 
transesterification occurred affording methyl levulinate (274) and 
benzyl alcohol as analyzed by means of GC-MS. The propensity of the 
benzyloxy group to undergo substitution posed a problem in the 
carboxylation step. Therefore, instead of preparing a mixed diester 
such as (273), which allows selective deprotection of the benzyl 
ester with catalytic hydrogenation, an alternative route was to 
prepare the dimethyl ester (275). Selective hydrolysis of the 
isolated methyl ester at the 6-position would yield the desired 
monoacid (267). 
(274) (275) 
Dimethyl 3-oxo-hexanedioate (275) was obtained in 90% yield by 
treatment of levulinic acid ( 256) with magnes i um methyl carbonate 
followed by Fischer esterification of the crude product. 1 28 
Selective mono-hydrolysis of the diester (275) was not a trivial 
problem. Seebach and coworkers 130 selectively hydrolyzed the diester 
(276) to the monoester (277) in 92% yield using 2.15 equivalents of 
potassium hydroxide in methanol/water at room temperature. They 
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attributed the selectivity to steric hindrance at the 4-position. 
This procedure was applied to the diester (275) in the hope that 
ionization of the 13-keto ester would permit selective hydrolysis of 
methyl ester at the 6-position. However , only small amounts of the 
desired monoester (267) and levulinic acid (256 ) were obtained, the 
major product being the diacid (278). Levulinic acid (256) was 
probably formed by decarboxylation of the diacid (278). 
Modifications of this procedure by varying the concentration of the 
aqueous base, the solvent system and the reaction temperature did not 
increase the yield of the monoacid (267). 
C02R I 
HO-C-H 
I 
Me-C-Me 
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(279) R = Me 
(280) R ~ H 
An obvious (perhaps naive) solution was to use only one 
equivalent of base in carrying ou t the hydrolysis. Rapoport 131 
succeeded in mono-saponification of the diester acetonide (279) to 
the monoester acetonide (280) by using one equivalent of potassium 
hydroxide. Using similar conditions, a mixture of the desired 
monoester (267) (12%), starting material (40%) and the diacid (278) 
(33%) were obtained. 
Selective mono-hydrolysis of the diester (275) was finally 
achieved following a method used by Ruggli and Maeder132 for the 
selective hydrolysis of the mixed diester (281). A large excess of 
methanolic potassium hydroxide was added to ne2t dimethyl 3-oxo-
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hexanedioate (275) at 0° C, precipitating the dipotassium salt (282). 
Acidification with dilute aqueous hydrochloric acid yielded the 
desired monoester (267) in 90% yield. Selective mono-saponification 
under the above conditions can be explained by the formation of a 6-
membered potassium chelate (282) at the 13-keto ester end of the 
molecule thereby protecting the 1-methyl ester from hydrolysis. 
0 0 
1 1 ~ _a.le 
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Following the procedure developed earlier, the aminophenol (257) 
was condensed with the monoacid (267) using DCC and the crude product 
was oxidized directly with Fremy's salt. However, the desired 
acylaminoquinone (266) was isolated only in low yield. The 13-keto 
ester moiety was suspected to be consuming DCC, but increasing the 
stoichiometric amount of DCC used only led to complication in the 
purification of the acylaminoquinone (266) due to the large amount of 
DCU formed. 
In order to determine if the 13-keto ester moiety was reacting 
with DCC, a series of 1 H n.m.r. experiments were carried out. Methyl 
acetoacetate and DCC were mixed in deuteriodichloromethane and 1 H 
n.m.r. spectra were taken at regular intervals. In this case, no 
reaction occurred, only the resonances due to the starting materials 
being observed. The same negative result was obtained when dimethyl 
3-oxo-hexanedioate (275) was used. Yhen one equivalent of levulinic 
acid (256) was treated with one equivalent of DCC, the 1H n.m.r. 
spectrum showed the presence of 0.5 equivalent of levulinic acid 
anhydride, 0.5 equivalent of DCC and 0.5 equivalent of DCU. 
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It has been established1229 that the primary reactive 
intermediate in a DCC coupling reaction is the Q-acylisourea (283) 
arising from addition of the carboxyl group to the reagent. From 
there, two pathways may be operating: direct attack of the amine on 
the Q-acylisourea (283) forming the amide bond ( pathway a), or the 
formation of a symmetrical anhydride which in turn acylates the amine 
(pathway b) (Scheme 48). From the above 1H n.m.r. experiment, it 
appeared that the condensation reaction between levulinic acid (256) 
and the amine (257) using DCC as the coupling reagent (as described 
in section 2.3.1) has proceeded via the anhydride route. 
+ 
Scheme 48 
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Also based on a 1H n.m.r. experiment, the monoacid (267) when 
treated with DCC yielded the Z-lactonic ester (284) exclusively. A 
possible explanation for the specific formation of the ~-isomer is 
that the Q-acylisourea formed by the reaction of the carboxyl group 
and DCC favoured a transition state for further reaction consisting 
of two six-membered rings stabilized by intramolecular hydrogen 
bonding of the enol hydrogen (Figure 10). On treatment of the n.m.r. 
solution with methanol, methanolysis of the lactone resulted in ring-
opening to give the diester (275). On a preparative scale, the Z-
lactonic ester (284) was isolated in 92% yield. The ~-isomer (285) 
was synthesized by heating the monoester (267) in pyridine and acetic 
anhydride at 150° for five minutes. 133 
Figure 10 
(284) 
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The assignment of the relative configuration of the Z- and E-
isomers was based on the chemical shift of the olefinic protons and 
on the fact that the lactone (284) isomerized to the lactone (285) 
under thermodynamic conditions. The chemical shift of the olefinic 
proton in the ~-isomer occurred at lower field (o 5.72) than in the 
Z-isomer (o 5.18) due to the deshielding effect of the lactone 
oxygen. The lactone (285) was recovered unchanged after dissolution 
in sulfuric acid or heating in dichloromethane, whereas the isomer 
(284) when subjected to these treatments isomerized to the isomer 
( 285). 
An attempt to assign the two isomers from nuclear Overhauser 
effects (n.O.e.) 13 4 experiments was not successful . Theoretically, 
irradiation of the H-3 protons in the ~-isomer (284) should gi ve an 
n.O.e. for the olefinic proton, whereas irradiation of the B-3 
protons in the E-isomer (285) should not affect the intensity of the 
band of the olefinic proton. However, no n.O.e. was observed in 
either isomer. Similarly, irradiating the olefinic proton in either 
compound did not result in any significant change in the intensity of 
the methylene groups. Probably this is due to the fact that the 
protons of the methylene groups in the isomer (284) relax one 
another, and the olefinic proton contributes little by comparison. 
A literature survey133 • 135 - 137 revealed that the Z-isomers of 
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such lactones are difficult to obtain, the ~- isomers predominating in 
many of the reactions used to synthesize the lactones. The only 
feasible method hitherto was by photochemical isomerization of the E-
isomers to give equilibrium mixtures of the two isomers which were 
separated by column chromatography. As many biologically active 
natural products are enol lactone derivatives 138 , this mild method 
of preparing the stereochemically pure ~-isomers could be used to 
obtain these relatively inaccessible species. 
An attempt to purify the ~-isomer (284) by flash column 
chromatography resulted in hydrolysis of the lactone to give the 
monoacid (267). 
Conceptually the lactonic ester (284) or (285) is an equivalent 
of the ~keto ester (267). The lactonic esters simultaneously 
provide activation for the acylation process and protect the ~keto 
ester moiety from reacting with the amine, the ~keto ester being 
deprotected in the same acylation step. Another advantage is that 
the lactonic ester (284) can be obtained pure by recrystallization. 
~o 
~~~a,te 
H O 0 
(286) 
On mixing the lactonic ester (284) with aniline in dichloromethane 
6 135 at room temperature methyl 3-oxo-5-(phenylcarbamoyl)pentanoate (28) 
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was obtained in 92% yield. The aminophenol (257) was treated 
similarly with the lactonic ester (284). The intermediate amide was 
no t isolated, the crude product being oxidized directly with Fremy's 
salt to afford the desired acylaminoquinone (266) in 80% overall 
yield. 
2.3.4. Attempts to Cyclize the Acylaminoquinone (266) 
2.3 . 4.1. Basic Reaction Conditions 
Attempts to cyclize the acylaminoquinone (266) in various basic 
conditions (sodium hydride in THF , aqueous or methanolic sodium 
bicarbonate, aqueous or methanolic sodium carbonate) only produced 
tars, the acylaminoquinone (266) not being sufficiently stable in 
basic solutions. In a model experiment designed to examine the 
stability and the reactivity of the acylaminoquinone nucleus, the 
acetylaminoquinone (264) was treated with methanolic sodium carbonate 
under similar reaction conditions to the acylaminoquinone (266) . The 
amide (287) and the amine (288) were isolated in 46% and 26% yields 
respectively. In both cases, a 1,4-addition of methoxide ion 
followed by reoxidation of the intermediate hydroquinone had taken 
place. In the latter case, the amide bond was also cleaved even 
under the mild conditions used. This is probably because 
acylaminoquinones are in fact vinylogous imides and are more reacti ve 
than normal amides. 
0 
MaJ~ 
~VNHAc 
0 
0 
:~~, 
0 
(287) (288) 
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2. 3.4.2. Acidic Reaction Conditions 
In view of the ease of nucleophilic addition of methoxide ion and 
cleavage of the amide bond in the acylaminoquinones, acid-catalyzed 
intramolecular Michael addition was attempted. On treatment with 
methanolic hydrobromic acid, addition of hydrogen bromide to the 
quinone (266) took place. Cyclization of the result i ng hydroquinone 
to the 6-keto ester carbonyl and dehydration then furnished the 
benzazocinone (289). Structural assignment of this product (289) 
followed from analytical and spectroscopic data. 
OH OH 
Br 
~, ~, 
[F(CH:i)4Oh B 
(291 ) 
~e cnµe 
(289) (290) 
Trifluoroacetic acid did not give any reaction at moderate 
temperature, whilst heating at 70-75° C overnight produced a complex 
product mixture which was not analyzed. 
With bor on trifluoride etherate as a Lewis acid i n THF , the 
bicyclic system (290) was formed i n small amount. The 1 H n.m. r . 
spectrum of the compound (290) was very similar to that of the 
benzazocinone (289) and the mass spectrum showed a molecular ion at 
m/z 277. However , at the reaction temperature (50°), the solvent THF 
was slowly cleaved to give the borate (291) 139 and isolation of the 
compound (290) was difficult. In an inert solvent such as toluene, a 
red resonance-stabilized boron difluoride complex (292) was formed 
immediately and could be isolated. It decomposed back to the 
starting acylaminoquinone (266) on standing in the refrigerator 
overnight. Prolonged heating of the complex (292) at 50° C in 
toluene did not result in any further react i on. 
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A similar boron difluoride complex of dibenzoylmethane (293) was 
characterized by Hauser and coworkers 1 4 0 in 1952. The mechanism for 
the reaction of the boron trifluoride etherate with the t>-keto ester 
(266) probably involved the elimination of HF from the initially 
formed boron trifluoride complex (294), the driving force being the 
formation of the resonance-stabilized boron difluoride complex (292). 
(292) (293) 
(294) 
Thus, it appeared that the desired Michael addition of the 
activated methylene group in the side chain of the acylaminoquinone 
(266) onto the quinone nucleus could not be effected under acidic or 
basic reaction conditions. Decomposition and other side reactions 
occurred instead. 
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2.3.4.3. Stereochemical Factors in the Cyclization Reaction 
Examination of Dreiding models of the acylaminoquinone (266) 
showed that only the ~-isomer would be able to a ttain the transition 
state required to cyclize intramolecularly onto the quinone nucleus . 
Also Dreiding models of the bicyclic quinone (295) showed that the 
eight-membered ring is strained when an amide group forms part of the 
ring. Considerable strain is released when the amide group is 
replaced by an aminomethylene group. 
Me 
(295) 
The conformational effects of an amide function were observed by 
Sainsbury and coworkers 1 4 1 who attempted the synthesis of nitrogen-
containing heterocycles by anodic oxidation of t he amides (296) 
(Scheme 49). They found that intramolecular coupl ing occurred only 
Ma:l 
(296) E-fonn 
Scheme 49 
Ma:l 
OMe 
NR 
I 
C-0 
with the tertiary amide (296, R=Me), whereas in the case of the 
secondary amide (296, R=H), an intermolecular reaction took place. 
This result was attributed to the preferred stereochemistry of the 
amides, the §-isomer required for intramolecular coupling being 
present only when the amide function was fully substituted. 
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It is also known that 142 acetanilide (297) prefers the(~)-
conformation with the carbonyl group cis to the benzene ring, whereas 
~-methylacetanilide (298) occurs as the E-isomer. 
(297) (298) 
From these considerations, it is probable that the 
acylaminoquinone (266) exists mainly in the Z-form and that the Z to 
§ interconversion required for the desired cyclization is at least 
slow compared to decomposition and other r eactions. In consequence, 
we have not been able to effect the second key bond formation by 
Michael addition onto the quinone ring. 
0 
~o Mev~~COzMe 
0 H 0 
Z-(266) 
0 
~l!: 
0 H 0 
E-(266) 
Two alternative possibilities were considered to overcome this 
conformational problem. ~-Alkylation of the amide (266) to a 
~-substituted acylamine such as (299) would probably force the 
acylaminoquinone into the (§)-conformation, but eventual cyclization 
82. 
would still require the closure of a strained eight-membered lactam 
ring. Alternatively, selective reduction of the amide functionality 
and subsequent protection of the resulting amine with an electron-
withdrawing group such as benzyloxycarbonyl or !-butyloxycarbonyl 
seemed a more attractive possibility, since it would remove both the 
conformational problem and the requirement to form a strained eight-
membered lactam ring. 
0 
~ff7 
0 Bn 0 
Z-(299) E-(299) 
2.3.5. Attempted Selective Reduction of the Amide Function in the 
Presence of a '3--Keto Ester Moiety 
Selective reduction of an amide by diborane in the presence of an 
acyl acetic ester group is not known. 143 To investigate the 
feasibility of this reduction step, the amides (286) and (300) were 
chosen as substrates. Treatment of the amide (286) in THF with BH 3 -
THF complex gave the alcohol (301) in 71% yield. Next, the ketone 
group was protected as its boron difluoride complex (302) by first 
treating the amide with boron trifluoride etherate. ~e envisaged 
that the oxygen centre of such a complex would be less electron rich 
and therefore less susceptible to attack by diborane. However on 
subsequent treatment with diborane, the alcohol (301) was again 
formed. 
~ 0 
~~~(Me 
H O O 
(286) 
°'~~= H OH 0 
(301) 
~o Me/Y~ CMe 
OH H O 0 
(300) 
(302) 
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Treating the amide (300) with diborane in THF at room temperature 
gave mainly the bicyclic lactam (303). The 18 n.m.r. spectrum of 
this compound (303) was very similar to those of the benzazocinones 
(289) and (290). The mass spectrum showed a molecular ion at m/z 
261. Further treatment of the unsaturated lactam (303) with diborane 
yielded the reduced amine (304) as evidenced by its mass spectrum, 1H 
n.m.r. and IR spectra. The unsaturated bicyclic lactam (303) was 
obtained independently by treatment of the amide (300) with dilute 
aqueous hydrochloric acid. 
V 1/ ~ ~o ~ ~ 
CDµe CDiiV!e 
(303) (304) 
These results showed that the amide functionality could not be 
reduced selectively in the presence of a t3-keto ester using diborane. 
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2.4. Outlook 
There are a number of alternative rout es to overcome the problem 
of the second key bond formation to close the eight-membered 
heterocyclic ring . The keto group in the monoacid (267) could be 
protected, for example, as the dithiane (305) before being coupled 
with the aminophenol (257). Selective reduction of the resulting 
amide (306) with diborane could then be possible. A shorter route, 
not involving protecting groups, would be to employ ~-alkylation 
rather than ~-acylation of the aminophenol (257). In both cases, the 
resulting amine would have to be protected before oxidation of the 
phenol to the quinone needed for the intramolecular Michael addition. 
(305) (306) 
Chapter 3 of this thesis investigates the feasibility of the 
latter of these possibilities and describes its successful 
application to the synthesis of an analogue of the mitomycins. 
CHAPTER 3 
A BIOMIMETIC SYNTHESIS OF AN ANALOGUE OF THE MITOMYCINS 
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3.1. Introduction 
Biosynthetic studies19 ' 65 have identified 3-amino-5-
hydroxybenzoic acid (36) and Q-glucosamine (10) as the primary 
biogenetic precursors of the mitomycin antibio t ics. Three crucial 
bond formations viz., the N-4--C-3 bond, the C-8a--C-9 bond and the 
N-4--C-9a bond, are mandatory in the construction of the framework of 
the mitomycins. In our biomimetic approach to the synthesis of this 
family of antibiotics, the three key bond formations are tested with 
model systems by steps which we consider mimic the overall in vivo 
enzymic processes. 
~)OH x~g OH D HO,,,. OH ,, . ·' + H ~ Me !\ NZ HOiC NH2 
0 
0 
(36) (10) ( I ) 
In our first approach described in the last chapter, the first 
key bond was formed by ~-acylation of the aminophenol (257). 
Attempts to effect the second key bond formation by an intramolecular 
cyclization onto the quinone nucleus in a Michael fashion to form an 
annulated eight-membered intermediate (295) were not successful. It 
was postulated that the quinone (266) might exist mainly in the Z-
form and the Z to E interconversion required for cyclization was not 
0 
~o 
~v~~COz~ 
0 H 0 
Z-(266) 
0 
~~~ 
0 H 0 
E-(266) 
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favourable. It was recognized that ~-alkylation of the 
acylaminoquinone (266) to an ~-substituted acylaminoquinone would 
probably provide the desired (~)-conformer, but the eventual 
cyclization would still require the closur e of a strained eight-
membered lactam and the problem of selectively r educing the amide 
functionality in the presence a 13,-keto ester group still remained. 
An attractive alternative route was to synthesize the corresponding 
quinone (307) where the amide was replaced by a protected alkylamino 
group. 
~ ~~s ~V~ Me OH o H o o I OOiBn 
(257) (295) (307) 
3.2. Synthetic Strategy 
The synthetic strategy is based on the three key bond formations 
as described in Chapter 2 except in this case the aliphatic fragment, 
now an alkylamine rather than an amide, is to be added in two stages, 
first by nucleophilic attack on a 4-bromoester followed by a two 
carbon extension using Masamune's methodology. 144 This avoids the 
problem of intramolecular substitution in a six-carbon s-bromo-13,-keto 
ester. An alternative solution i s to employ a protected 13,-keto ester 
such as the silyl enol ether (308). This would make the synthesis 
(308) 
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more convergent and mimic the biosynthetic route more closely. From 
a synthetic point of view, 4-bromoesters are more readily accessible, 
therefore we chose to investigate the feasibility of the two-stage 
addition of the 6-carbon side chain. 
The proposed synthetic scheme is outlined as below. 
Regioselective ~-alkylation145 • 146 of the aminophenol (257) with 4-
bromobutyrates (309a and 309b) and subsequent protection of the 
amines (310a and 310b) would give the carbamates (311a and 311b) 
(Scheme SO). The benzyloxycarbonyl group was proposed as the 
protecting group147 for the nitrogen in the oxidation step at a later 
+ 
(257) 
Br~ 
CR 
0 
(309a) R = Et 
(309b) R = Bu' 
(311a) R = Et 
(311 b) R aBu' 
(313) 
0 COiM> 0 
~W 
0 COiBn 
(314) 
Scheme 50 
(307) 
(315) 
(312) 
(310a) Ra Et 
(310b) R = Bu' 
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stage of the synthesis. Its electron-withdrawing ability should also 
assist in activating the quinone towards Michael addition in the 
formation of the second key bond. It is also conveniently removed 
under neutral conditions and is resistan t to acidic or basic 
hydrolysis. Another advantage is that simultaneous deprotection and 
reduction to a hydroquinone can be achieved by catalytic 
hydrogenation at the opportune juncture. Extension of the free acid 
(312) to the ~keto ester (313) was thought to be possible by 
sequential treatment with 1,1'-carbonyldiimidazole and magnesium 
di(methoxycarbonylacetate). 144 The key intermediate phenol (313) 
upon oxidation with Fremy's salt would furnish the desired quinone 
(307). The second and third key bond formations entail Michael 
addition of the side chain into the quinone nucleus and transannular 
cyclization respectively (see Chapter 2). 
The feasibility of these reactions was first investigated with 
the readily available ethyl 4-bromobutyrate (309a) and the 
aminophenol (257). 
3.3. Results and Discussion 
3.3.1 . Formation of the First Key Bond 
Treatment of y-butyrolactone with 48% hydrobromic ac i d and 
esterification of the resulting acid gave ethyl 4-bromobutyrate 
(309a) in 99% yield. 1 48 The first key bond formation was tested wi t h 
aniline as a substrate. Regioselective mono-~- alkylation
14 5
'
1 46 
was 
achieved in 91% yield by stirring aniline with ethyl 4-bromobutyrate 
(309a) in HMPA or in DMPU149 in the presence of an excess of sodium 
hydrogen carbonate at room temperature to give the aminoester (316). 
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The aminoester (316) was then treated with benzyl chloroformate and 
pyridine to give the ~-protected ester (317). Selective hydrolysis 
of the ethyl ester with 5% aqueous potassium hydroxide proceeded 
smoothly to give the acid (318) in 88% yield. The hydrolysis was not 
effected with 1% potassium hydroxide in dioxane even after prolonged 
stirring. 
Q I 
~ ~ OE! 
R 0 
(316) R-H 
(317) R • C01Bn 
Q 
~ ~OH 
OJ.iBn o 
(318) 
Using the same reaction conditions, the aminophenol (257) was 
selectively ~-alkylated with ethyl 4-bromobutyrate (309a) to give the 
unstable amine (310a) which was treated with benzyl chloroformate and 
pyridine immediately after removal of solvent. If left standing, the 
amine (310a) decomposed to a black tar. The carbamate (311a) was 
obtained in 80% overall yield from the aminophenol (257). Base 
hydrolysis of the ester (311a) with 5% aqueous potassium hydroxide, 
however, yielded quantitatively the benzoxazolone (319). Under the 
reaction conditions, in addition to saponification of the ethyl 
ester, the phenolic anion generated attacked the carbonyl of the 
benzyloxycarbonyl group, subsequent loss of the benzyloxy entity 
yielding the product (319). Most known benzoxazolones are stable, 
crystalline solids and hydrolysis by acid or alkali to the parent 
aminophenols only occur under drastic conditions (e.g . , heating for 
12 hours with 50% sulfuric acid at 160° C). 150 Hence, no attempt was 
made to ring-open the oxazolone (319). 
¥ OH Me N~ o-{ o 
0 
(319) 
90. 
Since the formation of the phenolic anion was causing problems in 
the basic hydrolysis of the ethyl ester group, a more compatible 
carboxyl protecting group was needed . The preferred 'candidate' 
should be cleaved under mildly acidic conditions in which the N-
benzyloxycarbonyl group would not be affected. 1 47 The !-butyl ester 
(309b) was chosen as a suitable substrate. 
4-Bromobutyric acid was prepared in 98% yield according to the 
procedure of Avison and Morrison. 151 !-Butylation with liquefied 
isobutene, catalyzed by concentrated sulfuric acid, in a Parr 
hydrogenator152 afforded !-butyl 4-bromobutyrate (309b) in 82% yield. 
Mono-~-alkylation of the aminophenol (257) with the !-butyl ester 
(309b) and subsequent protection of the resulting amine (310b) with 
benzyl chloroformate proceeded cleanly to give the carbamate (311b) 
in 80% overall yield. -Selective cleavage of the !-butyl ester with 
40% trifluoroacetic acid in dichloromethane at 0° C gave the acid 
(312) in 92% yield. An attempt to purify this acid (312) by 
distillation instead returned the benzoxazolone (319) quantitatively. 
To avoid the use of ester protecting groups, mono-~-alkylation 
was also examined using 4-bromobutyric acid and aniline as 
substrates. The work-up procedure was complicated due to the high 
water solubility of the product (320), which would be expected to 
exist as a zwitterion. An acid-base partition sequence was used to 
extract the desired product (320) but only low yields were obtained 
(30%-42%). This reaction was not carried out with the aminophenol 
(257) since from the above experience the resulting amine would 
probably be difficult to handle and would have to be protected 
immediately as the carbamate (312). The carbamate (312), however, 
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would probably not survive during work-up due to the facile formation 
of the benzoxazolone (319) under basic conditions. In any case, the 
protection and deprotection of the carboxyl function were simple and 
high yielding steps and the intermediates could be handled more 
easily. Therefore, this alternative route was not pursued. 
Q I 
~ ~OH 
H 0 
(320) 
A different approach to the synthesis of the quinone (321), an 
equivalent of the desired phenolic acid (312), was also investigated. 
The synthetic strategy was based on the displacement of halogen or 
alkoxy substituents on benzoquinones by amines. 153 For this purpose, 
commercially available 4-amino-~~butyric acid (322) and the quinone 
(323) were selected as the substrates (Scheme 51). ~olff-Kishner 
- I -¥ ¥ OHC QM, Mo ~ CMe 
OH OH 
(324) (325) (323) (322) 
t 
0 f; 00 
M, ~
0 H 0 
(321) 
Scheme 51 
reduction of commercial o-vanillin (324) afforded the phenol (325) in 
86% yield. 154 Oxidation with Fremy's salt proceeded smoothly to give 
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the required quinone (323) in 95% yield. The oxidative amination of 
the quinone (323) with the amine (322) was investigated under a 
variety of reaction conditions155 , but no desired product (321) was 
obtained. Under mild conditions (e.g. , stirring in methanol/water), 
starting materials were recovered while under more drastic conditions 
(e.g., refluxing in acetic acid), the t.l.c. showed a complex mixture 
and the reaction was not pursued further. Using ~-butylamine, the 
aminoquinone (326) and the diaminoquinone (327) were obtained in 11% 
and 19% yields respectively, along with 25% of the starting quinone 
(323). Substitution ortho to the olefinic methyl in the two products 
(326) and (327) was evidenced by the disappearance of the allylic 
coupling between the methyl group and the olefinic proton in the 1H 
n.m.r. spectra of both compounds. Since two major problems, namely 
regiospecificity and diamination, were inherent in this synthetic 
route no further effort was made along this line. 
0 
Bulm~ 
~¥Q~ 
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(326) (327) 
A two-carbon extension of the acid (312) to the t3-keto ester 
(313) was studied next. 
3.3.2. Extension of the Side Chain to Form a t>--Keto Ester 
Masamune and coworkers 1 44 reported an elegant method for a one-
pot synthesis of t3-keto esters by sequential treatment of an acid 
with 1,1'-carbonyldiimidazole and the mono magnesium salt of malonic 
acid half ester (Scheme 52). They claimed that the reaction 
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conditions were neutral and suitable for the f-acylation of acid- and 
base-sensitive synthetic intermediates. 156 This procedure was tested 
using acid (318) as a substrate. 
+ 
R-C-Im 
II 
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Methyl hydrogen malonate was prepared by mono-saponification of 
dimethyl malonate with one equivalent of methanolic potassium 
hydroxide. 157 The magnesium salt of methyl hydrogen malonate was 
generated according to Masamune's procedure1 44 by reacting magnesium 
methoxide (one equivalent) with methyl hydrogen malonate (two 
equivalents) in THF. Treating the magnesium chelate thus generated 
with the imidazolide prepared in situ from the acid (318) and 1,1'-
carbonyldiimidazole gave the t>-keto ester (328) in 77% yield. 
Q 
.~ak 
OOiBn O 0 
(328) 
However, treatment of the acid (312) under similar reaction 
conditions as described above did not give the desired t>-keto ester 
(313) in good yield. Different techniques for generating the 
magnesium salt of methyl hydrogen malonate were investigated, 
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including treatment of methyl hydrogen malonate with two equivalents 
of magnesium ethoxide or magnesium methoxide or with two equivalents 
of isopropyl magnesium bromide in THF. 158 - 160 The ethanol or 
methanol generated in the former case was removed prior to acylation. 
1,1'-Carbonyldiimidazole was purified by vacuum sublimation 
immediately before reaction. In spite of considerable modification 
of the reaction conditions, the desired 13-keto ester (313) was always 
contaminated with varying amounts of the benzoxazolone (329) and the 
lactone (330) (present as a mixture of rotamers at the amide bond). 
The formation of the two byproducts arose from intramolecular 
interaction by the phenolic hydroxyl group with the benzyloxycarbonyl 
function and the activated carboxyl group respectively. In 
particular, the formation of the lactone (330) was evidence for the 
generation in situ of the intermediate imidazolide. This reaction 
was not reproducible, the desired 13-keto ester (313) being obtained 
in variable yields, from 29% to 53%, with the maximum yield obtained 
with Masamune's procedure. 144 
¥ I Me N~CMe 
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3.3.3. Formation of the Second Key Bond 
Oxidation of the phenol (313) with Fremy's salt in aqueous buffer 
at pH 6.8 afforded the benzazocinone (314) in 60% yield (Scheme 53). 
Cyclization occurred spontaneously under the oxidation conditions. 
Clearly, an obligatory intermediate in this transformation was the 
quinone (307), the f3-keto ester functionality of which cyclized 
spontaneously onto the quinone nucleus in a Michael fashion, 
subsequent reoxidation of the hydroquinone (331) then giving the 
bicyclic compound (314). 
(313) (307) 
OH COp!e 0 
~W 
OH CDiBn 
~W 
0 CDiBn 
(331) (314) 
Scheme 53 
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The second crucial bond was thus formed by a Michael addition of 
the side chain onto the quinone nucleus. This facile cyclization to 
form the eight-membered heterocyclic ring supports the previous 
proposal (see section 2.3.4.3) that failure to cyclize the 
corresponding acylaminoquinone (266) is due to the conformational 
effects of the amide function. 
This oxidative cyclization reaction has been demonstrated by 
Day161 in a biomimetic approach to the nucleus of the napthalenoid 
ansamycin antibiotics. Oxidation of phenols bearing a heptan-3',5'-
dione substituent (e.g., 332) with Fremy's salt in aqueous buffer at 
pH 6.8 afforded napthoquinones (e.g., 333). 
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3.3.4. Formation of the Third Key Bond 
Catalytic hydrogenation of the quinone (314) in methanol using a 
palladium catalyst, followed by aerial oxidation, gave the 
pyrrolo[l,2-~]indoloquinone (337) in 78% yield (Scheme 54). 
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Reduction to the hydroquinone (331) and subsequent removal of the 
electron-withdrawing benzyloxycarbonyl protecting group to form the 
amine (334) rendered the nitrogen sufficiently nucleophilic to 
cyclize transannularly yielding the tricyclic intermediate (315). 
This represents the successful formation of the third key bond and 
the carbinolamine (315) thus formed carries the C-9a oxygen 
functionality typical of the natural mitomycins. However, not 
unexpectedly, this initial transannulated product (315) or its 
corresponding quinone was not isolable, dehydration occurring to give 
the indoloquinone (337) after reoxidation. The nucleophilic 
character of the nitrogen was probably also responsible for the 
facile loss of the C-9a hydroxyl group, the departure of the hydroxyl 
function at C-9a probably occurring via an iminium ion (335). The 
process is depicted here as occurring at the hydroquinone oxidation 
level, although recent findings by Danishefsky and coworkers 52 and 
Andrews and coworkers 51 indicate that hydroquinone radical anions are 
probably the active species undergoing elimination under reducing 
conditions (see section 1.4). The dehydration process was probably 
promoted by the residual acid in the palladium catalyst. However, 
adding sodium hydrogen carbonate to counteract the acidity slowed 
down the decarbamoylation reaction too much to be of synthetic 
interest. 
This reaction was studied using 1H n.m.r. spectroscopy in an 
attempt to observe the carbinolamine (315) and to confirm the 
mechanism postulated above. The 1H n.m .r . spectrum of the quinone 
(314) in methanol-d
4 
at 200 MHz was recorded. To this solution was 
added 5% palladium on carbon. The system was deoxygenated with 
nitrogen, then hydrogen was bubbled through the system. ijithin 
seconds, the yellow colour of the solution faded completely. 
-
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The 1H n.m.r. spectrum of the hydroquinone (331) was recorded and 
this confirmed that the quinone (314) was no longer present. 
Reduction of the quinone (314) to the hydroquinone (331) was a fast 
process, whereas hydrogenolysis of the benzyloxycarbonyl funct i on was 
very slow and solvent dependent . In acid- free deuteriochloroform, 
the decarbamoylation process was extremely slow, and even after 
sixteen hours, only the hydroquinone (331) was observed. In 
methanol-d
4
, neither the amine (334) nor the carbinolamine (315) was 
observed, only the dehydrated hydroquinone (336) and the hydroquinone 
(331) being identified after one hour. It is known that 
deiminomitomycin is much less stable than the naturally occurring 
mitomycins. 70 b Therefore, the instability of the carbinolamine (315) 
was not unexpected. 
The successful formation of the three key bonds with our model 
system provides a chemical basis for the proposed biosynthetic 
pathway to the mitomycins. That these react i ons have been shown to 
be feas i ble i n vitro lends support to the proposition t hat they form 
the basis of the biosynthetic pathway in vi vo. 
3 .3.5. Further Investigation of the Biosynthetic Hodel 
3 .3.5.1. Synthesis of 2-[~-(Benzyloxycarbonyl)-4-oxo-pentanamino]-6-
methyl-1,4-benzoquinone ( 338) 
Biosynthetic experiments with the label led aminohexose (l- 14 C, 6-
3H)-D-glucosamine resul t ed i n 1. 9% i ncorporat i on in mitomyc i n A (5) 
with a tritium retention of 91%, 1 9 a ' 59 thus suggesting that the 
oxidation level at the C-6 of the aminosugar (10) was unaltered 
during the biosynthesis. This result indicates that a doubly 
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activated methylene group as employed in the biomimetic sequence is 
not necessary for Michael addition to take place in vivo. Ve 
therefore investigated the viability of forming the second key bond 
in quinone (338) where the 13-keto ester is replaced by a terminal 
methyl group which is activated by only one carbonyl group. The 
result of this experiment would also direct us in the design of an 
appropriately functionalized aziridino-substituted aliphatic fragment 
of the type (339) necessary for the synthesis of the complete 
tetracyclic system of the mitomycins. If a singly activated 
methylene is sufficiently reactive, the 13-keto ester functionality or 
its latent form would not be essential i n the design of this 
aliphatic building block (339). 
(338) 
X 
(339) R = CHzOH, coµe 
X=OH, Br 
Z=H,COµe 
--yYa 
0 0 
(343) 
The apparently straightforward synthesis of the quinone (338) 
proved to be unexpectedly troublesome. Based on our previous work, 
the initial approach towards the quinone (338) was by ~-alkylating 
the aminophenol (257) with the bromoketone (340) followed by 
oxidation after protecting the resulting amine (341) as its benzyl 
carbamate (342) (Scheme 55). 5-Bromo-pentan-2-one (340) was obtained 
in 85% yield by the reaction of acetylbutyrolactone (343) with 
f d ,, 162a aqueous 48% hydrobromic acid under phase-trans er con 1t1ons. 
Direct conversion of 5-hydroxy-pentan-2-one with saturated aqueous 
hydrobromic acid did not give the bromoketone (340) in good 
yield. 162 b, c Treatment of the aminophenol (257) with the bromoketone 
100. 
(340) under the conditions employed previously for selective mono-N-
alkylation did not yield the desired amine (341). Only the 
benzoxazoline (344) was isolated in 62% yield. 
~ Me 
Br II 
OH 
(257) (340) 
t 
('1 Mey~~Me 
OH R 0 
(341) R 3 H 
(342) R a C02Bn 
0 
Scheme 55 
-
(344) 
(338) 
Presumably the carbonyl group was electrophilic enough to 
interact with the nucleophilic nitrogen, dehydration then affording 
an iminium intermediate which was attacked by the phenolic hydroxyl 
group to give the benzoxazoline (344). This problem could be 
overcome by protecting either the carbonyl group in the bromoketone 
(340) or the phenolic hydroxy group of the aminophenol (257). The 
ketal (345) was readily prepared by treatment of the bromoketone 
~/Me 
Br - ~ ./'--... 
0 0 
\_J 
( 345) 
(340) with ethylene glycol catalyzed by £-toluenesulfonic acid or 
pyridinium £-toluenesulfonate. 1 63 • 164 Another procedure used to 
prepare this ketal (345) employed ethylene ditriflate and 
trimethylsilyl triflate as acetalizing agent and catalyst 
101. 
respectively. 165 ~-Alkylation folloved by protection of the amino 
group, gave the phenol (346) in 54% yield. The 1,3-dioxolane group 
vas selectively cleaved by transacetalization vith vet acetone 
catalyzed by pyridinium p-toluenesulfonate1 64 to give the phenol 
(347) in quantitative yield . Hovever, oxida tion vith Fremy's salt in 
aqueous conditions 115 at pH 6.8 of either phenol (346) or (347) 
resulted in the decarbamoylated quinone (348) or (349) respectively 
in lov yield (ca. 20%). The reaction vas studied further using the 
ethyl ester (311a) as a substrate. Decarbamoylation also occurred in 
this case yielding a mixture of the quinone (350) and the 
corresponding decarbamoylated quinone (351) in 50% and 19% yields 
Mo 0 N~M< 
~ I o o 
OH COiBn \__j 
( 346 ) 
0 
Morr N~M< V 1 o o 
0 H ~ 
(348) 
(350) 
(347) 
0 
A .. ~v~
0 H 0 
(349) 
(351) 
respectively. As the carbamates (311a) and (347) vere found to be 
stable in aqueous buffer at pH 6.8 even after prolonged stirring at 
-
102. 
room temperature, it therefore appeared that the decarbamoylation had 
occurred at the quinone oxidation level under t he reaction 
conditions. This was supported by a micro experiment by stirring the 
quinone carbamate (350) in aqueous buffer at pH 6.8. 
Decarbamoylation took place and yielded the qui none (351) as 
evidenced by t.l.c. examination. The decarbamoylated quinone (351) 
gave a distinct pink colouration on the t.l.c. plate (Rt 0.63 , ethyl 
acetate/~-hexane/dichloromethane, 4:3:3), whereas the quinone (350) 
was yellow (Rf 0.38). The oxidation of the carbamate (347) with 
Fremy's salt was unduly slow and this probably contributed to the 
undesirable decarbamoylation. In view of the instability of the 
desired product (338) in the aqueous reaction solution, the oxidation 
was carried out using molecular oxygen catalyzed by 
bis(salicylidene)ethylenediiminocobalt (II) (salcomine) in 
methanol. 1 66 However, the rate of oxidation was slow and a mixture 
of products were obtained as determined by t.l.c. examination. This 
problem was finally solved by oxidizing the phenol (347) in a two 
phase system using tricaprylylmethylammonium chloride
1 6 7 
as the phase 
transfer catalyst, affording quinone (338) in 81% yield. 
The second option for the preparation of the quinone (338) was 
also investigated (Scheme 56). Protection of the phenolic hydroxyl 
group was circumvented by oxidizing the aminophenol (257) to the 
quinone (353), thus removing the possibi li ty of reaction a t t he 
phenolic hydroxyl group and achieving the desired final oxidation 
level in the one step. In contrast to the relative ease of the mono-
~-alkylation of the aminophenol (25 7) , t reatment of a solution of the 
highly coloured (dark purple) anion of the quinone (353), generated 
with a strong base (sodium hydride or LTMP), with the bromoketone 
(340) did not yield the desired product (338). It was recognized 
103. 
that the anion formed is highly delocalized and thus is unreactive 
towards alkylating agents. A more reactive alkylating agent, methyl 
iodide, was used but still no alkylated product was isolated. This 
route was not investigated any further since the quinone (338) was 
obtained in reasonable yields by the first rout e as described above. 
(257) 
3.3.5.2. 
(352) 
Br~Me 
0 
(340) 
Scheme 56 
• 
(338) 
Attempts to Cyclize the Keto Quinone (338) 
(353) 
Attempts to cyclize the quinone (338) by generating the anion 
with LOA yielded the reduced product, the hydroquinone (354), 
instead. This was not too surprising as LOA has been known to behave 
as a reducing agent. 168 • 169 For example , benzophenone (355) was 
reduced to benzhydrol (356) even at -78° C in THF. It has been 
proposed that the carbinol hydrogen comes from the LOA either by a 
single step '3-hydride transfer or by an initial one-electron transfer 
followed by transfer of a hydrogen atom. In cases where reduction of 
the carbonyl group occurs in competition with enolization by LOA, 
alternative amide bases such as LHMOS or LTMP 170 are used to avoid 
104. 
the problem. These bases do not bear any ~hydrogens and therefore 
should not effect reduction. Thus, LTMP was used as an alternative 
base for the enolization of the ketone (338). To our surprise, the 
hydroquinone (354) was again obtained (53%) along with the starting 
quinone (338) (7i.). 
( 354) (357) 
(355) (356) 
These results prompted us to investigate the reaction of LTMP 
with other 1,4-benzoquinones. Readily available 2-methoxy-6-methyl-
1,4-benzoquinone (323) (vide supra) and 2,6-dimethyl-1,4-benzoquinone 
(357) were also reduced under the same reaction conditions. Clearly, 
reduction to the corresponding hydroquinone was not peculiar to the 
quinone (338). ~hat remains unclear, however, is how LTMP which has 
no ~hydrogens effects the reduction process. To the best of our 
knowledge, no such reduction of quinones by nitrogen bases has been 
reported in the literature. A possible explanation could be the 
participation of a charge-transfer complex as quinones are known to 
show significant complexing ability with electron donors.
171
•
172 A 
charge-transfer complex could probably be formed initially between 
the quinone and the base followed by an electron-transfer to give the
 
semiquinone anion. A further electron-transfer process or a 
disproportionation of the semiquinone anion could afford the dianion
 
which on quenching forms the hydroquinone. 
105. 
In some cases where the crude reaction mixtures, obtained from 
treatment of the quinone (338) with LTMP, were re-oxidized with 
Fremy's salt, the £-quinone (358) was isolated in 18% to 23% yield. 
Formation of the £-quinone (358) could be explained by oxidation of 
the intermediate benzoxazolone (359), which could be formed from the 
primary product, the hydroquinone (354), by intramolecular 
interaction of the phenolic hydroxyl with the benzyloxycarbonyl 
group. As the para position of benzoxazolone (359) was not 
accessible, an £-quinone was formed. 115 
0 
0~ I Me 
lv!e ":::::,... N~ 
o-{ o 
0 
(358) (359) 
Once the quinone (338) was reduced to the hydroquinone (354), no 
Michael-type reaction could take place even if deprotonation at the 
~-carbon to the carbonyl was efficient . A deuteration experiment 
indicated about 50% deprotonation at the methyl carbonyl side chain. 
The acylaminoquinone (262), on the other hand, did not undergo 
reduction on treatment with LOA or LTMP (see Chapter 2). This cou~d 
be due to ionization at the amide NH, the resulting delocalization of 
electron density into the quinone nucleus then protecting it from 
electron-transfer reactions. 
0 
A 0 lv!ev~Me 
0 H 0 
(262) 
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A number of options to avoid the problem of the undesired 
reduction to the hydroquinone were considered but not carried out. 
Using the quinone monoketal (360) as the quinone equivalent might 
(360) 
eliminate the reduction problem since quinone monoketals are less 
susceptible to electron-transfer processes than the corresponding 
quinones. Moreover, regiochemical control is possible in the Michael 
addition. However, the preparation of this monoketal (360) might 
present some problems. One common route to such monoketals is by 
regioselective hydrolysis of the corresponding bisketals. In this 
case, the wrong regioisomer is expected based on Swenton's work in 
this area. 173 - 175 It has been found that the acetal more distant 
Mt() OMe 
°'~ 
+ 
MeO CM:e 
(361) (363) (364) 
(362) (365) 
Scheme 57 
from the 2-substituent is either selectively or exclusively 
hydrolyzed, as exemplified by the hydrolysis of the bisketals (361) 
[yielding two regioisomers (363) and (364) in 64% and 11% yields 
107. 
respectively] and (362) [yielding only a single isomer (365) in 79% 
yield] (Scheme 57). The other general route to quinone monoketals 
involves oxidation of hydroquinone monoethers with thallium 
trinitrate, DDQ or ferric chloride. This route requires the 
selective methylation of the hydroquinone (354) to give the 
appropriate E-methoxyphenol (366). The point of immediate concern is 
that under the basic reaction conditions normally employed for such 
reactions, ring-closure to the benzoxazolone (367) would probably 
pose a problem. Thus, though the use of monoketal (360) seemed an 
attractive solution to alleviate the reduction problem, this was not 
explored due to its relative inaccessiblity. 
(366) 
CMe 
A Me¥N~Me y 0 
0 
(367) 
An alternative possibility would be to synthesize the 
trimethylsilyl enol ether (368), an intramolecular Michael reaction 
(368) 
(257) 
+ 
Br~ 
Cl.5iMezllu1 
(369) 
of which with the quinone moiety activated by Lewis acid might 
provide a solution to the problem. 17 6 A retroanalysis showed that 
108. 
the bromo enol ether (369) would be required in the synthesis of the 
quinone (368). In view of the number of steps involved and the 
relative unavailability of the enol ether (359), this route was not 
investigated. 
3.4. Isolation of a Structurally Related Antibiotic 
In their screening program for antitumour compounds, Imanaka and 
coworkers 177 isolated a new antibiotic FR-900482 (370) from the 
fermentation broth of Streptomyces sandaensis. FR-900482 was found 
to be a tautomeric equilibrium of the structures I and II. Visual 
dissection of the C-0 skeleton of this compound also leads to the 
same two key biosynthetic intermediates, 3-amino-5-hydroxybenzoic 
acid (36) and ~-glucosamine (10). The oxidation levels of the C-6 
substituent and the A ring are different from the known mitomycins. 
A postulated biosynthetic pathway of this antibiotic is as follows. 
The N-4--C-3 bond could still be formed by a two-step imine formation 
and reduction mechanism. The C-8a--C-9 bond could be formed by a 
radical addition or coupling178 of the aminophenol (36) with the side 
chain. The transannular cyclization to C-9a in this case involves an 
oxygen centre instead of a nucleophilic nitrogen. A possible 
intermediate would be a hydroxylamine which has been shown to be an 
ambident nucleophile in reactions with carbonyl substrates.
179 
Oxidation of the intermediate secondary amine to a hydroxylamine (a 
facile laboratory operation) would provide for such a process. 
H 
OHC OHC 
II 
(370) 
109. 
The isolation of this new antibiotic does not conflict with the 
biogenetic pathway that we have proposed for the mitomycin 
antibiotics. Both FR-900482 (370) and the normal mitomycins could be 
derived from the same biogenetic precursors by minor variations of a 
common pathway. 
3.5. Conclusion and Outlook 
The successful biomimetic synthesis of an analogue of the 
mitomycins which has the pyrrolo[l,2-~]indole skeleton but lacks the 
aziridine ring and the heteroatom substituent at C-7 provides 
chemical evidence for the proposed biosynthetic pathway. Since the 
three key bonds can be formed readily in vitro, we believe that 
similar reactions can reasonably occur in vivo, with, of course, 
enzyme mediation. 
This sequence of reactions also provides an attractive approach 
to the synthesis of the mitomycins themselves. The facile synthesis 
of the mitomycin analogue (337) has been achieved from 2-amino-6-
methylphenol (257) in six steps and 20% overall yield. It was 
V~O.\;le Me N I 
OH COiBn O 0 
(313) (307) 
(314) (315) (337) 
110. 
noteworthy that intramolecular Michael addition of the intermediate 
(307) initially formed upon oxidation of the ~keto ester (313) was 
an extremely efficient process even in aqueous buffer at pH 6.8. The 
third key bond formation by transannular cyclization of the 
benzazocinone (314) has the potential to introduce the C-9a oxygen 
substituent, the most labile functionality in the mitomycins. Though 
the C-9a oxygenated carbinolamine (315) was not isolable due to 
facile dehydration, it has been found that the C-9a oxygen function 
is more stable when the 1,2-aziridine function is present.
70 These 
two key cyclizations proceeded in 50% overall yield. The efficiency 
of this approach could be improved by increasing the yield of the~ 
keto ester (313), the optimum yield at the present being 39% overall 
from the aminophenol (257). It should be possible to prepare the 
mitomycins themselves by this sequence of reactions with suitably 
substituted aromatic and aliphatic fragments. 
This approach has already been extended to the synthesis of the 
7-substituted mitosenes (371) and (372) in this laboratory.
180 
0 OOiMe ~~ 
0 
(371) X. NHAc 
(372) X-OMe 
Introduction of further functionalities present in the natural 
mitomycins into the indoloquinone (337), or its 7-substituted 
analogues (371) and (372) is deemed possible from previous work.
1
'
8
'
9 
The ester function at C-9 could be elaborated into the hydroxymethyl 
carbamate (373) according to the established method for converting 
the ester (101) to the carbamate (60) 81 (see section 1.6 . 2). The 
111. 
incorporation of an aziridine function into such indoloquinones, for 
example the conversion of the indoloquinone (106) to the aziridino 
analogue (107), has been achieved in this laboratory. 82 Since the 
indoloquinone (337) lacks only the C-7 substituent compared to the 
analogue (106), we feel that this procedure could be used to obtain 
the corresponding aziridine (374) without complications. 
0 OliOCONJ½ 0 
~¼ Me NCOiEt 
0 0 
(373) (374) 
0 cnµe 0 MO¼ Md) -
-Me N Me N<l:¥! 
0 0 
(106) (107) 
0 a:J.iEt 
~=-=qS MeO -
' -Me N Me 
0 0 
(101 ) (60) 
For a total synthesis of the mitomycins, the crucial problem of 
re-introducing the C-9a oxygen substituent into sµch indoloquinones 
would have to be addressed. Previous work10 in this area (see 
section 1.6.2) has indicated that this is not a satisfactory route to 
pursue. 
A more attractive option would be the construction of an 
aziridino- carrying analogue of the f3-keto ester (314) , transan:rnlar 
cyclization of which would be expected to have a good chance of 
112. 
proceeding with retention of the resulting C-9a oxygen substituent. 
In the present work, the obligatory C-9a oxygenated intermediate, the 
carbinolamine (315), from transannular cyclization of the ~keto 
ester (334), was not detected due t o facile dehydration . Kishi's 
work70 has indicated that the azir i dinated syst em is more stable. 
Accordingly, we chose to investigate the synthesis of an 
aziridino-substituted aliphatic fragment of the type (339) in order 
to construct the complete mitomycin skeleton by the biomimetic 
approach that we have developed. 
CHAPTER 4 
STUDIES DIRECTED TO~ARDS THE INTRODUCTION OF THE 
AZIRIDINE FUNCTIONALITY 
113. 
4.1. Introduction 
The mitomycins (1) are a class of antibiotics which possess 
potent antitumour and antibacterial activities. 1 Since their 
structures were elucidated 5 a in 1962, many synthetic approaches to 
their tetracyclic framework and that of the closely related 
aziridinomitosenes (375) have been examined. 1 • 8 • 9 • 72 The majority of 
the published routes are concerned with the formation of the 
tricyclic pyrrolo[l,2-~]indole ring system. There has been a more 
limited program for introducing the carbamate function at C-9 and for 
achieving the quinone oxidation level. 71 • 76 
0 0 
( 1 ) (375) 
X=HzN,McO Y =H, Mc 2-H, Mc X= HzN, OMc, Z= H, Mc 
0 O CRiOCONH.i 
MeO 
:qS Me 
0 0 
( 9) (60) 
1 . h' d ' 32181 fth 't . Structure-activity re at1ons 1p stu 1es ' o e mi omyc1ns 
hav~ demonstrated that the 1,2-aziridine function contributes 
significantly to their antitumour activities. For example, the 7-
methoxy-aziridinomitosene (9) possesses potent antibacterial and 
antitumour activities whereas the deaziridino analogue, 7-
methoxymitosene (60), lacks antitumour activity though it retains 
some antibacterial activity. This result has instigated numerous 
114 . 
efforts directed towards the synthesis of aziridinomitosene 
analogues. However, a general solution to the problem of introducing 
an aziridine function to form the complete tetracyclic system of the 
mitomycins has not been realized. 
4.2. Previous Approaches Towards the Incorporation of the 1,2-
Aziridine Function in the Hitomycins 
Introduction of the 1,2-aziridine moiety has been attempted at 
different stages of the synthesis of the mitomycins, for example, at 
the acyclic stage, at the pyrrolidine stage and at the pyrrolo[l,2-
~]indole stage. This section reviews the various approaches in this 
area. 
Remers and coworkers 182 were the first group to attempt 
aziridination on a pyrrolo[l,2-~]indole system. Although this goal 
was not achieved, their studies provided some insight into the 
reactivity of the pyrrolo[l,2-~]indole system. Starting from the 1-
ketopyrroloindole (376), Remers ~ al. proposed to generate a nitrene 
type intermediate at C-1 for insertion at C-2 to give an intermediate 
azirine (377) which could then be reduced to an aziridine (378) 
(Scheme 58). Treatment of the oxime tosylate (379), derived from the 
1-ketopyrroloindole (376), with sodium ethoxide did not yield any of 
the desired aziridine (378). An alternative nitrene precursor, the 
azide (380), was sought but it could not be synthesized from the 
hydrazine (381) under various reaction conditions. 
115. 
·~-cxtr ,P' I ' NOTs ·~v=o ,t_ • ~ I ; ~N ~ N 1, 
(379) (377) 
\ t 
·~~ ,P' I ' o ·~~ I ' ~ N ~ N NH 
(376) (378) 
j + M-cxtr : I ' NNHz ·~-cxtr 't. • ,P' I ' N3 1, 
~ N 
(381) (380) 
Scheme 58 
A different approach based on the Venker aziridine synthesis
183 
was also investigated182 (Scheme 59). Reduction of the 2-bromo-1-
ketopyrroloindole (382) with sodium borohydride afforded the 
bromohydrin (383). Azide displacement followed by catalytic 
reduction of the resulting hydroxy azide yielded the amino-alcohol 
(384). The 1-hydroxyl function could not be converted into a 
suitable leaving group and all attempts to convert the 2-amino-1-
hydroxy system to an aziridine (385) f a iled. Catalytic reduction of 
the acetoxy oxime (386) resulted in the formation of the cis-
acetamido alcohol (387) and the oxazoline (388) instead of the 
desired alternate l-amino-2-hydroxy system (389). An attempt to 
invert the configuration at C-2 by treating the alcohol (387) with 
thionyl chlorid€ failed to give the desired trans-acetamido chloride 
(390). 
~ I ' o BoO-cxtc 
::::,,,,_ N 
Br 
(382) 
I ' '.,,,OH BoO~ 
::::,,,,_ N 
l NHz 
(384) 
I ' .,,,OH Bl1)u=a 
::::,,,,_ N 
.• , , Br 
(383) 
)( • BoOYY\-__ 
~N~~ 
(385) 
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BoO-o=a:1 \ Nlii 
::::,,,,_ N 
.,,,QAc 
(389) 
(387) 
t 
BoO~NHAc 
~N0·•,,a 
(390) 
Scheme 59 
(388) 
The approach reported by Franck's group184 was based on dipolar 
cycloaddition of azides as a means to functionalize the 1,2-double 
bond of the indole lactam (393) (Scheme 60). The pyrroloindole (393) 
was obtained from the 9~-pyrrolo[l,2-~]indole (391) by alkylation at 
C-9 followed by singlet oxygen oxidation of the intermediate (392). 
Regiospecific addition of benzyl azide gave the triazole (394) whi ch 
on photolysis eliminated nitrogen to furnish the aziridine (395). 
This aziridination sequence only afforded about 3% yield with 4% 
conversion. 
117. 
[ cr.;00] o:500• 0:0 nBuLi to, a ...__,,,OBn I -= ~
0 
(391 ) (392) (393) 
Bn 
I 
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Scheme 60 
Hirata and coworkers 185 developed a route to the 
aziridinomitosene (401) using i odoazide chemistry (Scheme 61). The 
60-90% 
Me 
(396) 
Me 
___ =Y"y{_co,¼ 
60-80% Me~< .. J 
(399) R m NH2 • HCI (400) R a NH2 (404) R a NHCO2Me 
(397) 
no yields given 
(402) (403) 
Scheme 61 
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key 3g-pyrroloindole (397) was prepared by carboxylation of the anion 
derived from the 9g-pyrrolo[l,2-~]indole (396). Regiospecific 
addition of iodine azide to the 1,2-double bond gave the trans-
iodoazide (398) which on catalytic hydrogenation in the presence of 
hydrogen chloride afforded the iodo-amine hydrochloride (399). 
Treatment of the amine (400) or its hydrochloride (399) with sodium 
methoxide followed by methyl chloroformate afforded a mixture of the 
~-methoxycarbonyl-aziridinopyrrolo[l,2-~]indole (401) and the 
carbamates (402) and (403) (no yields given). When the amine (400) 
was protected as its carbamate (404) before treatment with sodium 
methoxide, the oxazoline (405) was produced instead. 
In their synthesis of the aziridinomitosene (150) (see section 
1.6.2), Rapoport and coworkers 90 incorporated the aziridine function 
on an acyclic precursor. The synthetic strategy entailed cyclization 
of a trans-l-activated-2-amino system. Their earlier attempts to 
effect aziridine ring closure on a tricyclic indoloquinone nucleus 
and on monocyclic derivatives were not successful. Epoxidation of 
the Q-vinylglycine derivative (406) gave a 4:1 ratio of the syn- and 
anti-epoxides (407) (Scheme 62). Treatment of the syn-epoxide (407) 
with methanolic hydrochloric acid afforded the ring-opened 
chlorohydrin (408). Hydrogenolysis followed by reductive N-
alkylation of the resulting amine afforded the syn-~-
benzylchlorohydrin (409). Carbamoylation and subsequent azide 
displacement of the chloride (410) yielded the azidoalcohol (411). 
Activation of the hydroxyl group as the mesylate (412) followed by 
removal of the i-butyl carbamate and refluxing the resulting 
secondary amine with diisopropylethylamine in acetonitrile gave the 
aziridine (413) [9 steps and about 15% yield from (406)). A two-
carbon extension to the ~keto ester (414) followed by reductive ring 
119. 
closure afforded the bicyclic aziridino pyrrolidine (415). 
Subsequent reduction yielded the aziridino homoproline (146) as a 
mixture of diastereomers. 
(150) 
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Scheme 62 
In Kishi's 70 total synthesis of racemic mitomycins (see section 
1.6.1), the aziridine function was introduced into the side chain 
before cyclization to form a benzazocinone. A double bond was 
Me 
OBn 
(42) 
Me 
(45a) 
Me 
MeO 
+ 
Me 
OBn 
(43) R - CN 
(44) R • °"½Ac 
(45b) 
(1: 1 mixture of diastereomeric diols) 
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introduced in conjugation with the cyano group using a selenoxide 
elimination method by treatment of the nitrile (42) with lithium 
diethylamide and phenylselenium bromide followed by hydrogen 
peroxide. The double bond was converted into an aziridine function 
in eight steps in about 30% yield. cis-Hydroxylation of the olefin 
(44) with osmium tetroxide yielded a 1:1 mixture of the 
diastereomeric diols (45a) and (45b). The transformations from the 
diol (45a) to an aziridine (421) are summarized in Scheme 63 where 
only the relevant portion of the molecule is depicted. 
Regioselective monomesylation of the diol (45a) at C-2 followed by 
treatment of the resulting mesylate (416) with sodium hydride gave an 
epoxide (417). Regiospecific opening of the epoxide with lithium 
azide yielded an azidohydrin (418) which upon mesylation afforded the 
mesylate (419). Reduction of the azido group with trimethylphosphite 
followed by treatment with sodium hydride gave an ~-phosphoryl-
aziridine (420) which was reduced with lithium aluminium hydride to 
give an aziridine (421). 
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~):OH 0: ~) ~):~ ''O ··'' ~ OH ~ ~ l 
(45a) (416) (417) (418) R =H (419) R =Ms 
~YN-P(OMe}i 
II 
~ 0 
(420) (421) 
Scheme 63 
Danishefsky ' s approach105 towards the introduction of the 
aziridine ring into the tricyclic olefin (227a) was similar to 
Kishi's 70 (Scheme 64). Stereospecific hydroxylation of the olef in 
(227a) with osmium tetroxide yielded the cis-diol (422). 
Monomesylation followed by displacement of the resulting mesylate 
(423) with tetra-~-butylammonium azide yielded the azidohydrin (424). 
The 1-hydroxyl group was mesylated and reduction of the resulting 
azidomesylate (425) with trimethylphosphite followed by treatment 
with sodium hydride gave the ~-phosphorylaziridine (426). Reduction 
with lithium aluminium hydride afforded the aziridine (427) [about 
27% overall yield from the olefin (227a)]. 
MeO 
Me 
OMe 
(227a) 
MeO 
Me 
CMc 
(424) R1 • H, R2 -N3 
(425) R1 a S02Mc, R2 • N3 
Scheme 64 
MeO 
Me 
MeO 
Me 
CMc 
(422) R - H 
(423) R. S02Me 
CMc 
NR 
(426) R- P(O)(OMc)z 
(427) R • H 
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The incorporation of an aziridine function onto the indoloquinone 
(106) has been achieved in this laboratory82 using selenium 
methodology and nitrene addition chemistry (Scheme 65). Treatment of 
0 OH 
% % MeO M,O \ \ Me Me 
0 CM)M 
(106) (428) 
OH 0 
MeO MeO 
SePh SePh 
M.e Me 
CMCM 0 
(429) l j (433) 
OH 0 % M.eO ~ M,O \ \ M.e Me 
CM)M 0 
(430) (434) 
j Nco,ia 
(431) t 
OH 0 COiMe CCliJ¼o 
MeO ¼O 
M.e NCOiEt Me NCOiEt 
CMCM 0 
(432) (107) 
Scheme 65 
the mono-protected hydroquinone ( 428) , deri ved from the indoloquinone 
(106), with lithium diethylamide and phenylselenyl chloride followed 
by oxidation of the resulting selenide (429) with ~-chloroperbenzoic 
acid furnished the 1,2-unsaturated hydroquinone (430). Addition of 
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carbethoxynitrene (431), generated by ~-elimination of E-
nitrobenzenesulfonoxycarbamate under phase transfer conditions, onto 
the 1,2-double bond gave a 27% yield of the desired aziridine (432) 
in one step from the olefin (430). Oxidative removal of the 
methoxymethylene ether with manganese dioxide afforded the 
aziridinomitosene (107). Attempts at direct introduction of an 
aziridine function to the 1,2-unsaturated quinone (434) resulted in 
failure. 
Thus, from the foregoing, the most attractive route towards the 
introduction of the 1,2-aziridine function into the mitomycin 
skeleton is the one-step nitrene addition developed in this 
laboratory. Kishi's and Danishefsky's aziridination procedures 
afforded comparable yields but in a multi-step sequence. 
4.3. Extension of the Biomimetic Approach to the Tetracyclic System 
of the Hitomycins 
Elaboration of the biomimetic approach developed by us to a total 
synthesis of the mitomycins would require the incorporation of an 
aziridine function. For a convergent synthesis, ideally the 
aziridine function or its equivalent should be incorporated in the 
aliphatic fragment before the first key bond formation. This leads 
to an aziridino aliphatic fragment such as (435). The chirality of 
the aziridine would be used to induce chirality at C-9a. The common 
mitomycins [mitomycins A (5), B (6), C (2) and porfiromycin (3)] have 
a 1S, 2S, 9aR configuration, and all but mitomycin B (6) have the 9S 
configuration. Kishi's work70 on the closely related benzazocinone 
(436) indicated that the desired relative stereochemistry at C-1, C-9 
and C-9a positions was produced on cyclization to the mitosane 
derivative (437). He proposed that the preferred conformation of the 
124. 
OH 
~: Me() Me 
Br 0 
(435) Z-H, CO2& (436) 
0 
X 
X 
0 
0 (437) X=OMe, Y=Z=Me 
(439) X = H, OMe, Nrfi, Y - H, (438) X=H,OMe,~ Z-H, COiEt Z-H, CO2.Et 
benzazocinone (436) vas I, due to stabilization by intramolecular 
hydrogen bonding, transannular cyclization via the derived oxonium 
ion vould then yield the correct stereochemistry at the four 
contiguous carbons (Figure 11). Analogously, transannular 
cyclization of the anticipated benzazocinone (438), after reduction 
of the ester and the quinone groups and deprotection of the amino 
function, should yield the desired mitosane derivative (439) upon 
reoxidation. 
H 
II 
Figure 11 
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4.3.1. Synthe tic Strategy 
The synthesis of the aliphatic six-carbon fragment is a task beth 
challenging and formidable. The complications anticipated arise from 
the dense array of highly labile groups, namely a ~keto ester 
moi e ty, an aziridine and a leaving group, all present in a compact 
molecule. Several approaches to to this problem were conceived, the 
route with the most potential being direct nitrene addition onto a 
double bond of a furanoid system. 
~e proposed to carry the ~keto ester moiety through the 
synthesis in a latent form, that is, as a substituted dihydrofuranoid 
ring. The aziridine function was to be fashioned from an endocyclic 
double bond ensuring stereospecific nitrene insertion. 
Retrosynthetic analysis led to the following synthetic strategies 
using the commercially available furan or the furanone (440) as a 
template for introducing the appropriate structural moieties. 
~o 
(440) 
The proposed approach starting from furan is outlined in Scheme 
66. Metallation of furan followed by alkylation with the 
bromoacetate (441) should furnish the necessary 6-carbon skeleton 
'masked' as the furylacetate (442). The transformation of the furan 
derivative (442) to the corresponding dihydrofuran (443) (a mixture 
of cis- and trans-isomers) has been achieved electrochemically. 186 
The stereochemistry of the dihydrofuran (443) is of no consequence 
since they would give rise to the same ~keto ester on ring-opening. 
Nitrene addition onto the double bond should give the bicyclic 
aziridino compound (444). The ~keto ester moiety could be 
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'unmasked' by mild acid hydrolysis. 187 ' 188 Two questions which are 
pertinent to this step are the stability of the aziridine ring under 
the reactioo conditions 26 and whether the resulting ~keto ester 
exists mainly in the open-chain form (445) or the ring-closed forms 
(446) and (447). The ~keto ester would have to be protected, for 
example, as the enol ether (448) to avoid a possible internal 
cyclization before the transformation of the aldehyde function to a 
leaving group such as the bromide (449). 
0 0 
(443) 
<XliEl 
I 
N 
Br'-../ <l:liM.e 
(441) 
:~i& 
(431) 
H~O¥fu 
0 0 
(445) 
Scheme 66 
<l:liEl 
I 
N 
(442) 
A rniOOiMc 
Md:)AOXCMe 
ffiiE.t 
I 
(444) 
(447) 
~~--
Br CM.e 
(449) 
127. 
Starting with the furanone (440) has the added advantage that it 
is at the correct oxidation level (Scheme 67). Direct nitrene 
addition would give the aziridino compound (450). The addition of a 
two-carbon piece would be necessary to furnish the required six-
carbon skeleton. The ~keto ester (452), from ring-opening of the 
intermediate (451), would again have to be protected before 
transformation of the alcohol function to a leaving group. 
~o 
(440) 
(452) 
:~i& 
(431) 
(450) (451) 
Br OMe 
(449) 
Scheme 67 
A multi-step sequence akin to Kishi's and Danishefsky's 
procedures for converting a double bond into an aziridine function 
was also considered as an alternative but it was recognized that such 
a sequence could not compete with a one-step aziridination if the 
latter should work. 
4.4. Results and Discussion 
4.4.1. Synthesis of methyl 2-(2,5-dihydro-2,5-dimethoxy)furyl-
acetate (443) 
Attempts to prepare methyl 2-furylacetate (442) directly by 
reaction of 2-lithiofuran189 and methyl bromoacetate (441) resulted 
in intractable tars. This could be due to a number of reasons. 
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2-Lithiofuran could have reacted with the ester functionality of the 
bromoacetate (441) to produce a highly activated tertiary alcohol 
which when exposed to air become oxidized to black resins . 190 
Alternatively, the anion of the furylaceta t e (442) could have been 
formed and reacted further to give polymeric materials. 
A more traditional approach to the acetate (442) was considered 
(Scheme 68). By standard procedures, hydrolysis of 2-furylaceto-
nitrile (453) should give 2-furylacetic acid (454) which could then 
be converted into methyl 2-furylacetate (442) by methylation with 
diazomethane. Furfuryl alcohol was converted into furfuryl chloride 
with thionyl chloride in pyridine in 60% yield by a literature 
procedure. 191 Amstutz and Sherman192 reported the preparation of 2-
furylacetonitrile (453) by treating furfuryl chloride with sodium 
cyanide in ~.~-dimethylformamide in good yield without any 
appreciable rearrangement to 5-methyl- 2-furonitrile (455), the major 
d . . t , 19 0a pro uct in previous prepara ions. However, this sequence of 
reaction was not carried through as a more direct route to methyl 2-
furylacetate (442) became available. 
°'~OH °'~a Q + 0 CHzCN ~~CN (453) (455) 
l 
Q 
0 ~COiR 
(454) R-H 
(442) R-Me 
Scheme 68 
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A survey of literature revealed that Eastwood and coworkers 193 
have synthesized the acid (454) in 40% yield from furfural, glyoxal 
bisulfite and sodium cyanide in aqueous sodium carbonate. The 
proposed mechanism of the reaction involved a ketene intermediate 
(458) (Scheme 69). It was proposed that glyoxal bisulfite first 
reacted with cyanide ion to give the glyoxal cyanohydrin (456). A 
mixed acyloin condensation with furfural gave the intermediate (457) 
which then suffered nucleophilic attack with concomitant loss of the 
secondary hydroxyl group to form the ketene (458). This ketene (458) 
could then be trapped by nucleophiles, hydroxide ion in this case, 
forming the acid (454). 
A · A · 
I I 
H-C-C-H 
I I 
OH OH 
+ 
0 0 H 
II 11 1 n 
H-C-C-C~~_) 
_) '-..J I ---.. o 
B· OH l 
O> OH H 
b~b ~ 
I I 110a? 
H CN o, 
0 OH H 
II It 1-0\\ H-C-C-C ~ 
{ I I o CN o· 
(456) (457) 
f)--CH=C=O 
(458) (454) 
Scheme 69 
The postulated ketene intermediate (458) raised the possibility 
of introducing methanol into the reaction mixture as a nucleophile. 
Accordingly, the reaction was repeated with methanol /water (1:1 
mixture) as a solvent medium, affording methyl 2-furylacetate (44 2) 
directly in 77% yield. 
Electrochemical methoxylation of methyl 2-furylacetate (442) in 
methanol at -50° C according to Janda et al. 186 b yielded the desired 
2,5-dihydro-2,5-dimethoxyfuran derivative (443) (as a mixture of cis 
and trans isomers) in 40% yield. The 1 H n.m.r. spectrum of this 
I 
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product agrees with the literature data. 186 b The yield was improved 
to 66% when the reaction was carried out using lithium perchlorate 
and sodium acetate as the electrolyte under anhydrous conditions. 
The 2 , 5-dihydrofuran (443) upon distillat ion (135°-140° C/20 mm) 
eliminated methanol to give the stereoisomeric dienes (459) and (460) 
(9:1) which were separable by flash column chromatography. 
J\ ,,,,COiMe 
MeOA~ 
(459) (460) 
Assignment of the isomers was based on their spectral properties. 
The mass spectra of both compounds showed molecular ions at m/z 170. 
The IR spectra showed strong absorption bands at 1712 cm- 1 indicative 
of conjugated unsaturated ester functions. The UV spectra showed 
absorption bands at A 278 nm. The 1 H n .m.r. spectra of the 
ma x 
isomers differed from each other , notably at the vinylic region 
(Figure 12). The exocyclic double bond of the isomer (459) was 
assigned the §-configuration on the basis that they proton was 
deshielded by the carbonyl group and as a result its absorption was 
shifted by 0.9 ppm downfield in the 1 H n.m.r. spectrum. It has been 
noted that in diene esters, large paramagnetic shifts to lower field 
are observed for y protons. 19 4 These isomeric dienes (459) and (460) 
are synthetic equivalents of the dihydrofuran (443). With the 
dihydrofuran (443) and the major E-diene (459) in hand, we examined 
the aziridination of the double bond via nitrene addition. 
Figure 12a 1H n.m.r. spectrum of methyl (E) - 5- methoxy- 2,5-
dihydrofuran- 2- ylideneacetate (459) in CDC1 3 
' l 
~COiM! 
MeO 0 
(459) 
=, H 
H3 
H-4 
b. ~ I 
8 7 6 5 4 
C02Me 
OMe 
....... ....L ....L 
3 
...l..__.,__. 
2 
....L ,.J 
0 
Figure 12b 1H n.m.r. spectrum of methyl (Z) - 5- methoxy- 2,5-
dihydrofuran- 2- ylideneacetate (460) in CDC1 3 
._L 
8 
~~ .. Me() 0 
I 
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4.4.2. Single-step Aziridioation 
4.4.2.1. via Nitrene Addition 
At the outset, we had hoped for direct formation of an aziridine 
function by the addition of nitrenes to a double bond. Initially, 
only nitrenes bearing a group which could be easily removed at a 
later stage of the synthesis were considered. Carbethoxynitrene 
(431) was proposed to be a suitable nitrene to use. 
Carbalkoxynitrenes have been generated by photochemical, thermal 
and ~-elimination routes. Loreta and coworkers 195 found that the~-
elimination route was the method of choice for a clean addition of 
carbethoxynitrene (431) to the double bond of allylic ethers. Also, 
success in this laboratory (vide supra) justified an attempt using 
this method. 
N02-o-S~-NHCOiEt 
(461) 
Ethyl £-nitrobenzenesulfonoxycarbamate (461) was prepared from N-
hydroxyurethane and E-nitrobenzenesulfonyl chloride according to the 
method described by Lwowski and Maricich. 196 The base decomposition 
of the carbamate (461) in an organic-aqueous sodium hydrogen 
carbonate two-phase system in the presence of triethylbenzylammonium 
chloride and the olefin (443) did not yield any of the desired 
aziridine, and only starting material was recovered (87%). A similar 
result was obtained from the homogeneous ~-elimination of the 
carbamate (461) with triethylamine. Rigorotls exclusion of oxygen 
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from the reaction mixture did not improve the situation. The 
byproducts of these reactions were not isolated . Among the known 
byproducts of the nitrene reaction by the ~-elimination route are 
ethyl carbamate (462) and diethyl hydrazad iformate (463) which arose 
from hydrogen abstraction and radical combinat ion reactions. 
Reacting the carbethoxynitrene (431) generated under both 
homogeneous and heterogeneous reaction conditions with cyclohexene 
gave the desired nitrene addition product, 7-carbethoxy-7-
azabicyclo[4.1.0]heptane (464) in 32% and 37% yields respectively. 197 
Thus it appeared that the nitrene (431) was generated under the 
reaction conditions but was not reacting with the olefin (443). 
(464) (465) 
co.a 
I 
~ MeO O COzM.c 
(466) 
Treatment of the ~-diene (459) with carbethoxynitrene (431) 
generated under phase transfer conditions resulted in addition to 
each double bond affording the aziridines (465) and (466) in 6% and 
3% yields, respectively, along with starting material (8%). Similar 
treatment under homogeneous reaction conditions did not yield any of 
the aziridines. 2(5~)-Furanone (440) also failed to give any 
aziridino products under similar reaction conditions, starting 
material being recovered in good yields. 
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Next, we turned our attention to the azido route for the 
generati on of the carbethoxynitrene species. The thermal and 
pho t ochemical reactions of ethyl azidoformate (467) with acyclic and 
monocyclic alkenes are well documented. 198 The reaction can be 
followed by the disappearance of the character ist ic azide peak (v 
max 
2170 cm- 1 ) in the IR spectrum of the azidoformate (467). In the 
absence of a reaction partner, the azide byproducts, the azo ester 
(468) and triethyl nitrilotriformate (469) have been isolated. The 
latter (469) arises from attack of nitrene on the azo ester (468), 
which in turn arises from reaction of the nitrene (431) with the 
starting material (467). 
(467) (468) 
N(COiEt)J 
(469) 
The photochemical reaction was carried out under various 
conditions (variations in reaction time, concentration and source of 
radiation) with the substrates (443), (440) and (459). The reaction 
was monitored by the disappearance of the azide peak in the IR 
spectra taken at regular intervals. The results from these 
experiments indicated that the dihydrofuran (443) was unreactive 
towards carbethoxynitrene (431) generated by photolysis. The IR 
spectra showed that the azide (467) was being consumed. However , 
starting material was recovered when the reaction time was relati vely 
short whereas longer irradiation periods yielded the isomeric dienes 
(459) and (460) in addition to starting material. The ~-diene (459), 
on the other hand, competed with the azide (467) for absorption of 
the incident radiation lying within the region of its absorption 
spectrum [(467), A 253 nm; (459), Amax 278 nm] when irradiated 
max 
I 
I 
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with a medium pressure mercury lamp. Irradiation of the E-isomer 
(459) and the azide (467) resulted in isomerization of the E-isomer 
(459) to yield a photost3tionary state having over 90% of the Z-
isomer (460), thus reflecting the higher absorptivity of the ~-isomer 
(E 12000) than the Z-isomer (E 6800). The az ide (467) was not 
consumed in this reaction. 2(5~)-Furanone (440) was also unreactive 
under the reaction conditions. 
Aziridination via thermal decomposition of ethyl azidoformate 
(467) was examined next. Ethyl azidoformate and the dihydrofuran 
(443) were thermolyzed in a sealed tube at 100° C for 16 hours. Only 
starting material and the isomeric dienes (459) and (460) were 
obtained. Similarly, refluxing the olefin (443) and ethyl 
azidoformate (467) in benzene only returned starting material. The 
1H n.m.r. spectra of the crude reaction mixture from both reactions 
showed the presence of azide byproducts. 
From the above experiments, it appeared that the dihydrofuran 
(443), 2(5~)-furanone (440) and the diene (459) were not sufficiently 
reactive for nitrene addition, and reaction of the last substrate 
(459) was complicated by a competing isomerization reaction in the 
photolyses. The double bond in the dihydrofuran (443) and the~-
diene (459) were deactivated due to the presence of the allylic 
oxygen centres. In the former substrate, steric hindrance around t he 
double bond probably also played a role in its unreactivity. In the 
furanone (440), the double bond too was deacti vated due to the 
electron-withdrawing lactone function. It was thought that the 
relatively electron poor substrates were probably not suitable for 
this addition mode with the electrophilic acyl nitrene (431). 198 
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Rees and coworkers 200 observed that aminonitrenes derived from 
certain ~-amino heterocycles react with electron- poor as well as 
electron-rich alkenes. The ambiphilic character of the aminonitrenes 
was ascribed to the resonance hybrids shown in Figure 13. In terms 
'----N-N : 
/ < 
Figure 13 
> '-,._ -j-_ -N=N / 
of the more recent frontier orbital theory 2 0 1 , parallel approach of 
the ambiphilic nitrene adds to electron-rich and electron-deficient 
alkenes using HOMO k - LUMO . or HOMO . - LUMOalken· as al ene nit rene ni trene Q 
the dominant interacting frontier orbitals 202 (Figure 14). 
,., 
,, ' 
-c · ~ I C-
., 
HOMO 
LUMO 
Figure 14 
Though the problem of removal of the heterocyclic group from the 
derived aziridines has not been resolved , 2 03 t he s~ccess of this 
class of reagents in the lit e r a t ure 204 promp t ed us t o inves t igate t he 
reaction of the phthalimidonit rene (470) with the subs t rates (440 ) , 
(443) and (459). ~-Aminophthalimide (471) was r eadily prepared 
following a literature procedure 2 0 4 by condensation of hydrazine 
hydrate and phthalimide. The phthalihydrazide (472) was obtained as 
a byproduct. Oxidation of ~-aminophthalimide (471) using lead 
tetraacetate as the oxidizing agent in dichloromethane in the 
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presence of the substrates (440), (443), and (459) did not yield any 
aziridino products, starting materials being recovered in all cases. 
0 0 0 CQ . Uj-~, o¢~ N-N : ~ 
0 0 0 
(470) (471 ) (472) 
It has been shown 2 05 that the carbomethoxy substituent on the 
alkene (473) prefers a syn-relationship to the phthalimide ring in 
the phthalimidonitrene (470) in the transition state for nitrene 
addition. This leads to the formation below -10° C of a kinetically 
favoured product (474) rather than the thermodynamically favoured 
product (475) formed above 0° C (Scheme 70). A phenyl substituent 
"-c0iMe 
(473) 
>~ 
H 
Pbthal/NV'<:OiMe 
(474) 
(475) 
Scheme 70 
0 
Phthal»-N~ 
0 
shows a similar propensi ty for a syn-rela tionship t o the heterocyclic 
ring in the kinetically formed produc t . 2 0 6 The aminonitrene (470) 
adds to styrene at temperatures below -20° C t o gi ve the syn-
substituted aziridine (476) (Scheme 71). On warming to 0° C, 
complete conversion t o the more stable product (477) occurs. 
Phthal Ph 
Ph <-20o "N~ H 
~ "'-./ .... 
(476) 
Scheme 71 
> (jJ 
Ph 
Phthal/N~H 
(477) 
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0 
Phthal--N~ 
0 
In accord with the assumption of the transition geometry as shown 
in Figure 14, an s-cis conformation of the substituent (phenyl, 
carbomethoxy) on the alkene has its n electrons positioned to overlap 
favourably with the E-orbital in the phthalimide ring adjacent to the 
nitrogen of the nitrene (Figure 15), 206 leading to the observed 
products. 
~ith a few exceptions, nitrene addition to alkenes whose 
U.JMO 
IDMO 
Figure 15 
substituents have orbitals that can overlap with the aminonitrene 
(470) give higher yields. Z-Penta-1,3-diene (478), in which the 
concentration of the s-cis configuration is negligible, fails to 
react with phthalimidonitrene (470) under conditions where isoprene 
reacts normally. 207 • 208 Thus, it appears that the ~-cis conformation 
favours aminonitrene addition. 
C 
~-~-(478) 
~-~(478) 
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Clearly, the preferred s-cis configuration could not be achieved 
in the §-diene (459) or the furanone (440), which could explain why 
both substrates failed to react with the aminonitrene (470). The 
dihydrofuran (443) has no substituent that can overlap with the E-
orbital in the heterocycle adjacent to N-1 of the nitrene (470) and 
therefore would be expected to be relatively unreactive towards the 
nitrene (470). 
4.4.2.2. via Triazolines 
In principle, this approach is an indirect nitrene addition in 
that cycloaddition first results in a triazoline and subsequent 
expulsion of nitrogen produces the desired aziridine 209 (Scheme 72). 
X >N-R 
Scheme 72 
A possible reagent to use is trimethylsilyl azide. 210 It has been 
shown that trimethylsilyl azide undergoes 1,3-dipolar cycloaddition 
to alkenes yielding 1-trimethylsilyl-62-1,2,3-triazoles which lose 
nitrogen on heating at a higher tem perature or on photolysis t o gi ve 
aziridines. The trimethylsilyl function, where retained, is very 
easily removed by water or dilute acid. 210 Addition is thought to be 
favoured by alkene angle strain and conjugation though the examples 
cited in the literature are limited. Since trimethylsilyl azide is 
commercially available and can be handled easily, we attempted the 
reaction with the substrates (440), (443) and (459) according to the 
literature procedure. 210 However, only starting materials were 
recovered and this avenue was not pursued further. 
4.4.2.3. via Sulfilimines 
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Furukawa and coworkers 211 ' 212 reported the Michael-type addition 
reaction of free diphenylsulfilimine (479) to electrophilic alkenes 
yielding the corresponding aziridines (Scheme 73). The mechanism 
appears to involve nucleophilic attack by nitrogen followed by 
nucleophilic displacement of a 13-carbanion centre on the amine 
nitrogen with concomitant loss of diphenylsulfide. 
Ph-S-Ph >=< II + 
N 
H 
(479) 
[ Ph-l-Ph l HN) )1-1( 
Scheme 73 
H 
N 
~ + PhSPh 
Treatment of the sulfilimine (479) with the ~-diene (459) yielded 
the 1,6-addition product (480) instead (70% , as a single 
diastereomer). The extensive delocalization of the carbanion 
probably stabilized the intermediate which on protonation resulted in 
the adduct (480). Analogous addition reactions have also been 
observed with olefins bear ing a strong electron-withdrawing 
substituent. 21 1 No reaction was observed wit h 2( SH) - fu r anone (440) 
as a substrate, only starting material being recovered even af t er 
1 d h , 21 3 pro onge eating. ~.~-Diphenyl - ~- e t hoxycarbonylsulfilimine 
(481) 214 failed to reac t wit h either subst r ate, possibly a result of 
the decreased nucleophilicity of the nitrogen due to the electron-
withdrawing carbethoxy substituent. 
I: 
4.4.3. 
Ph-S-Ph 
II 
N 
h COiMe Wd)A~ 
(480) 
Multi-step Aziridination 
+ 
Ph-S-Ph 
I 
N-
I 
c~ 
(481) 
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Having failed to achieve a one-step aziridination, we directed 
our investigations towards multi-step aziridination procedures. 
4.4.3.1. via Iodoazides 
Hassner 215 has described the use of iodoazides in the preparation 
of aziridines. Stereospecific addi t ion of iodine azide to an olefin 
via an iodonium intermediate yields the trans-addition product. 
Reductive cyclization , involving an inversion , yields the az i ridine 
with ci s -geome try (Scheme 74) . Several reducing agents, namely 
+ 
- [A ]-
Scheme 74 
-
H 
N 
-A 
lithium aluminium hydride , sodium bis - (2-me t hoxyethoxy)aluminium 
hydride and sodium borohydr i de have been used. 216 Brown and Levy
217 
have reported a variation to this procedure by treating the 
iodoazides with dichloroboranes. The resulting i>-iodo secondary 
amines, without isolation, undergo a ring-closure reaction with base , 
providing the corresponding aziridines in good yields (73-94%). N-
141. 
Phosphorylated aziridines (482) and (483) have also been prepared by 
the reaction of the iodoazide (484) with phosphines and phosphites 
(Scheme 75). 219 This approach has been employed by Hirata and 
coworkers185 in the synthesis of the aziridinopyrrolo[l,2-~]indole 
(401) (vide supra). 
(484) 
Scheme 75 
MeO 
(401) 
+pf'h I 
I 3 
H N 
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We,, ~We 
(482) 
(483) 
Encouraged by the versatility of this method and the relatively 
few steps involved, we attempted the reaction with the substrates 
(440), (443) and (459). No reaction was observed with the furanone 
(440) and the dihydrofuran (443), starting materials being recovered. 
The diene (459) reacted with the iodoazide, but the adducts could not 
be characterized. Attempts to convert the crude product into an 
aziridine were unsuccessful. Under similar reaction conditions, 
iodine azide added to cyclohexene yielding the expected trans-1-
azido-2-iodocyclohexane (485) in 94% yield, the 1H n.m.r. data of 
142. 
(485) 
which agreed with that published. 218 The pos tulated mechanism 
requires an electrophilic attack by iodine azide, thus the reaction 
is favoured by electron-rich double bonds. This could explain the 
lack of reactivity of the substrates (440) and (443), the latter 
possibly also due to steric hindered double bond. 
4.4.3.2. via Azidoalcohols 
Next, Kishi's 7 0 and Danishefsky's 105 aziridination sequences were 
considered (vide supra). ~e proposed to utilize the trans ring-
opening of epoxides with azide anion to gain access to the desired 
trans-azidoalcohols. The transformation of trans-azidoalcohols or 
the derived trans-aminoalcohols to aziridines has been achieved by 
various methods. 
Blum and coworkers 2 2 0 have reported the conversion of trans-
azidoalcohols to aziridines by treatment with tertiary phosphines. 
~ O:;? O:;? HO N3 N N 
PbJ + OH -
I 
H 
(486) (487) (488) 
Scheme 76 
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Yhen the trans-azidoalcohol (486) vas treated vith triphenylphosphine 
belov 20° C, the aziridinylphosphonium salt (487) could be isolated. 
Heating the phosphonium hydroxide (487) at reflux in methylene 
chloride for 15 minutes effected smooth conversion to the aziridine 
(488) (Scheme 76). Mechanistically, Blum and covorkers proposed a 
process similar to the Staudinger reaction. 221 Their argument vas 
primarily a stereochemical one. They observed that the threo-
azidoalcohol from cis-stilbene oxide vas converted to cis-2,3-
diphenylaziridine exclusively by an intramolecular nucleophilic 
substitution (pathvay a). The alternate SNi closure (pathvay b) vas 
ruled out since none of the trans-aziridine vas produced (Scheme 77). 
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Sherwood and Nelson 222 , on the other hand, have successfully 
prepared the aziridine (491) from the epoxide (489) via the azido 
tosylate (490) using hydrazine and Raney nickel catalyst (Scheme 78). 
This method has previously been applied to 1,2-trans-diaxial azido 
mesylates in steriodal systems and nucleosides. 223 - 227 In 1980, Blum 
and coworkers 228 described an improved synthesis of the polycyclic 
aziridine (488) by substituting the tertiary phosphine with 
triethylphosphite. 
(489) (490) 
Scheme 78 
(491) 
Recent research efforts have also been focused on the development 
of methods for the single-step conversion of 1,2-aminoalcohols to 
aziridines utilizing a variety of 'organophosphorus reagents'. 
Improved one-step methods include the reaction of 1,2-aminoalcohols 
with triphenylphosphine dibromide in the presence of 
triethylamine, 229 triphenylphosphine in the presence of carbon 
tetrachloride and triethylamine, 230 diphosphorus tetraiodide, 231 or 
the Mitsunobu reagent. 232 More recently, in 1986, Evans and 
coworkers 233 reported the use of diethoxytriphenylphosphorane for the 
cyclodehydration of 1,2-aminoalcohols to the corresponding 
aziridines. 
Since epoxides are precursors to the required trans-
azidoalcohols, we attempted epoxidation of the dihydrofuran (443) 
I 
I 
I 
I 
I ..._ 
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with ~-chloroperbenzoic acid. However, only starting material was 
recovered even at elevated temperature, 234 reflecting its electron 
deficient double bond. Steric hindrance at the double bond possibly 
also played a role. 
Indirect epoxidation procedures involving more reactive reagents 
were investigated. Treatment of the dihydrofuran (443) with !-butyl 
hypochlorite 235 only yielded the chlorohydrins (492) in 17% yield as 
compared to the 50-92% reported yields of related systems. 236 The 
stereoisomers obtained were not identified since all isomers would be 
expected to afford the structurally identical epoxide. Treatment of 
the chlorohydrins (492) with a suspension of powdered potassium 
hydroxide in anhydrous ether resulted in a black tar and a low mass 
recovery(< 10%), the t.l.c. of which showed at least four 
components. From a preparative point of view, this sequence of 
reactions was not worth pursuing any further. 
(OH)CI, OH(CJ) 
K QtiCOzMe MeOA aX-()Me 
(492) (49'.3) (494) 
Bilchi and Demole 237 reported a quantitative yield of the diol 
(493) on oxidation of the dihydrofuran (494) with potassium chlorate 
and a catalytic amount of osmium tetroxide in aqueous THF. Treatment 
of the dihydrofuran (443) under similar reaction conditions afforded 
a complex mixture on t.l.c. which showed at least five components and 
base-line materials. Four methoxy signals at o 3.31 ppm, 3.41 ppm, 
3.45 ppm and 3.49 ppm could be discerned from the 1H n.m.r. spectrum 
indicating that two major diastereomers were present in the mixture. 
The transformation of the crude diastereomeric product mixture to an 
epoxide was not pursued at this point since we succeeded in 
epoxidizing the furanone (440), the substrate with the more 
favourable oxidation level, in reasonable yield (55%) after some 
experimentation. 
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In a total synthesis of the fungal metabolite cerulenin (495), 
the ~,13-epoxy-y-lactone (496) was required as a key intermediate. 
Towards this end, Boeckman and Thomas 238 investigated extensively 
direct epoxidation of the unsaturated lactone (497, R=~-C 7H15 ) but to 
no avail. Among the reagents tried were m-chloroperbenzoic acid 
(with or without radical inhibitors), hydrogen peroxide in the 
presence of a tungsten catalyst, !-butylhydroperoxide in the presence 
of ~-benzyltrimethylammonium hydroxide, alkaline hydrogen peroxide 
and trifluoroperacetic acid. 
0 0 
(495) (496) 
(497) R-allcyl ( 498) R-al.kyl (499) R-allcyl 
Tishler and coworkers 239 also found t hat lactones of this type 
(497) were very difficult to epoxidize. They were finally able to 
achieve the epoxidation using an excess of sodium hypochlorite in 
pyridine solution at 0° C affording the ring-opened hydroxyepoxy acid 
(498) which regenerated the epoxylactone (499) on warming to 60° C. 
In our hands, commercially available sodium hypochlorite (4% 
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available chlorine or 12.5% available chlorine) was not satisfactory 
as the reaction on the lactone (440) only afforded a low yield (10-
20%) of the desired epoxide (500). Use of freshly prepared 240 sodium 
hypochlorite in aqueous solution at 0° C and subsequent ring closure 
of the intermediate hydroxyepoxy acid (498, R=H ) with Amberlyst 15 in 
the presence of molecular sieves improved the yield to 55%. 
(500) 
~ith the epoxide (500) as the available access to the desired 
trans-azidoalcohol, the next step was apparent. The reaction of 
azide nucleophiles with epoxides has been studied241 and it has been 
found that ring opening proceeds with inversion of configuration. 
Further, the presence of an adjacent carbonyl or ester group causes 
the epoxides to be attacked at the remote carbon. 242 Treatment of 
the epoxide (500) with trimethylsilyl azide/methanol (1:1) in~,~-
dimethylformamide 243 gave two isomers in the ratio of two to one in 
75% combined yield. 
The mass spectra of the isomers shoved molecular ions at m/z 143 
corresponding to the molecular formula C4H5N303 and structural 
formula (501). They were of little assistance in assigning the 
respective structures to the isomers because the fragmentation 
patterns of both compounds were virtually identical . 
X y 
0..0 
(501) X - OH, N3 
Y-N3, OH 
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The 300 MHz 1 H n.m.r. spectrum of the minor isomer was 
essentially first-order. The various coupling constants could be 
discerned more clearly after deuterium exchange (Figure 16) although 
the signals were shifted upfield slightly. Multiplets centred at o 
4.43 and 4.38 ppm represented the Mand N components of a AMNX spin 
system, where JMN=l0.6 Hz, J =0.8 Hz and J =3.0 Hz. Further 
- -AM -AN 
coupling between the A proton and the hydroxyl proton (~=1.6 Hz, 
removed on addition of deuterium oxide) suggested that it was the 
hydroxymethine proton. As the MN component of this spin system must 
represent the C-5 methylene, this confirmed placement of the hydroxyl 
group at C-4 and the azide at C-3. Thus the X component of the AMNX 
spin system could be assigned to the azidomethine proton resonance 
which, as expected, was only coupled to the hydroxymethine proton 
resonance (J =4.8 Hz). 
-U 
A doublet of quartets at o 4.45 ppm in the 
300 MHz 1H n.m.r. spectrum of the major isomer was at first somewhat 
puzzling. A closer examination indicated that the coupling constants 
of this proton to the other three protons are fortuitously similar 
and thus the signal due to the proton became a quartet after 
deuterium exchange (Figure 17). This proton was assigned to the 
hydroxymethine proton and was probably at C-4 since it was also 
coupled to the methylene protons at C-5 which resonanted at o 4.51 
and 4.10 ppm as doublets of doublets. The doublet at o 4.24 ppm was 
assigned to the azidomethine proton which again was only coupled to 
the hydroxymethine proton resonance (~=6.8 Hz). Thus, from the 
analysis of the 1 H n.m.r. spectra, the hydroxyl functionality occurs 
at C-4 in both isomers. The difference between the minor and the 
major isomers would then appear to centre around the relative 
stereochemistry of the hydroxyl and the azido substituents, hence 
structures (502) and (503). The 1H NMR data for the two isomers are 
r · 1 
Figure 16 Expanded 1H n.m.r. spectrum of the minor isomer 
(502) after deuterium exchange 
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(502) (503) 
summarized in Table I below. The proton ass ignments shown were based 
on the observed chemical shifts and the splitting patterns which in 
turn were verified by spin-simulated spectra (Figure 18). In 
general, the simulated spectra agreed well with the recorded spectra. 
Table I 1H n.m.r. data for the isomers obtained from ring-opening of the epoxide (500) 
00~0 HO~O 
minor isomer (502) (503) 
Chemical sliif t Splitting pattern Coupling constant Assignment 
(o, ppm) (J, Hz) 
4.28 d 4.8 H3 
4.38 ddd 10.6, 3.0, 1.5 HS 
4.43 dd 10.6, 0.8 HS' 
4.58 m 4.8, 3.0, 0.8, 1.6 H4 
2.66 1.6, 1.5 OH 
major isomer 
4.10 dd 8.7, 6.5 HS 
4.24 d 6.8 H3 
4.45 dq 6.8, 6.5, 6.8, 3.0 H4 
4.51 dd 8.7, 6.8 HS' 
2.82 d 3.0 OH 
Tentative assignment of the stereoisomers (502) and (503) was 
confirmed chemically. Treatment of the separated isomers with mesyl 
chloride and triethylamine in dichloromethane at 0° C resulted in 
Figure 18a Simulated 1H n.m.r. spectrum of the minor 
isomer (502) with the coupling constants to the 
OH proton removed 
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Figure 18b Simulated 1H n.m.r. spectrum of the major 
isomer (503) with the coupling constants to the 
OH proton removed 
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elimination of methanesulfonic acid from the mesylates generated in 
situ affording a single unsaturated azide. This confirmed that the 
two isomers were in fact stereoisomers. The position of the azide 
substituent in this elimination product, and therefore also in the 
two parent isomeric alcohols (502) and (503) , was verified by 
converting the azide into the known amine (504) by selective 
catalytic hydrogenation. The spectral properties of the amine (504) 
agreed well with the published data. 2 44 The unsaturated azide thus 
has the structure (505). 
rSO eta 
(504) (505) 
Two observations in the opening of the epoxide (500) were in 
disagreement with the literature. 24 1 • 242 Firstly, cleavage had 
occurred at the carbon atom adjacent to the carbonyl group 
regiospecifically. Secondly, one of the isomers was produced with 
overall retention of configuration. From the point of view of 
mechanism, it is highly unlikely that a free carbonium ion~ to the 
carbonyl has formed during the opening of the epoxide giving rise to 
the cis-isomer (503) and the trans-isomer (502). Hence, the cis-
isomer (503) probably arose by equilibration of the trans-product 
(502). The azide group is known t o exert an electron-wit hdrawing 
effect by induction 245 leading to an increase in the acidity of the 
proton at C-3 thus facilitating the process. Equilibration to the 
cis-isomer probably may be favoured by hydrogen bonding between the 
azido and the hydroxyl groups. 
I 
I 
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Although the spectral and chemical evidence established that the 
two stereoisomeric azidoalcohols (502) and (503) were produced by the 
ring-opening of the epoxide (500), we were unable to determine which 
was the major isomer at this point. The cis or trans relative 
orientation of the substituent groups at C-3 and C-4 in the two 
isomers (502) and (503) could not be determined unequivocally from 
the vicinal coupling constants of the protons at C-3 and C-4 of the 
two isomers (~3 • 4 4.8 and 6.8 Hz respectively). 1H N.m.r. data on 
saturated five-membered lactones 246 show that the coupling constants 
of the protons at C-3 and C-4 of cis-isomers generally lie in the 
range 5.0 to 9.0 Hz while those of trans-isomers are 10.0 to 12.0 Hz. 
Ve therefore turned to lanthanide-shift experiments in an attempt 
to verify the relative stereochemistry of the two isomeric 
azidoalcohols obtained. In addition to effecting simplification and 
resolution enhancement of complex n.m.r. spectra, use of shift 
reagents can give valuable information about the geometrical 
structure and conformation of molecules in solution. 247 It has been 
shown that the strength of coordination of functional groups to 
lanthanide-shift reagents decreases in the series OH> C=O > -0- > 
CO Rand that the induced shift decreases with increasing distance 
2 
between a proton and the complexed functional group. Based on these 
properties of lanthanide-shift reagents, we hoped to assign the 
stereoisomeric structures (502) and (503) to the two isomers by the 
induced shifts of the protons. 
The alcohol function, being a strong donor, would be expected to 
complex preferentially to the lanthanide-shift reagent whatever the 
competing donor, under normal circumstances. The azido group, 
through its non-bonding electron pairs, could also act as an 
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electron-donor and thus would be expected to complex also with the 
lanthanide-shift reagent. The lactone function has been found to be 
a weak complexing ligand. In the trans-isomer, the disposition of 
the two groups at C-3 and C-4 is such that the lanthanide-shift 
reagent should be able to approach the hydroxyl group freely and thus 
it would be expected to be the dominant donor. On the other hand, 
steric hindrance around the hydroxyl group in the cis-isomer would 
enable complexation at the azido group, though also more hindered, to 
become more competitive. 
Successive 300 MHz 1H n.m.r. spectra of the two isomers in 
anhydrous deuteriochloroform were recorded with increasing amounts of 
added deuterio-tris-(1,1,1,2,2,3,3-heptafluoro-7,7-dimethyl-octane-
4,6-dionato)europium (III) [Eu(fod-d 9 ) 3 ]. The changes in the 
chemical shifts of the various protons were expressed graphically as 
a function of the molar ratio of the lanthanide-shift reagent to the 
substrates (Figure 19). For the minor isomer, the maximum induced 
shift was observed for the hydroxyl proton followed by the methine 
proton at C-4, as expected since it is nearest to the hydroxyl group 
(Figure 19a). The induced shifts of the adjacent proton at C-3 and 
that proton at C-5 which probably lies on the same side as the 
hydroxyl group were about the same. This indicated that they are of 
comparable distances from the complexed hydroxyl group and this 
necessitates the azide group to be on the opposite side of the 
hydroxyl group. The other proton at C-5, which is on the opposite 
side of the hydroxyl group, is furthest away from the complexing 
centre and therefore was affected the least. The induced shift 
pattern was quite different in the major isomer (Figure 19b). 
Firstly, the induced shifts for all the protons were much smaller 
than those for the minor isomer though the experiments were done at 
Figure 19a Graph of induced chemical shifts (Hz) versus 
molar ratio of Eu(fod - d9 ) 3 to the minor isomer .. 
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comparable concentrations (ca. 5% concentration difference). 
Secondly, the induced shifts for the protons at C-3 and C-4 were 
about the same. These observations were consistent with the two 
groups being cis to each other. Steric hindrance would prevent 
efficient binding to the shift reagent therefore resulting in 
significantly lower induced shifts in all the protons including the 
hydroxyl proton. The comparable shifts observed for the protons at 
C-3 and C-4 suggested that the azido group at C-3 now became a 
competitive donor. The induced shift of that proton at C-5 on the 
same side as the complexing donors was considerably larger than that 
of the proton on the opposite side as expected. 
In accord with the reasoning above, the minor isomer was 
tentatively assigned the trans stereochemistry, that is (502), and 
the major isomer, the cis stereochemistry, that is (503). The 
preference for the cis-isomer (503) probably arise as a result of 
stabilization by hydrogen bonding between the azido group and the 
hydroxyl group. A more rigorous proof of the relative stereochemical 
assignment of the isomers, by converting the trans-azidoalcohol (502) 
into an aziridine, was considered but not undertaken. 
4.5. Conclusion and Outlook 
Although the goal of synthesizing the aziridino aliphatic 
fragment (435) has not been achieved, the studies described above 
provide considerable insight into the chemistry of the furanoid 
systems, the dihydrofuran (443), the furanone (440) and the §-diene 
(459). ~e had expected that the double bond of these furanoid 
systems would succumb to aziridination via nitrene addition, or 
perhaps to some of the more recently developed reagents. However, 
154. 
the three substrates proved to be very unreactive towards the 
reagents tried. The alternative multi-step procedure, via 
azidoalcohols, regrettably, became a requirement. However, cl~avage 
of the epoxide (500) unexpectedly yielded the cis-azidoalcohol (503) 
in 52% yield along with the trans-isomer (502) i n 27% yield. If the 
isomerization of the initially formed trans-isomer (502) could be 
avoided by modification of the reaction conditions, a reasonable 
yield of the desired trans-azidoalcohol (502) would be obtained. 
This route might then be worth pursuing further though from the above 
experience, the propensity of the 4-hydroxyl function or its 
activated derivatives towards elimination would probably pose a 
problem. 
Since aziridination of the cyclic systems studied proved to be 
difficult, it might be better to introduce the strained aziridine 
functionality onto an acyclic fragment. The known mono-protected 
cis-diol (506), from which achiral and chiral epoxides have been 
prepared, 24 8 could be used as a precursor to the az i ridine (435), 
conceivably via the azidoalcohol route. 249 
H ~ N n n BnO OH BnO OH 
(506) (507) Br 
(435) Z - H, C02Et 
Recently, Cardillo and coworkers 250 have reported the synthesis 
of the cis-aziridine (507) in four steps from the mono-protected cis-
diol (506) in about 50% overall yield. Elaboration of this aziridine 
(507) to the desired six-carbon aziridine fragment (435) would 
155. 
involve oxidation of the free hydroxyl to an acid 251 and a two-carbon 
extension to a 13-keto ester using Hasamune's methodology1 44 (see 
Chapter 3). If the aziridine function of (507) is stable under these 
further reaction conditions this could be a quick entry into the 
desired aziridino aliphatic fragment (435). 
EXPERIMENTAL 
1~6. 
1. General Procedures 
Melting points were determined on a Reichert hot-stage apparatus 
and are uncorrected. Microanalyses were carried out by the 
Australian National University Microanalytical Service. 
Ultra-violet and visible spectra were recorded on a Varian OMS 90 
spectrophotometer. Infra-red spectra were recorded on a Perkin Elmer 
683 spectrophotometer. 
1 H n.m.r. and 13 C n . m.r. spectra were recorded on a Jeol JNM 
FX200 spectrometer operating at 200 MHz and 50.1 MHz respectively. 
All spectra were recorded in deuteriochloroform (CDC1 3 ) unless 
otherwise indicated. Tetramethylsilane is used as an internal 
reference and resonances are quoted in ppm on the 1H and 13 C o scales 
respectively. 
Mass spectra were recorded on AEI 902 and V.G.-Micromass 7070F 
double-focussing mass spectrometers. Peaks with intensity greater 
than 20% were recorded unless additional data was pertinent. High 
resolution mass measurements were determined on the AEI 902 
spectrometer. 
~here necessary, solvents and reagents were pur i fied and dried 
according to the procedures described in Perrin~ al. 2 5 2 All 
organic solvents were distilled before use. Petroleum ether refers 
to the light petroleum fraction bp 40 °-60° C. 
Flash column chromatography was carried out using 230-400 mesh 
silica gel. 2 5 3 For thin layer chromatography (t.l.c.), 0.25 mm 
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plates were used for analytical purposes and 2 mm Merck silica gel 60 
F254 for preparative work. 
The molarity of ~-butyllithium was determined by titration 
against 2,5-dimethoxybenzyl alcohol as a sel f-indicating primary 
standard according to the method of ~inkle, Lansinger and Ronald . 254 
Buffer-washed silica (ca. pH 7.3) was prepared in the following 
manner. Buffered aqueous solutions at pH 7.6 were prepared by mixing 
disodium hydrogen orthophosphate (218 ml, 0.2 M) with sodium 
dihydrogen orthophosphate (33 ml , 0.2 M) and diluted to 500 ml. A 
slurry of silica gel (200 g, 230-400 mesh) was made in this solution 
and soaked for 1 h. Then it was filtered and sucked dry on a water 
pump. The silica gel was acti vated by heating at 105°-110° C for 16 h. 
Buffered aqueous solutions at pH 6.8 referred to in Fremy's salt 
oxidations were prepared by dissolving disodium hydrogen phosphate 
(355 mg) and potassium dihydrogen orthophosphate (340 mg) in 
distilled water (100 ml). 
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2. Chapter 2 
6-methyl-2-nitrophenol (258) 
Concentrated sulfuric acid (12.5 g, 6.8 ml , 0.125 mol) was added 
slowly to water (20 ml) contained in a three-necked flask (100 ml) 
with efficient stirring. Sodium nitrate (7.5 g, 0.0875 mol) was 
dissolved in the diluted acid and then cooled to ca. 5° C in an ice-
bath. £-Cresol (5.4 g, 5.15 ml, 0.05 mol) was added dropwise to the 
mixture, keeping the temperature below 10° C. The reaction mixture 
turned dark red. It was stirred at room temperature for a further 
3 h. The course of the reaction was followed by t.l.c. The mother 
liqour was decanted from the resinous nitro compounds. The residue 
was washed with water (3 x 15 ml) and then steam-distilled. 6-
methyl-2-nitrophenol (258), being more volatile, distilled over and 
crystallized out. Recrystallization from aqueous ethanol gave light 
yellow prisms (1.91 g, 25%), mp 68°-70° C (lit. 255 • 2 56 mp 69.5° C). 
(Found: C, 54.77; H, 4.60; N, 8.98; C7 H7N0 3 requires C, 54.90; H, 
4.61; N, 9.15 %). UV: >-. 357, 282 nm. 
max 
1 H NMR: & 2.34 (s, 3H, 
CH
3
), 6.87 (dd, lH, ~ 7.2 and 8.6 Hz, H4), 7.45 (d, lH, ~ 7.2 Hz, 
HS), 7.96 (d, lH, ~ 8.6 Hz, H3). MS: m/z 153 (M, 69.3%), 136 (M-08, 
6.1), 123 (M-NO, 5.2), 107 (M-N0 2 , 14.9), 105 (123-8 20, 10.9), 79 (M-
NO -CO, 11), 78 (CH, 26.8), 77 (C6 H5 , 46.8), 40 (100). 2 6 6 
2-amino-6-methylphenol ( 257) 
a. Catalytic hydrogenation 
6-Methyl-2-nitrophenol (258) (522mg, 3.41 mmol) dissolved in 
ethanol (18 ml) was added to a suspension of palladium on carbon 
159. 
(10%, 188 mg) in the same solvent (7 ml) under hydrogen. The 
reaction was stopped after the uptake of hydrogen had ceased. Acetic 
acid (50 µl) was added to the reaction mixture and the catalyst was 
filtered off under nitrogen and washed with ethyl acetate (3 x 5 ml). 
After removal of solvent under reduced pressure, the crude product 
was sublimed at 40°-60° C/0.05-0.1 mm to give the desired aminophenol 
(257) as white crystals (390 mg, 93%), mp 88°-89° C (lit. 118 mp 89° 
C). UV: A (MeOH) 284 (€ 1995), 235 (€ 5777) nm IR: ~ 3608 
max max 
(OH), 3390 (NH), 1618 and 1485 (C=C) cm- 1 • 1 H NMR: o 2.24 (s, 3H, 
CH 3 ), 6.67 (m, 3H, H3, H4, HS). MS: m/z 123 (M, 100%), 122 (29.0), 
106 (M-08, 10.3), 94 (C6H60, 13.8), 78 (C 6H6 , 17.7). 
b. Reduction with sodium hydrosulfite in aqueous sodium hydroxide 
6-Methyl-2-nitrophenol (258) (0.992 g, 6.48 mmol) was dissolved 
in aqueous sodium hydroxide (3%, 20 ml) giving a dark-red solution. 
The solution was heated to 90° C and sodium hydrosulfite (3.968 g of 
85% assay, 19.44 mmol) was added at such a rate as to keep the 
temperature below 100° C. The reaction mixture turned pale yellow. 
Charcoal (0.2 g) was added and stirring was continued for a few min. 
The reaction mixture was filtered and the filtrate was cooled in ice-
water. Yhite flaky crystals appeared and were filtered off. 
Recrystallization from carbon tetrachloride gave 2-amino-6-
methylphenol (257) (0.183 g, 23%) as colourless plates, mp 89° C. 
c. Reduction with sodium hydrosulfite in aqueous ammonium 
hydroxide 119 
6-Methyl-2-nitrophenol (258) (0.5 g, 3.27 mmol) was dissolved in 
a mixture of water (10 ml) and concentrated ammonium hydroxide (2.5 
160. 
ml) to give a red colour solution. This was added slowly to a 
s olution of sodium hydrosulfite (2.0g, 3.27 mmol) in water (15 ml). 
The red colour of the solution turned to pale yellow. The pH of the 
s olution was adjusted from pH 9.0 to pH 6.5 before extracting with 
ether (3 x 15 ml). The combined ether extrac t was washed with brine 
(2 x 25 ml), dried (MgS0 4 ) and treated with charcoal. Removal of 
solvent gave crude 2-amino-6-methylphenol (257) (0.288 g, 72%), mp 
85°-88° c. 
2- acetylamino-6-methylphenol (263) 
2-Amino-6-methylphenol (257) (49.7 mg, 0.4 mmol) was suspended in 
water (1.6 ml). Acetic anhydride (41.3 mg, 38 µl, 0.4 mmol) was 
added dropwise. A t.l.c. examination showed the appearance of a new 
component which was more polar. The reaction mixture was allowed to 
stir at room temperature overnight. It was then acidified to pH 5 
and extracted with ether (3 x 3 ml). The combined ether extracts was 
washed with brine (2 ml) and dried (Na 2S0 4 ) . Removal of solvent gave 
a crude mixture (61 mg) which was purified by flash column 
chromatography (ethyl acetate/petroleum ether, 6:4) to give 2-
acetylamino-6-methylphenol (263) (55 mg, 90%), mp 65.5°-66.5° C 
(CC1 4 ), (lit. 118 mp 78°-79° C). UV: A 284 (€ 3342), 243 (€ 7638) max 
nm. 1 H NMR: o 2.26 (s, 3H, 6-CH 3), 2.30 (s, 3H, COCH3), 6.79 (m, 28, 
84, HS), 7.03 (m, lH, H3), 7 . 49 (bs, lH, OH), 8.63 ( bs, l H, NH). MS: 
m/z 165 (M, 22.2%), 147 (M-8 20, 18.0), 123 (M-C 2H20, 100), 122 (M-
CH3CO, 14.4), 106 (123-0H, 13.3) , 94 (C6H6 0, 6.9), 78 (C6 H6 , 9.9), 43 
(CH3CO, 15.8). 
161. 
2-acetylamino-6-methyl-1,4-benzoquinone (264) 
Fremy's salt (203 mg, 0.756 mmol) dissolved in aqueous buffer (pH 
6.8, 10 ml) was added to a stirred solution of t he phenol (263) (52 
mg, 0.315 mmol) dissolved in methanol (7 ml) and buffer (pH 6.8, 5 
ml). After stirring at room temperature for 0.5 h, dilute sulfuric 
acid (1 M) was added until the solution was pH 3. The reaction 
mixture was then extracted with ethyl acetate (4 x 20 ml) until he 
organic layer was colourless. The combined ethyl acetate extracts 
was washed with brine (30 ml) and dried (MgS0 4 ). Removal of solvent 
gave an orange-yellow solid (55 mg, 98%) which was sublimed at 60° 
C/0.15 mm to give 2-acetylamino-6-methyl-1,4-benzoquinone (264) (45 
mg, 80%), mp 117°-119° C. (Found: 59.94; H, 5.09; N, 7.84; C9 H9 N0 3 
requires C, 60.33; H, 5.06; N, 7.82%). UV: >-. (MeOH) 386 ( £ 1549), max 
270 (€ 12024), 223 (€ 12389) nm. IR: \I (nujol) 3280 (NH), 1670 max 
(amide I), 1650 (quinone CO), 1620 (amide II) cm- 1 • 1H NMR: o 2.08 
(d, 3H, ~ 1.5 Hz, 6-CH 3 ), 2.24 (s , 3H, NHCOCH 3 ), 6.57 (m, lH, H3), 
7.53 (d, lH, ~ 2.4 Hz, H3) , 8.07 (bs, lH, NH). MS: m/ z 179 (M, 
100%), 137 (M-C
2
H
2
0, 27.9), 109 (137-CO, 32.1), 68 (C 4 H40, 16.9), 43 
(CH 3CO, 69.4). 
6-methyl-2-(4-oxo-pentanamido)-1,4-benzoquinone (262) 
Levulinic acid (256) (145 mg, 128.7 µl , 1.26 mmol) was dissolved 
in dichloromethane (3 ml) and the reaction flask was deoxygenated and 
filled with nitrogen. Dicyclohexylcarbodiimide (207 mg, 1.0 mmol) 
dissolved in the same solvent (1.5 ml) was added dropwise at 0° C, 
followed by 2-amino-6-methylphenol (257) (103 mg, 0.83 mmol) in 
dichloromethane (2.5 ml). A white precipitate fell out. After 
162. 
stirring at 0° C for 1.5 h, the white precipitate was filtered off. 
The filtrate was evaporated to dryness under reduced pressure. The 
semi-solid produce was dissolved in methanol (18 ml) and aqueous 
buffer (pH 6.8, 13 ml). Fremy's salt (539 mg, 2.0 mmol) was 
dissolved in the same buffer (26 ml) and added dropwise. After 
stirring for 0.5 hat room temperature, the reaction mixture was 
adjusted to pH 3 by dropwise addition of dilute sulfuric acid (1 M) 
and extracted with chloroform until the chloroform layer was 
colourless. The combined chloroform extracts was washed with brine, 
dried (MgS0 4 ) and the solvent removed under reduced pressure to give 
a crude product (235 mg) which was purified by flash column 
chromatography (ethyl acetate/petroleum ether, 1:1, Rf=0.48) to give 
6-methyl-2-(4-oxo-pentanamido)-1,4-benzoquinone (262) (155 mg, 80%), 
mp 148°-155° C (yellow prisms). (Found: M, 235.0845; C
12
H
13
N0
4 
requires 235.0844). UV: A (MeOH) 380 (8 1774), 272 (8 13040), 225 
max 
(8 13846) nm. IR: ~ (CHC1 3 ) 3375 (NH), 1715 (ketone CO), 1670 max 
(amide I), 1654 (quinone CO), 1615 (amide II), 1505 cm- 1 • 1H NMR: o 
2.08 (d, 3H, ~ 1.7 Hz, 6-CH 3 ), 2.22 (s, 3H, COCH 3 ), 2.68 (t, 2H, J 
7.0 Hz, CH 2COCH 3 ), 2.87 (t, 2H, ~ 7.0 Hz, CH 2CH 2COCH 3 ), 6.55 (m, lH, 
HS), 7.47 (d, lH, ~ 2.7 Hz, 83), 8.32 (bs, lH, NH). MS: m/z 235 (M, 
12.1%), 219 (M+2H-H 20, 2.3), 204 (219-CH 3 , 0.3), 192 (M-COCH 3 , 0.5), 
176 (204-CO, 1.6), 164 (M-C 4H702 , 6.1), 121 (C7H502 , 0.8), 99 
(CHO, 100), 71 (C 8
7
0, 16.7), 43 (CH 3 CO, 69.9). 5 7 2 4 
some attempts to cyclize 6-methyl-2(4-oxo-pentanamido)-l,4-
benzoquinone (262) 
a. The quinone (262) (18.3 mg, 0.078 mmol) was dissolved in 
ether/DME (4:1, 2.0 ml) under nitrogen. Sodium hydride (2.3 mg, 
0.094 mmol) was then added. The reaction mixture turned brown, then 
163. 
dark green. It was allowed to stir at room temperature overnight and 
then quenched with aqueous buffer pH 6.8 (3.0 ml). The reaction 
mixture was extracted with chloroform (3 x 5 ml). The combined 
chloroform extracts was washed with brine (2 x 3 ml) and dried 
(MgS0 4 ) to give starting material (11 mg, 60% r ecovery). 
b. The quinone (262) (20.6 mg, 0.088 mmol) was dissolved in THF (3.0 
ml) under nitrogen. Sodium hydride (7.6 mg, 0.315 mmol) was then 
added to the solution. The reaction mixture was stirred at room 
temperature. No observable change was detected on t.l.c. 
examinations. After stirring for 3 h, the reaction mixture was 
quenched with saturated ammonium chloride (2.0 ml) and extracted with 
chloroform. Removal of solvent under reduced pressure gave starting 
material (17 mg, 60% recovery). 
c. ~-Butyllithium (18 mg, 176 µl of 1.6 M solution in ~-hexane, 0.28 
mmol) was added slowly to diisopropylamine (28 mg, 39 µl, 0.28 mmol) 
in THF (2.0 ml) at -20° C and the reaction mixture was then warmed to 
0° C and stirred for 20 min. It was then cooled to -78° C and the 
quinone (262) (20 mg, 0.085 mmol) dissolved in THF (1.0 ml) was then 
added dropwise whereupon the reaction mixture turned green. The 
reaction mixture was allowed to stir at -78° C and then quenched with 
saturated ammonium chloride (2.0 ml) and extracted with chloroform (3 
x 5 ml). Removal of solvent under reduced pressure gave starting 
material (13 mg, 65% recovery). 
some attempts to trap the anion of the quinone (262) with various 
electrophiles 
164. 
a. ~-Butyllithium (4.4 mg, 72 µl of 0.95 M solution in ~-hexane, 
0.068 mmol) was added to diisopropylamine (6.9 mg, 9.6 µl, 0.068 
mmol) in THF (2.0 ml) at -20° and warmed to 0° C for 15 min. The 
reaction mixture was then cooled to -78° and the quinone (262) (6.7 
mg, 0.029 mmol) dissolved in THF (1.0 ml) was t hen added dropwise at 
-78° C and then stirred at the same temperature for 1 h. ~(tert-
butyldimethylsilyl)-~-methyltrifluoroacetamide (MTBSTFA) (7.6 mg, 7.4 
µl, 0.032 mmol) was then added at -78° C. The reaction mixture was 
then warmed to 0° C whereupon it turned brown. It was allowed to 
stir at 0° C for 1 h. Saturated ammonium chloride solution (3 ml) 
was added to quench the reaction and the solution was extracted with 
chloroform (3 x 5 ml). Removal of solvent under reduced pressure 
gave a complex mixture (by t.l.c. examination) which was not studied 
further . 
b. ~-Butyllithium (3.3 mg, 32 µl of 1.6 M solution in ~-hexane, 
0.051 mmol) was added to diisopropylamine (5.2 mg, 7.1 µl, 0.051 
mmol) in THF (2.0 ml) at -20° C and the reaction mixture was warmed 
to 0° C and stirred for 15 min. It was then cooled to -78° C and the 
quinone (262) (10.0 mg, 0.043 mmol) dissolved in THF (1.0 ml) was 
then added dropwise whereupon the reaction mixture turned red-brown. 
It was allowed to stir at -78° C for 1 hand then warmed to 0° C. 
tert-Butyldimethylsilyi chloride (11.5 mg, 0.077 mmol) dissolved in 
THF (1.0 ml) was then added. The reaction mixture was allowed to 
stir at 0° C for 10 min. It was then diluted with ether (3.0 ml) and 
washed with 5% aqueous sodium hydrogen carbonate (2 x 1.0 ml), dried 
(Na SO) and evaporated under reduced pressure to give a complex 
2 4 
mixture (14 mg) (by t.l.c. examination). 
165. 
c. ~-Butyllithium (11.4 mg, 187 µl of 0.95 M solution in ~-hexane, 
0.18 mmol) was added to diisopropylamine (18.0 mg, 24.8 µl, o.18 
mmol) in THF (2.0 ml) at -20° C and then warmed to 0° C for 15 min. 
It was then cooled to -78° C and the quinone (262) (19 mg, 0.081 
mmol) dissolved in THF (1.0 ml) was added. After stirring at -78° C 
for 1 h, methyl chloroformate (7.7 mg, 6.3 µl, 0.081 mmol) was then 
added. The reaction mixture was then allowed to warm to 0° C slowly. 
At 0° C, a 0.5 ml aliquot was withdrawn and quenched with saturated 
ammonium chloride and then extracted with chloroform. The 1H n.m.r. 
spectrum and t.l.c. showed mainly starting material. The remaining 
reaction mixture was treated with more methyl chloroformate (77 mg, 
63 µl, 0.81 mmol) and stirred at 0° C for 0.5 h. The reaction 
mixture turned brown and the usual work-up gave a complex mixture. 
d. ~-Butyllithium (11.0 mg, 180 µl of 0.95 M solution in ~-hexane, 
0.17 mmol) was added dropwise to diisopropylamine (17.3 mg, 24 µl, 
0.17 mmol) in THF (2.0 ml) at -20° C and then stirred at 0° C for 20 
min. I t was then cooled to -78° C and the quinone (262) (32 mg, 
0.137 mmol) dissolved in THF (1.5 ml) was then added dropwise. The 
reaction mixture was stirred at -78° C for 20 min and methyl 
chloroformate (25.9 mg, 21 µl, 0.27 mmol) was then added. It was 
slowly warmed to 0° C. The solution changed from greenish black at 
-78° C to purple at -40° C and to brownish yellow at 0° C. The 
reaction mixture was allowed to stir at 0° C for 15 min and saturated 
ammonium chloride (2.0 ml) was then added. It was extracted with 
chloroform (4 x 5 ml). The combined extracts was washed with brine 
(4 ml) and dried (Na 2 S04 ). Removal of solvent under reduced pressure 
gave a green residue which by t.l.c. showed starting material as the 
major component. 
166. 
e. Similar result was obtained with LTMP as a base. 
1-methyl hydrogen 3-oxc-hexanedioate (267) 
a. hydrolysis of dimethyl 3-oxo-hexanedioate (275) 
An ice-cold solution of potassium hydroxide (6.0 g, 0.1 mol) in 
anhydrous methanol (20 ml) was added dropwise to neat dimethyl 3-oxo-
hexanedioate (275) (1.1 g, 5.85 mmol) at 0° C. A white precipitate 
fell out. After stirring at room temperature for 5 h, the reaction 
mixture was filtered and the white residue was pressed between two 
clay tiles and dried over calcium chloride in vacuo. The filtrate 
was acidified to pH 3 by dropwise addition of concentrated 
hydrochloric acid (10 M) and extracted with ether (3 x 25 ml). The 
combined ether extracts was dried (Na2 S0 4 ) and evaporated to give 1-
methyl hydrogen 3-oxo-hexanedioate (267) (87 mg, 8%). The residue 
was dried for 2.5 hand then acidified to pH 4 with ice-cold dilute 
aqueous hydrochloric acid (2M). Sodium chloride was added to 
saturate the solution and then it was extracted with ethyl acetate (5 
x 10 ml). The combined ethyl acetate extracts was dried (Na 2 S0 4 ) and 
evaporation under reduced pressure gave a crude product (0.95 g, 
94%). Recrystallization from carbon tetrachloride gave pure 1-methyl 
hydrogen 3-oxo-hexanedioate (267) (0.82 g, 81%), mp 50° C. (Found: 
C, 48.01; H, 5.72; CH O requires C, 48 . 28; H, 5.79%) . 1H NMR: o 
7 l O 5 
2.67 (t, 2H, ~' 6.0 Hz, CH 2CO), 2.87 (t, 2H, ~ 6.1 Hz, CH 2C0 2H), 3.52 
(s, 2H, CH
2
C0
2
CH
3
), 3.74 (s, 3H, C0 2CH 3 ). MS: m/z 174 (M, 1.1%), 156 
(M-H
2
0, 6.8), 143 (M-OCH 3 , 4.6), 142 (M-CH 30H, 4.2), 125 (143-H 20, 
10.7), 119 (M-C0
2
CH
3
, 15.6), 101 (M-C 3 H5 02 , 100), 74 (C 3 H6 02 , 28.4), 
73 (C
3
H
5
0
2
, 18.2), 59 (C2H30 2 , 33.3), 57 (20.6), 55 (26.6), 43 
(25.5). 
167. 
b. attempted preparation from levulinic acid (256) 
n-Butyllithium (242 mg, 2.49 ml of 1.52 M solution inn-hexane 
- - , 
3.79 mmol) was added to diisopropylamine (383 mg, 0.53 ml, 3.79 
mmol) in THF (12 ml) at -20° C and then stirred at 0° C for 20 min. 
It was cooled to -78° C and levulinic acid (256) (200 mg, 176 µl, 
1.72 mmol) was then added dropwise. After stirring for 0.5 h, the 
reaction mixture became inhomogeneous. THEDA (1.0 ml) was added but 
it did not solubilize the reaction mixture. After stirring at -78° C 
for 1 h, methyl chloroformate (163 mg, 133 µl, 1.72 mmol) was then 
added. The reaction mixture was then warmed to -20° C and dilute 
hydrochloric acid was then added dropwise till pH 2.5. It was then 
extracted with dichloromethane (4 x 10 ml) and dried (MgS0 4 ). 
Removal of solvent under reduced pressure gave a crude product 
mixture (260 mg) which contained methyl ~,~-diisopropylcarbamate 
(268) 257 and starting material. 
Using DMPU/THF (1:2) as a solvent medium gave similar results, 
the reaction mixture being inhomogeneous. 
benzyl levulinate (269) 126 
A mixture of levulinic acid (256) (5.2 g, 4.58 ml, 0.045 mol), 
benzyl alcohol (16.0 g, 15.4 ml, 0.15 mol) in toluene (51 ml) was 
treated with a current of dry hydrogen chloride gas until 1.8 g was 
absorbed. The reaction mixture was heated to reflux for 4 h during 
which ca. 1.0 ml of water was collected in the Dean and Stark 
apparatus. The solvent was removed under reduced pressure and the 
residue fractionated to give benzyl alcohol (9.4 g) and benzyl 
levulinate (269) (7.4 g, 80%), bp 108°-112° C/0.1 mm (lit. 126 bp 
168. 
181°-183° C/17 mm). IR: vmax (NaCl) 2900-2980 (aromatic CH), 1740 
and 1720 (CO) cm- 1 • 1H NMR: o 2.18 (s, 3H, CH
3
), 2.63 (m, 2H, 
CH 2 CH 2CO), 2.74 (m, 2H, C82 CH 2CO), 5.11 (s, 2B, CH 2C6H5 ), 7.35 (m, 
SH, C6H5 ). MS: m/z 206 (M, 0.5%), 178 (M-CO, 1.6), 107 (C7H70, 
43.1), 99 (33.8), 91 (C
7
H
7
, 100). 
attempted preparation of 5-benzyl 1-methyl 3-oxo-hexanedioate (273) 
~-Butyllithium (68 mg, 0.7 ml of 1.52 M solution in ~-hexane, 
1.07 mmol) was added dropwise to a solution of 2,2,6,6-
tetramethylpiperidine (151 mg, 181 µl, 1.07 mmol) in THF (9.7 ml) at 
-50° C and warmed to 0° C for 20 min. It was cooled to -78° c and 
benzyl levulinate (269) (200 mg, 0.97 mmol) was added. After 1 h, a 
2 ml aliquot was withdrawn and quenched with deuterium oxide. After 
the usual work-up, deuterated and undeuterated benzyl levulinate 
(269) and benzyl alcohol were detected from 18 NMR and MS. Methyl 
chloroformate (73 mg, 60 µl, 0.776 mmol) was added and the reaction 
mixture was stirred at -78° C for 1 h. It was then warmed to room 
temperature and saturated ammonium chloride was added. The reaction 
mixture was extracted with ether (3 x 15 ml), washed with brine (5 
ml) and dried (Na 2S0 4 ). Removal of solvent under reduced pressure 
yielded an orange oil (164 mg) which was purified by flash column 
chromatography to give starting material (14 mg, 7%), benzyl methyl 
carbonate (270) 258 (32 mg, 20 %). IR: v 2990, 1745, 1268 cm- 1 • 
max 
1H NMR: o 3.78 (s, 3H, C0 2CH3 ), 5.15 (s, 2H, CH 2 ), 7.30 (m, SH, 
C6 H5 ). MS: m/z 167 (M+l, 6.1%), 166 (M, 5.7), 107 (C6H5 CH 20, 13.9), 
105 (100), 91 (C
7
H
7
, 81), 77 (C
6
H
5
, 26), 59 (C0 2CH 3 , 3.0) 
magnesium methyl carbonate 259 
169. 
Magnesium turnings (12.0 g, 0.5 mol) was placed in a three-necked 
round-bottom flask fitted with a water-condenser and a pressure-
equalizing separating funnel. A crystal of iodine was put in and the 
flask was heated to sublime the iodine. Methanol (10 ml) was added 
and the flask heated to initiate the reaction. The brown colour of 
iodine disappeared and the rest of the methanol (195 ml) was added 
slowly to maintain a gentle reflux. After the magnesium had reacted 
completely, the excess methanol was removed at water pump vacuum. 
~,~-Dimethylformamide (150 ml) was added and carbon dioxide was 
bubbled as quickly as it could be absorbed for 0.5 h. Then the 
excess methanol (80 ml) was distilled off until the head temperature 
reached 140° C. Carbon dioxide was bubbled through slowly during 
distillation and cooling to ensure saturation. The reagent was 
estimated to be of molarity 2.8 M by back titration. 
dimethyl 3-oxo-hexanedioate (275) 
A solution of levulinic acid (256) (1.06 g, 0.1 mmol) and 
magnesium methyl carbonate (39.8 ml of 2.31 M solution in~,~-
dimethylformamide, 92 mmol) were heated at 120°-135° C for 21 h. 
~,~-Dimethylformamide was removed by distillation under vacuum (0.1 
mm) at 40°-50° c. Trituration of the syrupy residue with ether gave, 
after filtration and air-drying, a creamy solid (20 g). The solid 
was suspended in methanol (82 ml) and cooled to -10° C. Hydrogen 
chloride gas was passed into the mixture until saturation had 
occurred. After standing overnight (19 h) at 20°-25° C, the mixture 
was concentrated at 40° C under reduced pressure. The syrupy residue 
was poured into ice and the aqueous solution was extracted with 
chloroform (4 x 40 ml). The combined organic extracts was washed 
with saturated sodium hydrogen carbonate solution (2 x 15 ml), water 
170. 
(10 ml) and dried (Na2S0 4 ). Removal of solvent gave a crude product 
(2.5 g) which was purified by distillation to give dimethyl 3-oxo-
hexanedioate (275) (1.5 g, 90%), bp 82°-86° C/0.05-0.1 mm 
(Kugelrohr). (lit. 128 b bp 94°-96° C/0.35mm). IR: \> (NaCl) 1740 
max 
and 1720 cm- 1 (CO). 1 H NMR: & 2.54 (t, 2H, :I_ 6.7 Hz, HS), 2.81 (t, 
2H, J 6.6 Hz, H4), 3.45 (s, 2H, H2), 3.60 (s, 3H, CH CH CO CH), 3.67 
-
2 2 2 3 
(s, 3H, COCH 2C0 2CH 3). MS: m/z 188 (M, 1.3%), 157 (M-OCH3, 14.2), 156 
(M-CH 30H, 18.0), 129 (M-C0 2CH 3, 19.6), 125 (156-0CH3, 14.5), 115 (M-
C3H502, 100), 101 (M-C 4H702 , 43.4), 97 (129-CH30H, 9.2), 87 (115-CO, 
11.0), 59 (C 2H302 , 39.2), 55 (38.0). 
methyl (~)-5-oxo-tetrahydrofuran-2-ylideneacetate (285) 
1-Methyl hydrogen 3-oxo-hexanedioate (267) ( 51 mg, 0.29 mmol) 
was dissolved in pyridine (0.14 ml) at 40°-50° C. Acetic anhydride 
was added after cooling the solution to room temperature. The 
reaction mixture was then put into an oil bath heated at 140°-150° C 
for 5 min whereupon it turned brown. It was then cooled in an ice-
bath quickly and ice (0.6 g) was added. A precipitate fell out. The 
precipitate was filtered and pressed between 2 clay tiles and dried 
over calcium chloride in vacuo. Recrystallization gave pure methyl 
(~)-5-oxo-tetrahydrofuran-2-ylideneacetate (285) (20 mg, 44%) as 
prisms, mp 98°-103° C (ethyl acetate/~-hexane) (lit. 133 mp 108° C). 
(Found: C, 53.35, H, 5.06; C7H804 requires C, 53.85, H, 5.16%) . IR: 
v 1820 (lactone CO), 1717 (ester CO), 1665, 1440, 1368 cm- 1 • 1 H 
max 
NMR: & 2.70-2.78 (m, 2H, H4), 3. 34-3.44 (m, 2H, H3), 3.73 (s, 3H, 
CO CH), 5.72 (t, lH, J 2.2 Hz, CH). MS: m/z 156 (M, 36.6%), 128 (M-
2 3 -
CO, 100), 125 (M-OCH3, 95.0), 124 (M-CH 3 0H, 47.3), 101 (80.6), 97 (M-
CO CH, 47.8), 96 (124-CO, 68.2), 69 (77.9). 
2 3 
171. 
methyl (Z)-5-oxo-tetrahydrofuran-2-ylideneacetate (284) 
DCC (108 mg, 0.53 mmol) dissolved in dry dichloromethane (0.6 ml) 
was added to a solution of 1-methyl hydrogen 3-oxo-hexanedioate (267) 
(86 mg, 0.5 mmol) in the same solvent (0 . 8 ml) at 0° C under 
nitrogen. A white precipitate fell out. After stirring at 0° C for 
1 h, the reaction mixture was filtered. The filtrate was evaporated 
under reduced pressure to give a white solid (87 mg) which was 
recrystallized to give pure methyl (Z)-5-oxo-tetrahydrofuran-2-
ylideneacetate (284) (72 mg, 92%) as prisms, mp 89.5°-92° c 
(chloroform/~-hexane). (Found: C, 53.40; H, 5.12; C7 H8 04 requires C, 
53.85; H, 5.16%). IR: v 1830 (lactone CO), 1720 (ester CO), 1655, 
ma x 
1530 cm- 1 • 1H NMR: & 2.71 (m, 2H, HJ), 3.01 (m, 2H, 83), 3.74 (s, 
38, C0
2
CH
3
), 5.18 (t, 18, ~ 1.6 Hz, CH). MS: m/z 156 (M, 25.5%), 128 
(M-CO, 91.0), 125 (M-OCH
3
, 82.4), 124 (M-CH 308, 23.2), 101 (48.4), 97 
(M-C0
2
CH
3
, 23.2), 96 (124-CO, 27.0), 69 (100), 55 (35.5) . 
acid-catalyzed isomerization of methyl (Z)-5-oxo-tetrahydrofuran-2-
ylideneacetate (284) 
One drop of deuterioacetic acid was added to a solution of methyl 
(Z)-5-oxo-tetrahydrofuran-2-ylideneacetate (285) (8.0 mg, 0 .051 mmol) 
in deuteriochloroform. After standing overnight, the 1H n.m.r. 
spectrum was recorded and from the integration, the ratio of methyl 
(~)-5-oxo-tetrahydrofuran-2-ylideneacetate (284) to methyl (~)-5-oxo-
tetrahydrofuran-2-ylideneacetate (285) was estimated to be 1 to 3.2. 
methyl 3-oxo-5-(phenylcarbamoyl)pentanoate (286) 
172. 
Methyl (~)-5-oxo-tetrahydrofuran-2-ylideneacetate (284) (50.8 mg, 
0.33 mmol) was dissolved in dry dichloromethane (1.0 ml) and cooled 
in an ice-bath. Aniline (30.3 mg, 30 µl, 0.33 mmol) was then added 
dropwise and the reaction mixture was allowed to stir at room 
temperature for 24 h. Removal of solvent gave a crystalline crude 
product (81 mg) which was recrystallized to give pure methyl 3-oxo-5-
(phenylcarbamoyl)pentanoate (286) (75 mg, 92%) as needles, mp 87°-
880 C (ethyl acetate/~-hexane) (lit. 135 86.5°-87.5° C). (Found: c, 
62.30; H, 6.02; C13 H1504N requires C, 62.68; H, 6.07%) . IR: ~max 
3430 (NH), 1745 (ester CO), 1720 (ketone CO), 1670 (amide I), 1600 
(amide II), 1520 (Aromatic C-C), 1440 cm- 1 • 1 H NMR: o 2.69 (t, 28, 
H4), 3.01 (t, 2H, HS), 3.56 (s, 2H, H2), 3.75 (s, 3H, C0
2
CH
3
), 7.03-
7.52 (m, SH, C6H5 ). MS: m/z 249 (M, 15 . 6%), 217 (M-CH 30H, 5.0), 190 
(M-C0 2CH 3 , 0.2), 176 (M-C 3H502 , 11.0), 148 (M-C 4H503 , 3.7), 125 
(23.7), 120 (C 7H6NO, 4.4), 115 (C 5H703 , 4.9), 93 (C 6H7N, 100), 77 
(C6 H5 , 11.1), 59 (C 2H302 , 8.8), 55 (21.6). 
2-(5-(methoxycarbonyl)-4-oxo-pentanami do]-6-methyl-
1,4-benzoquinone (266) 
2-Amino-6-methylphenol (257) (18 mg, 0.15 mmol), dissolved in dry 
dichloromethane (0.25 ml), was added dropwise to a solution of methyl 
(~)-5-oxo-tetrahydrofuran-2-ylideneacetate (284) (23 mg, 0.15 mmol) 
in the same solvent (0.6 ml) at 0° C under nitrogen. The reaction 
mixture was stirred at 0° C for 2 hand then at room temperature for 
another 2 h. The solvent was removed under reduced pressure and the 
residue was dissolved in a mixture of aqueous buffer solution (pH 
6.8) (2.2 ml) and methanol (3.0 ml). Fremy's salt (98 mg, 0.37 
mmol), dissolved in the same buffer (4.5 ml), was then added 
dropwise. The reaction mixture was stirred at room temperature for 
173. 
0.5 h, then it was acidified to pH 3 and extracted with chloroform 
(10 ml portion) until the chloroform extract was colourless. The 
combined chloroform extracts was washed with brine, dried (Na 2S0 4 ) 
and evaporated under reduced pressure to give a crude product (34 
mg). Purification by flash column chromatography (ethyl 
acetate/dichloromethane, 1:1) gave dimethyl 3-oxo-hexanedioate (275) 
(1.2 mg, 5%) and pure 2-[5-(methoxycarbonyl)-4-oxo-pentanamido]-6-
methyl-1,4-benzoquinone (266) (27 mg, 79%), mp 128.5°-129.5° C 
(dichloromethane/~-hexane) . (Found: C, 57.10; H, 5.16; C14 H15N0 6 
requires C, 57.34; H, 5.16%). UV: A 412, 271, 224 nm. 
max 
IR: ~ 
max 
3370 (NH), 1750 (~keto CO), 1720 (ester CO), 1668 (amide I), 1652 
(quinone CO), 1610 (amide II), 1500 cm- 1 • 1 8 NMR: o 2.07 (d, 38, ~ 
1.7 Hz, 6-CH3), 2.73 (t, 2H, J 6.2 Hz, NBCOC8 2CH2), 2.98 (t, 28, ~ 
6.2 Hz, NHCH 2), 3.54 (s, 28, CH 2C02CB3), 3.75 (s, 3H, C0 2C8 3), 6.55 
(m, lH, HS), 7.46 (d, 18, ~ 2.4 Hz, H3), 8.23 (bs, lH, NH). MS: m/z 
293 (M, 14.4%), 262 (M-OCH3, 4.9), 261 (M-CH30H, 24.9), 233 (M-CH 308-
CO, 2.3), 220 (M-C 3H502, 8.8), 219 (M-C3H602, 16.8), 192 (M-
COCH2C02CH3, 7.7), 191 (219-CO, 11.9) , 176 (191-CH 3 , 14.7), 157 (M-
C7H602N, 37.8), 138 (27.7), 129 (157-CO, 100), 125 (70.5), 115 
(23.0), 97 (47.5), 69 (25.5), 59 (C 2H302, 0.2), 54 (61.7). 
attempted cyclization of 2-[5-(methoxycarbonyl)-4-oxo-pentanamido]-6-
methyl-1,4-benzoquinone (266) 
basic reaction conditions 
a. 2-[5-(methoxycarbonyl)-4-oxo-pentanamido]-6-methyl-1,4-
benzoquinone (266) (5 mg, 0.017 mmol) was suspended in 5% aqueous 
sodium carbonate (1.0 ml) in an opened flask. After stirring at room 
temperature for 5 min, the reaction mixture turned black. Palladium 
174. 
on carbon (5%, 1 mg) was then added and the reaction mixture was 
allowed to stir at room temperature for 2 h. Dilute aqueous 
hydrochloric acid (lM) was added dropwise till the solution was pH 3. 
The catalyst was filtered off and the residue was washed with ethyl 
acetate (2 x 2 ml). The filtrate was extrac ted with ethyl acetate (3 
x 2 ml). The combined ethyl acetate extracts and washings were dried 
(Na 2S0 4 ) and evaporated under reduced pressure to give a complex 
mixture (5.1 mg) by t.l.c. 
b. 2-[5-(methoxycarbonyl)-4-oxo-pentanamido]-6-methyl-1,4-
benzoquinone (266) (5.4 mg, 0.018 mmol) was dissolved in methanolic 
sodium carbonate (0.01 M, 2.0 ml) to give a black solution. Oxygen 
gas was bubbled through the reaction mixture for 2 h. Then palladium 
on carbon (10%, 1 mg) was added and the reaction mixture was allowed 
to stir for another 10 h before being acidified to pH 3 and extracted 
with chloroform (3 x 3 ml). The combined chloroform extracts was 
dried (Na
2
S0
4
) and removal of solvent gave a crude mixture (4.4 mg), 
the t.l.c. and 1 H n.m.r. spectrum of which showed starting material 
and at least four other components. 
c. The acylaminoquinone (266) (10 mg, 0.034 mmol) was dissolved in 
anhydrous methanol (1.4 ml). Saturated methanolic sodium carbonate 
(2.0 ml) was then added. The reaction mixture turned black 
immediately. After stirring at room temperature overnight , it was 
then acidified to pH 4 by dropwise addition of dilute aqueous 
hydrochloric acid (lM) and extracted with ethyl acetate. Removal of 
solvent only gave low mass recovery of a complex mixture (4 mg). 
d. The acylaminoquinone (266) (10 mg, 0.034 mmol) was dissolved in 
dry THF (2 ml) under nitrogen. Sodium hydride (2.6 mg, 50% 
175. 
dispersion in mineral oil) was added. The reaction mixture turned 
black. A t.l.c. examination showed some starting material and base-
line material. The reaction mixture was quenched with ammonium 
chloride and the pH adjusted to 4 before being extracted with ethyl 
acetate. Removal of solvent gave a complex crude mixture as 
determined by 1H n.m.r. spectrum and t.l.c. 
acidic reaction conditions 
9-bromo-2-(carbomethoxymethylene)-8-hydroxy-10-methyl-3,4,5,6-
tetrahydro-1,6-benzoxazocin-5(2H)-one (289) 
a. The acylaminoquinone (266) (6.0 mg, 0.02 mmol) was dissolved in 
dry THF (1.8 ml) and cooled in an ice-bath. Methanolic hydrobromic 
acid (25 µl) was added dropwise and the reaction mixture was allowed 
to stir at room temperature for 20 h. It was then diluted with 
chloroform (10 ml), washed with water (2 x 2 ml), brine (2 ml) and 
dried (MgS0 4 ). Removal of solvent yielded a crude product (4 mg) 
which was purified by flash chromatography (dichloromethane/ethyl 
acetate, 1:1) to give 9-bromo-2-(carbomethoxymethylene)-8-hydroxy-10-
methyl-3,4,5,6-tetrahydro-1,6-benzoxazocin-5(2H)-one (289) (3.0 mg). 
(Found: M, 355.0055; C1 4H1 4BrN0 5 requires 355.0059; M-CH 30H, 
322.9793; C H BrNO requires 322.9792). UV: A 261, 299 nm. IR: 1 3 1 0 4 max 
v 3335 (OH), 1736 (ester CO), 1705, 1635 cm- 1 • 1 H NMR: o 2. 40 (s, 
max 
3H, Ar-CH
3
), 2.77 (t, 2H, J 7.5 Hz, CH 2 CONH), 3.45 (m, 2H, 
CH CH CONH), 3.67 (s, 3H, CO CH), 5.16 (m, lH, CH), 5.45 (bs, lH, 
2 2 2 3 
NH), 6.71 (s, lH, H3). MS: m/z 357/355 (M, 9.4, 10.0%), 325/323 (M-
CH OH, 24.1, 25.0), 284/282 (M-C HO, 15.1, 17.1), 277 (357-HBr , 
3 3 5 2 
43.1), 246 (32.1), 245 (277-CH30H, 100), 242/240 (32.7, 29.0), 222 
(30.3), 218 (20.8), 217 (32.5), 216 (77.2), 204 (62.2), 190 (23.9), 
176. 
189 (63.0), 188 (53.6), 176 (46.8), 162 (84.9), 69 (21.3), 68 (26.5), 
67 (41.4), 65 (24.0), 59 (C 2H502 , 19.7), 55 (36.7), 53 (52.1), 51 
(21. 7). 
2-(carbomethoxymethylene)-8-hydroxy-10-methyl-3, 4,S,6-tetrahydro 1,6 
benzoxazocin-5(28)-one (290) 
b. The acylaminoquinone (266) (5.0 mg, 0.017 mmol) was dissolved in 
THF (2 ml) under nitrogen. Boron trifluoride etherate (100 µl) was 
then added. The reaction mixture was allowed to stir at room 
temperature overnight. A t.l.c. examination showed only starting 
material. The reaction mixture was then heated to 60° C and kept at 
that temperature for 2 days before diluting with ethyl acetate and 
washed with water. The organic layer was dried (MgS04) and 
evaporated to give a sticky crude product (60 mg) which contained the 
borate (291) 139 from ring-opening of THF. Purification on silica gel 
gave 2-(carbomethoxymethylene)-8-hydroxy-10-methyl-3,4,5,6-
tetrahydro-1,6-benzoxazocin-5(2H)-one (290) (1.2 mg). (Found: M, 
277.0950; C14H1505N requires 277.0951 ). UV: Amax (MeOH) 285, 245 nm. 
IR: ~ 3355 (OH), 1736, 1705, 1605 cm-1. 1H NMR: o 2.08 (s, 3H, 
max 
Ar-CH 3), 2.77 (m, 2H, CH 2CONH), 3.43 (m, 2H, CH2CH 2CONH), 3.68 (s, 
3H, C0
2
CH 3), 5.00 (m, lH, CH), 6.75 (m, 2H, H3, HS). MS: m/z 277(M, 
13.5%), 275 (M-2H, 76.7), 273 (20.1), 245 (M-CH30H, 14.9), 244 (M-2H-
OCH3, 17.1), 217 (M-CH
3
0H-CO, 16.1), 216 (275-C0 2 CH 3 , 100), 215 (275-
CH30H-CO, 10.3), 188 (216-CO, 45.9), 53 (26.8), 43 (CH 3CO, 13.4). 
2-(carbomethoxymethylene) - 10-methyl-3,4,5,6-tetrahydro-1,6-
benzoxazocin-5(2B)-one (303) 
177. 
Dilute aqueous hydrochloric acid (2M, 1.5 ml) was added to the 
crude product (31 mg), obtained from the reaction of 2-amino-6-
methylphenol (257) (14 mg, 0.11 mmol) and methyl (~)-5-oxo-
tetrahydrofuran-2-ylideneacetate (284) (17 mg, 0.11 mmol), in 
dichloromethane (1.5 ml) at 0° C. After stirr ing vigorously at 0° C 
for 2 h, the reaction mixture was extracted with dichloromethane (3 x 
3 ml). The combined extracts was dried (MgS0 4 ) and evaporated to 
give a crude product (31 mg) which was purified on silica gel and 
recrystallized to give 2-(carbomethoxymethylene)-10-methyl-3,4,5,6-
tetrahydro-1,6-benzoxazocin-5(2H)-one (303) as needles, mp 164° C 
(ethyl acetate/~-hexane). (Found: C, 64.37; R, 5.61; N, 5.64; 
C14 H15N0 4 requires C, 64.36; H, 5.79; N, 5.36%). 
(ester CO), 1705 (amide I), 1630 (amide II) cm- 1 • 
IR: ~ 1738 
max 
1H NMR: o 2.29 (s, 
3H, Ar-CH 3 ), 2.76 (t, 28, J 7.4 Hz, CH 2CONH), 3.43 (m, 28, 
CH 2CH 2CONH), 3.66 (s, 3H, C0 2CH3 ), 5.06 (t, lH, ~ 2.0 Hz, CH), 5.43 
(bs, lH, NH), 6.94 (d, 2H, ~ 4.9 Hz, 83, 85), 7.21 (t, 18, ~ 4.7 Hz, 
84). MS: m/z 261 (M, 60.7%), 230 (M-OCH 3 , 19.8), 229 (M-CH 30H, 
13.5), 206 (20.3), 202 (25.4), 201 (21.6), 188 (100), 160 (33.7), 146 
(43.6), 86 (39.5) , 84 (59.8), 77 (C6H5 , 14.3), 56 (51.6), 55 (24.4), 
43 (CH 3CO, 15.8). 
2-acetylamino-5-methoxy-6-methyl-1,4-benzoquinone (287) and 2-amino-
5-methoxy-6-methyl-1,4-benzoquinone (288) 
2-Acetylamino-6-methyl-1, 4- benzoquinone (263) (5.7 mg, 0.028 
mmol) was dissolved in dry methanol (0.2 ml) and cooled to 0° C. 
Saturated methanolic sodium carbonate (0.3 ml) was then added 
dropwise to the stirred solution. The reaction mixture turned from 
yellow to orange-red to purple after stirring for two days. It was 
quenched with dropwise addition of dilute aqueous hydrochloric acid 
178. 
(2M) to pH 4 and extracted with chloroform (3 x 5 ml). The combined 
chloroform extracts was washed with brine and dried (MgS0
4
). Removal 
of solvent under reduced pressure gav~ a crude product mixture which 
was purified by flash chromatography to give 2-acetylamino-5-methoxy-
6-methyl-1,4-benzoquinone (287) (1.2 mg, 26%) and 2-amino-5-methoxy-
6-methyl-1,4-benzoquinone (288) (2.7 mg, 46%). 2-Acetylamino-5-
methoxy-6-methyl-1,4-benzoquinone (287): (Found: M, 209.0688; 
clOHl lN04 requires 209.0684). 18 NMR: o 1.94 (s, 3H, 6-CH3), 2.23 
(s, 3H, NHC0C83), 4.12 (s, 38, 0C8 3), 7.34 (s, 18, 83), 8.18 (bs, lH, 
NH). MS: m/z 209 (M, 8.3%), 167 (M-C 2820, 100), 166 (M-C0CH3, 44.1), 
152 (167-C83, 16.9), 68 (36.5), 43 (C83C0, 92.8). 2-Amino-5-methoxy-
6-methyl-1,4-benzoquinone (288): (Found: M, 167.0582; C8H9N0 3 
requires 167.0581). 18 NMR: o 1.91 (s, 38, 6-CH 3 ), 4.10 (s, 38, 
0C8 3 ), 5.04 (bs, 28, NH 2 ), 5.53 (s lH, 83). MS: m/z 168 (M+l, 8.9%), 
167 (M, 100), 166 (40.1), 152 (M-CH 3 , 12.5), 138 (M+2-0CH 3 , 17.8), 
124 (138-N8 2 , 152-C0, 13.1), 109 (124-CH 3 , 11.0), 108 (124-NH 2 , 7.3), 
96 (124-C0, 14.0), 83 (28.1), 81 (109-C0, 6.3), 80 (108-C0, 7.1), 68 
(96-C0, 36.6), 41 (C 2 H0, 20.3) . 
reduction with diborane 
a. 
methyl 3-hydroxy-5-(phenylcarbamoyl)pentanoate (301) 
The amide (286) (19.5 mg, 0 . 078 mmol) was dissolved in THF (1 ml) 
under nitrogen and cooled to 0° c. Borane-THF complex (1 M solution, 
156 µl, 0.156 mmol) was then added at 0° C and the reaction mixture 
allowed to stir at room temperature overnight. Methanol (5 ml) was 
then added and the reaction mixture was stirred for 1 h before the 
solvent was evaporated. This procedure was repeated twice. The 
crude product (21 mg) after the final evaporation was purified on 
179. 
silica gel to give methyl 3-hydroxy-5-(phenylcarbamoyl)pentanoate 
(301) (11.4 mg, 58%). (Found: M, 251.1154; C13 H1704N requires 
251.1158). IR: vmax 3430 (NH), 1720 (ester CO), 1690 (amide I), 1600 
(amide II), 1525 (aromatic CH) cm- 1 • l H NMR: o 1.95 (m, 2H, 
CH 2CHOH), 2.53 (m, 4H, CH2CH 2CHOHCH 2C0 2CH 3 ), 3. 72 (s, 3H, C0 2CH 3 ), 
4 . 10 (m, lH, CHOH), 7.10 (t, lH, ~ 7.3 Hz, H3), 7.33 (d, 2H, ~ 7.3 
Hz, HZ and H4), 7.50 (d, 2H, J 7.3 Hz, Hl and HS), 7.71 (bs,, lH, 
NH). MS: m/z 251 (M, 2.4%), 233 (M-H 20, 2.7), 219 (M-CH 30H, 1.3), 
191 (M-C 2H302 , 0.3), 177 (219-C 2H20, 4.8), 93 (C6H6N, 100), 86 (44), 
77 (C6 H5 , 4.9). 
b. 
2-(carbomethoxymethyl)-10-methyl-3,4,S,6-tetrahydro-2H-1,6-
benzoxazocine (304) 
The amine (300) (7.9 mg, 0.064 mmol), dissolved in 
dichloromethane (0.3 ml), was added to the lactonic ester (284) (10 
mg, 0.064 mmol) in dichloromethane at 0° C under nitrogen. The 
reaction mixture was stirred at 0° C for 2 h, then the solvent was 
removed and the crude product was dried in vacuo. Borane-THF complex 
(lM solution, 130µ1, 0.130 mmol) was then added dropwise at 0° C and 
the reaction mixture was allowed to stir at 0° C overnight. Methanol 
(5 ml) was then added and the resulting reaction mixture was stirred 
for 1 h before the solvent was removed. This procedure was repeated 
twice. The 1H n.m.r. spectrum of the crude product (20 mg) showed 
the presence of the benzazocinone (303). Further treatment of this 
crude product with borane-THF complex gave 2(carbomethoxymethyl)-10-
methyl-3,4 , 5,6-tetrahydro-2H-1,6-benzoxazocine (304) (4.3 mg, 26%). 
(Found: M, 249.1360; C1 4 H19 N0 3 requires 249.1366). IR: vmax 3320 
(NH), 1730 (ester CO), 1660, 1470 cm- 1 • 1 H NMR: o 1.98 (m, 2 H, 
180. 
CH 2CH 2NH) , 2.26 (s, 3H, 10-CH 3 ), 2.32 (m, 2H, CH 2CH 2CH 2NH), 2.82 (m, 
2H, CH 2C0 2CH 3 ), 3 . 25 (m, 2H, NCH 2 ), 3.57 (s, 3H, C0 2CH 3 ), 6.75 (t, 
lH, ~ 7.8 Hz, H8), 6.93 (d, lH, ~ 7.8 Hz, H7 or H9), 7.05 (d, lH, J 
7.8 Hz, H9 or H7). MS: m/z 249 (M, 54.9%), 234 (M-CH 3 , 3.8), 217 (M-
CH30H, 2.8), 176 (M-C 3H50 2 , 100), 147 (25.3), 134 (49.5) 91 (9.5), 77 
(20.0). 
3. Chapter 3 
2- [N- (benzyloxycarbonyl)-3-(t-butoxycarbonyl)propanamino] 6-
methylphenol (311b) 
181. 
2-Amino-6-methylphenol (257) (103 mg, 0.84 mmol) was dissolved in 
DMPU (0.8 ml). Solid sodium hydrogen carbonate (84 mg, 1.0 mmol) was 
then added via a solid addition device. The !-butyl ester (309b) 
(224 mg, 1.0 mmol) was then added and the reaction mixture was 
stirred under nitrogen. After stirring at room temperature for 2 
days, ethyl acetate (0.3 ml) was added and the precipitate formed was 
filtered off. Acetic acid (0.6 ml) was added and the mixture was 
chromatographed on buffer-washed silica gel (ca. pH 7.3) (ethyl 
acetate/dichloromethane/~-hexane, 2:4:4) to give the unstable a~ine, 
2-[3-(t-butoxycarbonyl)propanamino]-6-methylphenol (310b) (200mg, 
0.755 mmol, 89%). 1 H NMR: o 1.44 (s, 9H, C(CH 3 ) 3 ), 1.91 (m, 2H, 
CH
2
CH
2
CH
2
), 2.21 (s, 3H, Ar-CH 3 ), 2.35 (t, 2H, CH 2C0 2C4H9 ), 3.12 (t, 
2H, NCH
2
), 6.54-6.81 (m, 3H, H3, H4, HS). MS: m/z 265 (M, 40.5%), 
209 (M-C
4
H
8
, 64.1), 192 (M-C 4H90, 57.7), 136 (M-C7H13 02 , 100), 122 
(M-C
8
H
15
0
2
, 3.8), 91 (C 7H7 , 3.8), 55 (C 4H7 , 12.0). The amine (310b) 
was immediately dissolved in THF (3.5 ml) and cooled to -20° C. 
Pyridine (72 mg, 73µ1, 0.906 mmol) was then added, followed by benzyl 
chloroformate (154 mg, 129 µl, 0.906 mmol). The reaction mixture was 
allowed to stir at 0° C for 2h. Vater was then added to dissolve the 
pyridinium salt, the pH of the solution was found to be 4.7. The 
reaction mixture was extracted with dichloromethane (3 x 10 ml), and 
the combined extracts was washed with brine and dried (Na 2S0 4 ). 
Removal of solvent gave a crude mixture (380 mg) which was then 
purified by flash chromatography to give pure 2-[N-
(benzyloxycarbonyl)-3-(t-butoxycarbonyl)propanamino]-6-methylphenol 
182. 
(311b) (274 mg, 0.687 mmol, 91%). (Found: C, 68.80; H, 7.45; N, 
3.35; C23 H29 N0 5 requires C, 69.15; H, 7.32; N, 3.51%). IR: \I 3310 max 
(b, OH), 1715 (CO), 1480 cm- 1 • 
1.78 (m, 2H, CH 2CH 2CH 2 ), 2.29 (s, 3H, Ar-CH 3 ), 2.38 (m, 2H, 
CH 2 C0 2C4H9 ), 3.82 (m, 2H, NCH 2 ), 5.13 (bs, 2H, CH 2C6H5 ), 6.22-7.12 
(m, 3H, H3, 84, HS), 7.30 ~m, SH, C6H5 ). MS: m/z 399 (M, 0.6%), 343 
(H-C 4 H8 , 10.0), 235 (343-C7 H8 0, 8.8), 208 (343-C8 H702 , 44.7), 190 
(208-8 20, 11.9), 91 (C 7 H7 , 100). 
ethyl anilinobutyrate (316) 
Aniline (0.93 g, 0.98 ml, 0.01 mol) was dissolved in dry HHPA (10 
ml). Solid sodium hydrogen carbonate (1.008 g, 0.012 mol) was added 
via a solid addition device. The ethyl ester (309a) (1.95 g, 0.01 
mol) was then added and the reaction mixture was allowed to stir at 
room temperature for 24 h. Ethyl acetate (3 ml) was added and the 
precipitate thrown down was filtered off. The filtrate was 
concentrated and then purified by flash chromatography (ethyl 
acetate/dichloromethane/ ~-hexane, 4:3:3) to give ethyl 
anilinobutyrate (316) (1.86 g, 90%), mp 41°-41.5° C (ethyl acetate/n-
hexane). (Found: C, 69.21; H, 8.70; N, 6.66; C12 H17N0 2 requires C, 
69.54; H, 8.27; N, 6.76%). 
(Aromatic C-C), 1500 (o NH) 
IR: \l 3420 (NH), 1727 (CO), 1602 
max 
cm- 1 • 1 H NMR: o 1.25 (t, 3H, J 7.1 Hz, 
CO CH CH), 1.95 (m, 2H, CH 2 CH2 CH 2 ), 2.42 (t , 2H, J 7.2 Hz, 2 2 3 -
CH
2
C0
2
CH
2
CH
3
), 3.18 (t, 2H, ~ 6.8 Hz, NCH 2 ), 4.12 (q, 2H, ~ 7.1 Hz, 
C0
2
CH
2
CH
3
), 6.64 (m, 2H, H2', H6'), 6.74 (m, lH, 84'), 7.18 (m, 2H, 
H3', HS'). MS: m/z 207 (M, 37.6%), 162 (M-OC 2 H5 , 18.9), 106 (C 7 H8 N, 
ethyl (N-benzyloxycarbonylanilino)butyrate (317) 
183. 
The amine (316) (51 mg, 0.25 mmol) was dissolved in THF (1.2 ml) 
and cooled to -20° C. Pyridine (23.7 mg, 24 µl, 0.3 mmol) was then 
added followed by benzyl chloroformate (51 mg, 43 µl, 0.3 mmol). A 
white precipitate was thrown down. The reaction mixture was allowed 
to stir at -20° to 0° C for 1 h. Aqueous buffer solution (pH 6.8, 2 
ml) was then added and the reaction mixture was extracted with 
dichloromethane (3 x 4 ml). The combined extracts was dried (Na 2S0 4 ) 
and evaporated under reduced pressure to give ethyl (N-
benzyloxycarbonylanilino)butyrate (317) (84 mg, 0.244 mmol, 98%). 
(Found: C, 70.45; H, 8.01; C20 H23 N0 4 requires C, 70.35; H, 6.79%). 
IR: v 1732 and 1700 (CO) cm- 1 • 1 H NMR: 5 1.21 (t, 3H, J 7.1 Hz, 
max 
C0 2CH 2 CH 3 ), 1.88 (m, 2H, CH 2CH2 CH 2 ), 2.31 (t, 2H, ~ 7.4 Hz, 
CH2C0 2 CH 2 CH 3 ), 3.74 (t, 2H, ~ 7.3 Hz, NCH 2), 4.08 (q, 2H, ~ 7.1 Hz, 
C0 2CH 2 CH 3 ), 5.14 (s, 2H, CH 2C6H5 ), 7.12-7.41 (m, 10 H, 2xC6H5 ). MS: 
m/z 341 (M, 3.3%), 296 (M-OC2HS, 11.7), 234 (H-c,s,o, 14.5), 206 (H-
CsH,02, 58.0), 108 (C,H80, 31.0), 107 (C,H,o, 34.5), 77 (C6HS, 100). 
2-[N-(benzyloxycarbonyl)-3-(ethoxycarbonyl)propanamino]-6-
methylphenol (311a) 
The aminophenol (257) (100 mg, 0.81 mmol) was dissolved in HHPA 
(1 ml) under nitrogen. Solid sodium hydrogen carbonate (82 mg, 0.98 
mmol) was then added followed by the ethyl ester (309a) (158 mg, 0.81 
mmol). The reaction mixture was allowed to stir at room temperature 
for 28 h. Ethyl acetate (0.3 ml) was added and the precipitate 
thrown down was filtered. The filtrate was then chromatographed on 
silica gel to give the unstable amine, 2-(3-
ethoxycarbonyl)propanamino-6-methylphenol (310a) (139 mg, 0.58 mmol) 
which was immediately protected as its carbamate, 2-[N-
(benzyloxycarbonyl)-3-(ethoxycarbonyl)propanamino]-6-methylphenol 
(311a) (213 mg, 71% overall yield). 
184. 
2-(3-ethoxycarbonylpropanamino)-6-methylphenol (310a) 1 H NMR: o 
1.26 (t, 3H, J 7.1 Hz, C0 2 CH 2 CH ), 1.94 (m, 2H, CH CH CH) 2 23 (s 
- 3 2 2 2 1 • ' 
3H, 6-CH 3 ), 2.44 (t, 2H, J 7.1 Hz, CH CO CH CH), 3.17 (m 2H 
- 2223 '' 
NHCH 2 ), 4.13 (q, 2H, J 7.1 Hz, C0 2CH 2CH 3 ), m6.62-6.77 (m, 3H, 83, 84, 
HS). 
2-[N-(benzyloxycarbonyl) -3- (ethoxycarbonyl)propanamino]-6-
methylphenol (311a) (Found: M, 371.1730, C21 H25 N0 5 requires 
371.1734). 1 H NMR: o 1.21 (t, 3H, J 7.1 Hz, CO CH CH), 1.82 (m, 2H, 
- 2 2 3 
CH 2CH 2 CH 2 ), 2.27 (s, 3H, 6-CH 3 ), 2.41 (m, 2H, CH 2C0 2CH 2CH 3 ), 3.71 (m, 
2H, NCH 2 ), 4.03 (q, 2H, J 7.1 Hz, CO CH CH), 5.08 (bs, 2H, CH CH), 
- 2 2 3 265 
6.81 (t, lH, 84), 6.92 (d, lH, H3 or HS), 7.08 (d, lH, HS or 83), 
7.28 (m, SH, CH 2C6H5 ). MS: m/z 371 (M, 2.8%), 264 (M-C7H70, 12.3), 
263 (M-C7H8 0, 70.6), 236 (M-C 8H7 02 , 14.2), 218 (236-8 20, 45.7), 190 
(218-CO, 17.0), 176 (100), 175 (69.5), 162 (29.8), 149 (28.4), 108 
(C7H80, 50.2), 107 (C 7H70, 41.1), 91 (75), 87 (58.3), 79 (51.8), 77 
(37.2), 65 (21.8). 
ethyl 4-bromobutyrate (309a) 
A solution of y-butyrolactone (6.45 g, 5.8 ml, 0.075 mol) in 
ethanol (25 ml) was cooled to 0° C and a stream of hydrogen bromide 
was passed in for 6 h. After standing at 0° C overnight, the 
reaction mixture was poured into ice-cold water (120 ml). The oil 
which separated was decanted, the aqueous layer was extracted with 
ethyl bromide (3 x 10 ml) and the extracts were combined with the 
oil, washed with ice-cold 3% aqueous sodium hydroxide (2 x 10 ml), 
brine (2 x 10 ml) and dried (Na 2S0 4 ). Removal of solvent under 
reduced pressure gave a colourless oil (14.95 g) which was distilled 
to give ethyl 4-bromobutyrate (309a) (14.43 g, 99%), bp 75° C/5 mm 
(lit. 148 bp 101°-102° C/26 mm). 1H NMR: o 1.26 (t, 3H, J 7. 1 Hz, 
185. 
C0 2 CH 2CH 3 ), 2.18 (m, 2H, CH 2CH2 CH 2 ), 2.49 (t, 2H, ~ 7.1 Hz, 
CH2C0 2CH 2CH 3 ), 3.47 (t, 2H, ~ 6.3 Hz, CH 2Br), 4.12 (q, 2H, 
C0 2CH 2CH 3 ), MS: m/z 197/195 (M, 0.5, 0.5%), 168/166 (M-C 2H5 , 4.33, 
4.39), 151/149 (M-C 2H60, 35.0, 35.4), 123/121 (151/149-CO, 11.5, 
12.2), 115 (M-HBr, 4.6), 88 (C 4H802 , 100), 73 (C 3H502 , 6.4), 60 
(23.4), 45 (C 2H50, 14.7). 
t-Butyl 4-bromobutyrate (309b) 
y-Bromobutyric acid (0.95 g, 5.7 mmol) was dissolved in ether 
(9.5 ml) in a pressure bottle. Concentrated sulfuric acid (0.9 ml) 
and liquefied isobutene (9.5 ml) was then added. The reaction 
mixture was shaken on a Parr hydrogenation apparatus for 6 h. The 
solution was adjusted to pH 10 with cold aqueous sodium hydroxide (3 
M) and sodium chloride was added to saturate the solution. It was 
then extracted with ethyl acetate and dried (K2C0 3 ). Removal of 
solvent gave a crude product (1.05 g, 82%) which was distilled to 
give pure t-butyl 4-bromobutyrate (309b), bp 50° C/0.25 mm. (Found: 
C, 42.95; H, 6.85; Br, 35.73; C8H15Br0 2 requires C, 43.07; H, 6.78; 
Br, 35.81%). IR: \I 
max 
(NaCl) 2980, 1730 (CO), 1368 (!-butyl), 1160, 
1130, 848 cm- 1 • 1 H NMR: o 1.45 (s, 9H, C(CH 3 ) 3 ), 2.15 (m, 2H, 
CH
2
CH
2
CH
2
), 2.41 (t, 2H, { 7.1 Hz, CH 2CO), 3.46 (t, 2H, { 6.6 Hz, 
CH
2
Br). MS: m/z 169/167 (M-C 4H7 , 5.7, 5.7%), 151/149 (M-C 4H90, 56.8, 
56.3), 123/121 (M-C
5
H
9
0
2
, 17.9, 18.6), 87 (169 / 167-HBr, 14.1) , 59 
(61.3), 56 (15.1), 55 (C 4H7 , 100), 54 (79.8) , 52 (20.8). 
(N-benzyloxycarbonylanilino)butyric acid (318) 
The ethyl ester (317) (0.386 g, 1.13 mmol) was dissolved in 
methanol (3.8 ml) and cooled in a water-bath. Aqueous potassium 
186. 
hydroxide (5%, 1.8 ml) was then added dropwise. A white precipitate 
fell out. On further stirring and warming to room temperature, it 
dissolved again. After stirring at room temperature for 3 h, the 
reaction mixture was extracted with ethyl acetate. The aqueous layer 
was then adjusted to pH 2 by slow, dropwise additi on of aqueous 
hydrochloric acid (2M). Sodium chloride was added to saturate the 
solution before being extracted with ethyl acetate. Removal of 
solvent gave a yellowish oil (313 mg, 88%) which was distilled to 
give (N-benzyloxycarbonylanilino)butyric acid (318) as a colourless 
oil , bp 180° C/0.2 mm. 
C, 69.00; B, 6.11%). 
(Found: C, 68.86; H, 6.01; C18 H19 N0 4 requires 
IR: \J 3500 (OH), 1700 (CO), 1600 cm-1 • 18 
max 
NMR: o 1.86 (m, 2H, J 7.1 and 7.3 Hz, CH2 C8 CO H), 2.36 (t, 2H, J 7.3 
- 2 2 -
Hz, CH 2C0 2H), 3.75 (t, 2H, ~ 7.1 Hz, NCH 2 ), 5.13 (bs, 2H, CH 2C6H5 ), 
7.14-7.40 (m, lOH, 2xC 6H5 ). MS: m/z 313 (M, 21.6%), 
269 (M-C0 2 , 5.1), 196 (M-C 3H502 , 39.2), 178 (M-C0 2CH 2C6H5 , 1.4), 160 
(178-8
2
0, 2.3), 132 (160-CO, 2.5), 91 (C7H7 , 100), 77 (C 6 H5 , 9.9). 
methyl 3-oxo-6-(N-benzyloxycarbonylanilino)hexanoate (328) 
Magnesium methoxide (5.7 mg, 0.066 mmol) was dissolved in dry THF 
(0.3 ml). Methyl hydrogen malonate (16 mg, 0.13 mmol) was then added 
and the mixture was stirred for 1 h. The solvent was removed under 
reduced pressure and the residue was dried on the high vacuum pump to 
remove any residual methanol. 
The acid (318) (20 mg, 0.06 mmol) was dissolved in THF (0.3 ml). 
Carbonyldiimidazole (13.6 mg, 0.084 mmol) was then added. After 
stirring at room temperature for 6 h, the reaction mixture was then 
added to the magnesium salt of methyl hydrogen malonate prepared 
above. The mixture was stirred at room temperature for 18 h. The 
solvent was removed under reduced pressure and water was added to 
quench the reaction. The pH of the solution was found to be 8.5. 
187. 
The aqueous layer was extracted with ethyl acetate and the combined 
extracts was dried (MgS0 4 ). Removal of solvent gave a crude product 
(36 mg) which was purified by flash column chromatography (ethyl 
acetate/~-hexane/dichloromethane, 4:3:3, Rt 0.51) to give pure methyl 
3-oxo-6-(N-benzyloxycarbonylanilino)hexanoate (328), mp 84°-85.5° c. 
(Found: C, 68.49; H, 6.09; C21 H2 3 N0 5 requires C, 68 . 28; H, 6.28%). 
IR: v (NaCl) 3460, 2950, 1742 (ketone CO), 1700 (carbamate and 
max 
ester CO), 1600, 1495, 1405, 1250 cm- 1 • 1H NMR: o 1.83 (m, 2H, 
CH 2 CH2 CH 2 ), 2.55 (t, 2H, { 7.1 Hz, CH 2 CH 2CH2CO), 3.37 (bs, 2H, 
CH 2C0 2CH 3 ), 3.70 (s, 3H, C0 2CH 3 ), 3.72 (t, 28, NCH 2 ), 5.14 (bs, 2H, 
CH 2C6H5 ), 7.29 (m, SH, C6 H5 ). 
7-methyl-3-(carboxypropyl)-2-benzoxazolone (319) 
The ethyl ester (311a) (12 mg, 0.0323 mmol) was dissolved in 
anhydrous methanol (0.15 ml). Aqueous potassium hydroxide (5%, 0.05 
ml) was then added and the reaction mixture turned brown immediately. 
The reaction mixture was allowed to stir at room temperature for 6 h 
and then it was diluted with water and extracted with ethyl acetate 
to give benzyl alcohol (3 mg). The aqueous layer was then acidified 
to pH 2 and saturated with sodium chloride before it was re-extracted 
with ethyl acetate. The combined ethyl acetate extracts was dried 
and evaporated to gi ve a crude solid which was purified by 
recrystallization to gi ve 7-methyl-3-(carboxypropyl)-2-benzoxazolone 
(319) (7.2 mg, 95%), mp 144° C (chloroform/~-hexane). (Found: C, 
61.28; H, 5.70; N, 5.83; C12 H13 N0 4 requires C, 61.27; H, 5.57; N, 
5.95%). UV: A 273, 231 nm. 
max 
IR: v 3020 (hydrogen bonded OH), 
max 
1765 and 1730 (sh) (CO), 1470 cm- 1 • 1H NMR: o 2.11 (m, 2H, 
188. 
CH 2 CH2CH 2), 2.39 (s, 3H, CH 3 ), 2.49 (t, 2H, ~ 7.0 Hz, CH 2C0 2H), 3.91 
(t, 2H, ~ 7.1 Hz, NCH 2 ), 6.85 (d, lH, J 7.3 Hz, H4 or H6), 6.94 (d, 
lH, ~ 7.7 Hz, H6 or H4), 7.09 (t, lH, HS). MS: m/z 235 (M, 92.2%), 
218 (M-OH, 4.0), 190 (M-C0 2H, 2.4), 176 (M-C 2H302, 28.6), 175 (190-
CH3, 51.5), 162 (M-C3H502, 45.9), 149 (M-C HO , 100}, 148 (M-C HO, 46 2 472 
8.3), 134 (149-CH3, 5.6), 91 (C7H7, 35.0), 87 (C4H702 , 14.2), 78 
(C
6
H6, 9.4), 77 (C 6 H5 , 10 .6). 
2-[N-(benzyloxycarbonyl)-3-carboxypropanamino]-6-methylphenol (312) 
The !-butyl ester (311b) (62 mg, 0.155 mmol) was stirred in 40% 
trifluoroacetic acid in dichloromethane (1.5 ml) for 0.5 hat room 
temperature. The solvent was evaporated under reduced pressure and 
the residual triflouroacetic acid was removed on a high vacuum pump 
to give 2-[N-(benzyloxycarbonyl)-3-carboxypropanamino]-6-methylphenol 
(312) (53 mg, 100%) as a thick oil. (Found: C, 66.21; B, 6.27; 
C
19
H
21
N0 5 requires C, 66.46; H, 6.16%). IR: vmax 3300 (b, OH), 1710 
(CO), 1480, 1410 cm- 1 • 1 H NMR: o 1.85 (m, 28, CH 2CH2CH 2 ), 2.29 (s, 
3H, Ar-CH), 2.42 (m, 2H, CH CO H), 3.74 (m, 2H, NCH 2), 5.14 (bs, 2H, 3 2 2 
CH CH), 6.50 (bs, 18, OH), 6.83 (m, lH, 84), 6.94 (m, lH, H3 or 
2 6 5 
HS), 7.18 (d, lH, ~ 7.3 Hz, HS or H3), 7.50 (m, 58, C6 H5 ). MS: m/z 
343 (M, 1.9%), 325 (M-H 20, 0.7), 299 (M-C0 2 , 3.2), 281 (299- 820, 
0.8), 236 (M-OCH 2C6H5 , 15.5), 235 (M-HOCH 2C6H5 , 100), 218 (235-0H, 
3.8), 208 (M-C0 2CH 2C6H5 , 22.6), 190 (235-C0 2H, 11.1), 176 (235-
C2H302, _34.9), 175 (190-CH 3, 58.8), 162 (190-CO, 50.1), 149 (208-C0 2-
CH3, 84.1), 134 (162-CO, 9.5), 118 (162-C0 2, 15.4), 108 (HOCH 2C6 H5 , 
35.9), 107 (OCH 2C6H5 , 27.7), 91 (C7H7 , 61.5), 79 (C6H7 , 31.4), 77 
(C
6
H
5
, 23.1). 
189. 
An attempt to purify the acid (312) by distillation (150° C/0.1 
mm) gave instead 7-methyl-3-(carboxypropyl)-2-benzoxazolone (319) 
quantitatively. 
extension of the acid (312) to 2-(N-(benzyloxycarbonyl)-5-
(methoxycarbonyl)-4-oxo-pentanamino]-6-methylphenol (313) 
The magnesium salt of methyl hydrogen malonate (0.24 mmol) was 
generated as described above for the preparation of the f>-keto ester 
(328). 
The acid (312) (69 mg, 0.20 mmol) and carbonyldiimidazole (45 mg, 
0.28 mmol) were stirred in dry THF (1.0 ml) at room temperature for 6 
h. The reaction mixture was then added to the magnesium salt of 
methyl hydrogen malonate above and stirred at room temperature for 18 
h. The solvent was removed under reduced pressure and water was 
added to quench the reaction. The pH of the solution was found to be 
8.5. The aqueous layer was extracted with ethyl acetate and the 
combined extracts was dried (MgS0 4 ) and evaporated under reduced 
pressure to give a crude product (88 mg). Purification on silica gel 
(ethyl acetate/~-hexane/dichloromethane, 4:3:3) yielded the following 
products : 
2-[N-(benzyloxycarbonyl)-5-(methoxycarbonyl)-4-oxo-pentanamino]-6-
methylphenol (313) (43 mg, 53%). (Found: C, 66.22; H, 6.27; 
C H NO requires C, 66.15; H, 6.31%). IR: v 3340 (OH), 1748 and 
22 25 6 max 
1715 (CO) cm- 1 • 1H NMR: o 1.75 (m, 2H, CH 2CH 2CH2CO), 2.31 (s, 3H, 
6-CH
3
), 2.67 (m, 2H, CH
2
CH 2CH 2CO), 3.35 (m, 2H, CH 2CH2CH 2CO), 3.69 
(s, 3H, C0
2
CH
3
), 3.75 (m, 2H, CH 2C0 2CH 3 ), 5.12 (bs, 2H, CH 2C6H5 ), 
6.72-7.09 (m, 3H, H3, H4, HS), 7.28 (m, SH, C6H5 ). MS: m/z 399 (M, 
6.5%), 367 (M-CH
3
0H, 2.0), 291 (M-HOCH 2C6H5 , 4.8), 264 (M-C0 2CH 2C6 H5 , 
190. 
34.9), 232 (291-C0 2CH 3 , 21.1 ), 218 (291-C HO, 2.7), 204 (264-C8 OH-3 5 2 3 
CO, 0.8), 190 (291-C 4H503 , 7.6), 175 (190-CH 3 , 20.0), 162 (190-CO, 
7.2), 134 (162-CO, 47.5), 108 (HOCH CH, 4.60), 107 (OCH CH, 4.4), 2 6 5 2 6 5 
91 (C 7H7 , 100), 79 (C 6H7 , 6.5), 77 (C6H5 , 7.9). 
7-methyl-3-[4-oxo-5-(methoxycarbonyl)pentyl]-2-benzoxazolone (329) (9 
mg, 16%). mp 106°-107° C. (Found: C, 62.04; H, 6.00; N, 4.50; 
C15 H17N0 5 requires C, 61.85; H, 5.88; N, 4.81%). (Found: M, 
291.1107; C15H17N0 5 requires 291.1108). UV: Amax 272, 230 nm. IR: 
~ 1760 and 1720 (CO), 1475 cm- 1 1H NMR: 5 2.07 (m, 28, 
max 
CH 2CB 2CH 2 ), 2.38 (s, 38, 7-CH 3 ), 2.67 (t, 2H, J 6.6 Hz, CH 2CH 2CB 2CO), 
3.47 (s, 2H, CH 2C0 2C8 3 ), 3.73 (s, 38, C0 2C8 3 ), 3.84 (t, 2H, ~ 7.0 Hz, 
NCH
2
), 6.95 (m, 28, H3, HS), 7.09 (m, lH, H4). MS: m/z 291 (M, 
16.3), 259 (M-CH
3
0H, 4 . 2), 176 (23), 175 (100), 101 (32.3), 91 
(29.5), 69 (26.8), 65 (20.8), 59 (26.2), 43 (49.4). 
6-(benzyloxycarbonyl)-10-methyl-3,4,5,6-tetrahydro-1 ,6-benzoxacin-
2(2H)-one (330) (3 mg, 5%, as 2 rotamers). mp 109°-109.5° C (ethyl 
acetate/!!-hexane). (Found: C, 69.88; H, 6.03; N, 4.29; C19 H19 N0 4 
requires C, 70.14; H, 5.89; N, 4.30%) . UV: A 266 nm. IR: ~ max max 
1755 (lactonic CO), 1710 (carbamate CO) -1 cm . 1 H NMR: 5 1.98-2.42 
(m, CB CB CO, 2 rotamers), 2.32 (s, Ar-CH 3 , 2 rotamers), 3.64 (m, 2 2 2 
NCH
2
, 2 rotamers), 5.08 (bs, CH2C6H5 , major rotamer), 5.17 (bs, 
CB
2
C
6
H
5
, minor rotamer), 7.00-7.42 (m, CH 2C6H5 , 83, H4, HS, 2 
rotamers). MS: m/z 325 (M, 1.6%), 297 (M-CO, 0.2), 281 (M-C0 2 , 5.8), 
234 (M-CH
2
C
6
H
5
, 1.0), 218 (M-OCH 2C6H5 , 3.7), 190 (M-C0 2CH 2C6H5 , 
35.4), 175 (190-CH
3
, 1.4), 162 (190-CO, 9.8), 134 (190-C 3 H4 0, 6.7), 
107 (CH
2
C
6
H
5
, 1.8), 91 (C 7H7 , 100), 77 (C6H5 , 3.3) . 
1 (benzyloxycarbonyl) -l,2,3,4,5,6-hexahydro-6-methoxycarbonyl-9-
methyl-1 - benzazocin-5, 7,10-trione (314) 
191. 
The '3--keto ester (313) (8.6 mg, 0.0216 mmol) was dissolved in 
acetone (0.5 ml). Fremy's salt (40 mg, 0 . 151 mmol), dissolved in 
aqueous buffer pH 6.8 (2 ml), was added in three portions with 1 h 
interval. The ratio of the organic solvent to the aqueous buffer was 
kept constant by adding acetone (0.5 ml) to the reaction mixture 
whenever the Fremy's salt solution was added to prevent 
precipitation. After stirring at room temperature for 7 h, saturated 
ammonium chloride was added to quench the reaction mixture. It was 
then extracted with dichloromethane until the organic layer was 
colourless. The combined extracts was dried (Na 2 S0 4 ) and evaporated 
to give a crude product which was purified by preparative t.l.c. to 
give 1-(benzyloxycarbonyl)-1,2,3 ,4, 5,6-hexahydro-6-methoxycarbonyl-9-
methyl-l-benzazocin-5,7 ,10-trione (314) (5.7 mg, 64%), as a mixture 
of keto-enol tautomers, mp 138° C (ethyl acetate/~-hexane). (Found: 
C, 63.92; H, 5.36! N, 3.47; C22 H21 N0 7 requires C, 64.23; H, 5.14; N, 
3.40%). IR: v 1714 (CO), 1662, 1610 cm- 1 • 1 H NMR: o 1.71-2.00 
ma x 
(m, H2), 2.10 (d, J 1.8 Hz, 6-CH ), 2.45-2.65 (m, Hl), 3.40 (s, 
- 3 
CO CH), 3. 1 (s, CO CH), 4.22-4.37 (m, H3), 4.44-4.57 (m, H3), 5.02 
2 3 2 3 
(ABq, J 12.5 Hz, CH CH), 5.12 (ABq, J 12.5 Hz, CH 2C6 H5 ), 6.70 (m, 
- 2 6 5 -
H7), 7.13 (m, C
6
H
5
), 7.28 (m, C6 H5 ), 13.02 (bs, OH), 13.08 (bs, OH). 
MS: m/z 411 (M, 0.1%), 381 (M+2-CH 30H, 5.8), 352 (M-C0 2CH3 , 0.1), 305 
(M+2-HOCH
2
C
6
H
5
, 0.1), 274 (M-OCH 2C6 H5 , 9.3), 273 (M-HOCH 2C6 H5 , 55.3), 
258 (273-CH
3
, 0.6), 246 (381-C0 2CH 2C6H5 , 41.3), 228 (246-H 20, 3.0), 
218 (246-CO, 6.1), 217 (246-CHO , 9.3), 202 (217-CH 3 , 3.7), 108 
(HOCH
2
C
6
H
5
, 8.5), 107 (OCH 2C6 H5 , 7.3) , 91 (C 7 H7 , 100), 79 (C 6 H7 , 
11.9), 77 (C6 H5 , 12.4). 
methyl 2,3 dihydro-5,8-dioxo-6-methyl-lH-pyrrolo[l,2-a]indole-9-
carboxylate (337) 
192. 
The benzazocinone (314) (4 mg, 9.7 x 10- 3 mmol) was dissolved in 
anhydrous methanol (0.5 ml) and 5% palladium on carbon (1.5 mg) was 
added. The system was evacuated and then filled with hydrogen. This 
procedure was repeated three times. Then the reaction mixture was 
allowed to stir at room temperature for 2.5 h. The catalyst was 
filtered off and washed with methanol (2 x 2 ml). The filtrate and 
the washings were combined and evaporated under reduced pressure to 
give a yellow solid which was recrystallized to give methyl 2,3-
dihydro-5,8-dioxo-6-methyl-lH-pyrrolo[l,2-a]indole-9-carboxylate 
(337) as yellow prisms, mp 183° C (ethyl acetate/~-hexane). (Found: 
M, 259.0846; C14813 N0 4 requires 259.0896). UV: >-. 420, 328, 268, max 
237 nm. IR: 
" max 
1725 (ester CO), 1650 (quinone CO) cm- 1 • 1 H NMR: 
o 2.05 (d, 3H, ~ 1.8 Hz, 6-CH 3 ), 2.65 (m, 2H, H2), 3.14 (t, 2H, ~ 7.7 
Hz, Hl), 3.87 (s, 3B, C0 2C8 3 , 4.33 (t, 28, ~ 7.3 Hz, 83), 6.46 (m, 
lH, 87). MS: m/z 259 (M, 40.8%), 244 (M-CH 3 , 0.3), 228 (M-OCH 3 , 
100), 227 (M-CH
3
0H, 65.3), 199 (227-CO, 31.5), 171 (199-CO, 5.7). 
2-methoxy-5-butyl-6-methyl-1,4-benzoquinone (326) and 2,5-dibutyl-6-
methyl-1,4-benzoquinone (327) 
The quinone (323) (12 mg, 0.08 mmol) and ~-butylamine (5.8 mg, 
115 µl of 6% solution) in methanol (1.5 ml) were stirred at room 
temperature overnight. The solvent was evaporated and water (2 ml) 
was then added. The aqueous layer was then extracted with ethyl 
acetate. The combined ethyl acetate extracts was dried (Na 2 S0 4 ) and 
evaporated to give a crude mixture which was purified on silica gel 
(ethyl acetate/~-hexane / dichloromethane, 4:3:3) to give starting 
material (3 mg, 25%), 2-methoxy-5-butyl-6-methyl-1,4-benzoquinone 
(326) (2 mg, 11%) and 2,5-dibutyl-6-methyl-1,4-benzoquinone (327) (4 
mg, 19%). 2-methoxy-5-butyl-6-methyl-1,4-benzoquinone (326): (Found: 
193. 
M, 223.1201, C12 H1703N requires M, 223.1209). 1 H NMR: o 0.95 (t, 3H, 
J 7.3 Hz, CH,CH 3 ), 1.43 (m, 2H, NCH CH CH), 1.56 (m, 2H, NCH CH) - , 2 2 2 2 2' 
2.10 (s, 3H, 6-CH 3 ), 3.52 (q, 2H, NCH 2 ), 3.81 (s, 3H, OCH 3 ), 5.69 (s, 
lH, H3), 5.82 (bs, lH, NH). MS: m/z 223 (M, 100%), 222 (29.9), 194 
(M-C 2H5 , 50.2), 180 (M-C 3H7 , 84.9), 166 (M-C 4H9 , 18.4), 152 (180-CO, 
42.2), 150 (28.1), 148 (26.1), 138 (166-CO, 15.8), 124 (152-CO, 
37.6), 123 (25.4), 122 (25.5), 109 (124-CH 3 , 19.5), 69 (70.4), 68 
(25.1), 53 (25.6). 2,5-dibutyl-6-methyl-1,4-benzoquinone (327): 
(Found: M, 264.1835; C15H24 N202 requires 264.1839). 
1 H NMR: o 0.98 
(m, 6H, CH,CH 2CH3 ), 1.42 (m, 4H, CH CH2CH ), 1.63 (m, 4H, CH CH CH), , 2 3 2 2 3 
2.08 (s, 3H, 6-CH 3 ), 3.12 and 3.58 (m, 4H, CH CH CH CH), 5.26 (s, 2 2 2 3 
lH, 83), 6.67 (bs, 2H, NH). MS: m/z 264 (M, 93.8%), 249 (M-CH 3 , 
4.0), 235 (39.6), 221 (M-C
3
H
7
, 100), 208 (M-C 4H8 , 19.8), 193 (221-CO, 
14.4), 177 (11.4), 165 (17.0). 
3a,5-dimethyl-1,3-dihydropyrrolo[2,1-b]benzoxazole (344) 
The aminophenol (257) (74 mg, 0.6 mmol) was dissolved in DMPU 
(0.6 ml) under nitrogen. Solid sodium hydrogen carbonate (60.5 mg, 
0.72 mmol) was then added followed by the bromoketone (340) (99 mg, 
0.6 mmol). The reaction mixture was allowed to stir at room 
temperature for 19 hand then work-up as usual. The product (77 mg) 
obtained after flash chromatography was purified by distillation to 
give pure 3a,5-dimethyl-1,3-dihydropyrrolo[2,1-b]benzoxazole (344) 
(61 mg, 54%), bp 45°/0.05 mm. (Found: C, 76.23; H, 7.71; C12 H15 NO 
requires C, 76.15; H, 7.99%). UV: A 290, 241 nm. 1H NMR: o 1.55 
max 
(s, 3H, 3a-CH ), 1.81 (m, 2H, H2), 2.06 (m, 2H, Hl), 2.18 (s, 3H, Ar-
3 
CH), 3.10 (m, lH, H3), 3.41 (m, lH, 83), 6.68 (m, 38, 86, 87, HS). 
3 
MS: m/z 189 (M, 67.9%), 174 (M-CH 3 , 87.5), 161 (M-CO, 53.9), 147 
(24.7), 91 (C
7
H
7
, 100), 78 (C6 H6 , 13.0), 77 (C 6 H5 , 36.0), 71 (23.7), 
69 (37.5), 65 (24.6), 55 (73.7), 43 (53.1), 41 (71.2), 39 (24.4). 
194. 
2-[N-(benzyloxycarbonyl)-3-(2-methyl-1,3-dioxolan-2-yl)propanamino] 
6-methylphenol (346) 
The aminophenol (257) (25 mg, 0.203 mmol), the ketal (345) (51 
mg, 0.244 mmol) and solid sodium hydrogen carbonate (20 mg, 0.244 
mmol) were stirred in HMPA (0.2 ml) under nitrogen at room 
temperature for 24 h. The reaction mixture was then cooled to -20° 
to 0° C, benzyl chloroformate (42 mg, 0.244 mmol, 35 µl) and pyridine 
(19.3 mg, 20 µl) were then added and the reaction mixture was stirred 
at 0° C for 2 h. Yater was added and the aqueous layer was extracted 
with ethyl acetate. Removal of solvent gave a crude product (129 mg) 
which was purified on silica gel, followed by recrystallization to 
give pure 2-[N-(benzyloxycarbonyl)-3-(2-methyl-1,3-dioxolan-2-
yl)propanamino]-6-methylphenol (346) (38 mg, 50%), mp 90.5°-91.5° C 
(ethyl acetate/~-hexane) (Found: C, 68.58; H, 7.11; N, 3.54; 
C22 H27 N05 requires C, 68.55; H, 7.06; N, 3.63%). IR: vmax 3400 (OH), 
1700 (CO), 1600 (Aromatic C-C), 1480, 1418, 1300, 928 (ketal) cm- 1 • 
1 H NMR: o 1.24 (s , 3H, terminal CH 3 ), 1.62 (m, 4H, NCH 2CH2CH2 ), 2.28 
(s, 3H, Ar-CH
3
), 3.70 (m, 2H, NCH 2), 3.87 (m, 4H, -OCH 2CH 20-), 5.17 
(bs, 2H, CH CH), 6.81 (m, lH, 84), 6.94 (d, lH, J 6.6 Hz, H3 or 
2 6 5 
HS), 7.07 (d, lH, l 7.3 Hz, HS or H3), 7.30 (m, SH, C6H5) .. MS: m/z 
385 (M, 2.7%), 370 (M-CH 3 , 0.5), 324 (M-C2H502 , 0.1), 277 (M-
HOCH2C6H5, 8.6), 262 (277-CH 3 , 18.3), 250 (M-C0 2CH2C6H5, 2.1), 234 
(262-CO, 6.8), 188 (250-C 2H602, 1.5), 175 (262-C 4H702, 18 .1), 162 
(250-C
4
H
8
0
2
, 4.8), 108 (HOCH 2C6H5, 24.0), 107 (OCH 2C6H5, 19.7), 91 
(CH, 41.0), 87 (CHO, 100), 79 (C6H7 , 26.5), 77 (C6H5, 16.5), 43 7 7 4 7 2 
(39.9). 
2[N (benzyloxycarbonyl)-4-oxo-pentanamino]-6-methylphenol (347) 
195. 
The carbamate (346) (35.9 mg, 0.093 mmol) and pyridinium E-
sulfonate (12 mg, 0.047 mmol) were heated to reflux in water/acetone 
mixture (5 : 95) for 2 h . Ethyl acetate was added to the reaction 
mixture and the organic phase was washed with water, dried (Na SO) 2 4 
and evaporated to give a crude product (32 mg) which was purified by 
flash chromatography (ethyl acetate/~-hexane/dichloromethane, 2: 4:4) 
to give 2[N-(benzyloxycarbonyl)-4-oxo-pentanamino]-6-methylphenol 
(347) (30 mg, 95%). (Found: C, 70.23; H, 6.89; C20 H23 N0 4 requires C, 
70 . 36; H, 6.79%). IR: vma x 3320 (OH), 1710 and 1695 (sh) (CO), 1602, 
1469, 1412, 1308 cm- 1 • 
(bs, 3H, COCH 3 ), 2.30 (s, 3H, Ar-CH 3 ), 2.52 (m, 2H, CH 2COCH 3 ), 3.80 
(m, 2H, NCH 2 ), 5.08 (bs, 2H, CH 2C6 H5 ), 6.71-7.11 (m, 3H, H3, H4, HS), 
7.29 (m, SH, CH 2C6H5 ). MS: m/z 341 (M, 1.8%), 233 (M-C 7 H803 , 12.6), 
206 (m-C8 H7 02 , 30.1), 175 (41.5) , 108 (C 7H80, 21.0) , 107 (C 7 H70, 
19.0), 91 (C7H7 , 100), 85 (34.8), 79 (34.1), 77 (25.0). 
2-[N-(benzyloxycarbonyl)-4-oxo-pentanamino)-6-methyl-1,4-benzoquinone 
(338) 
The phenol (347) (122 mg, 0.36 mmol) was dissolved in benzene 
(4.2 ml). Tricaprylymethylammonium chloride (90 mg, 0.179 mmol), 
dissolved in benzene (1 ml), was then added followed by Fremy's salt 
(773 mg, 2.88 mmol) in aqueous buffer pH 6.8 (25 ml). The reaction 
mixture was allowed to stir at r oom temperature for 22 h. The 
reaction mixture was extracted with chloroform until the organic 
layer was colourless. The combined extracts was dried (MgS0 4 ) and 
evaporated to gi ve a crude mi xture which was purified by flash 
chromatography (ethyl acetate/ dichloromethane, 1.5:8.5) to give 2-[N-
(benzyloxycarbonyl)-4-oxo-pentanamino)-6-methyl-1,4-benzoquinone 
(338) (34 mg, 82%) . (Found: C, 67.41; H, 6.17; C20 H21 N0 5 requires C, 
196. 
67.59; H, 5.96%). IR: vmax 1715 (ketone CO), 1660 (quinone CO), 
1610, 1400 cm- 1 • 18 NMR: o 1.78 (m, 2H,CH CH CH), 2.01 (d, 3H, J 2 2 2 
1.7 Hz, 6-CH 3 ), 2.11 (s, 3H, COCH 3 ), 2.52 (t, 2H, ~ 6.9 Hz, 
CH 2COCH 3), 3.64 (t, 38, ~ 7.0 Hz, NCH 2), 5.09 (s, 2H, CH 2C6H5), 6.49 
(d, lH, ~ 2.5 Hz, H3), 6.55 (m lH, HS), 7.20-7. 38 (m, SH, CH) . MS: 6 5 
m/z 355 (M, 0.1%), 311 (M-C0 2, 0.2), 264 (M-C7H7, 2.4), 220 (M-
C7H802, 4.7), 91 (C7H7, 100), 85 (12.6), 65 (9.0). 
2-(3-(ethoxycarbonyl)propanamino]-6-methyl-1,4-benzoquinone (351) and 
2-[N-(benzyloxycarbonyl)-3-(ethoxycarbonyl)propanamino]-6-methyl-1,4-
benzoquinone (350) 
The aminophenol (310a) (49 mg, 0.132 mmol) was dissolved in 
acetone (2.9 ml) and aqueous buffer pH 6.8 (2.1 ml). Fremy's salt 
(88 mg, 0.33 mmol), dissolved in the same buffer (4.4 ml) was then 
added. The reaction mixture was allowed to stir at room temperature 
for 2 days before it was worked-up as usual to give a crude product 
(51 mg) which was purified by flash chromatography to give 2-[N-
(benzyloxycarbonyl)-3-(ethoxycarbonyl)propanamino]-6-methyl-1,4-
benzoquinone (350) (26 mg, 51%) and 2-(3-
(ethoxycarbonyl)propanamino]-6-methyl-1,4-benzoquinone (351) (6.3 mg, 
19%). 
2-[N-(benzyloxycarbonyl)-3-(ethoxycarbonyl)propanamino]-6-methyl-1,4-
benzoquinone (350): (Found: C, 65.08; H, 5.99; C21 H23 N0 6 requires C, 
65.51; H, 6.02%). UV: >.. 365, 279 (sh), 252 nm. max IR: v 1730, max 
1715, 1650 (CO) cm- 1 • 
1.88 (m, 2H, CH 2CH 2CH 2), 2. 01 (d, 3H, ~ 1.5 Hz, 6-CH3), 2.37 (m, 2H, 
CH2C0 2CH 2CH 3), 3.66 (t, 2H, ~ 6.8 Hz, NCH 2), 4.09 (q, 2H
, J 7.0 Hz, 
C0
2
CH 2CH 3), 5.08 (s, 2H, CH 2C6H5 ), 6.49 (d, lH, ~ 2.5 Hz, H
3), 6.54 
(m, lH, HS), 7.19-7.41 (m, SH, CH 2C6H5 ). MS: m/z 385 (M, 12.0%), 340 
197. 
(M-OC 2H5 , 18.9), 277 (M-C 7H80, 14.5), 250 (M-C 88702 , 50 . 2), 91 (C 7H7 , 
100) . 
2-[3-(ethoxycarbonyl)propanamino]-6-methyl-1,4-benzoquinone (351): 
(Found: C, 62.01; H, 6.72; C13 H17N0 4 requires C, 62.16; H, 6.83%). 
UV: Amax 486, 277 nm. IR: ~max 3430 (NH), 17 30 (ester CO), 1650 
(quinone CO) cm- 1 • 18 NMR: & 1.27 (t, 38, J 7.1 Hz, CO CH CH), 
- 2 2 3 
1.91-2.08 (m, 28, CH 2C0 2CH 2CH 3 ), 2.01 (d, 3H, ~ 1.7 Hz, 6-CH 3 ), 2.41 
(m, 2H, · CH 2 CB2 CH 2 ), 3.16 (m, 2H, NCH 2 ), 4.16 (q, 28, ~ 7.1 Hz, 
C0 2CH 2CH 3 ), 5.44 (d, lH, ~ 2.4 Hz, 83), 5.79 (bs, lH, NH), 6.47 (m, 
18, HS). MS: m/z 251 (M, 21.5%), 236 (M-CH 3 , 2.1), 207 (M-C0 2 , 0.5), 
206 (M-OC 2H5 , 18.5), 91 (C7H7 , 100). 
6-methyl-2-(3(2-methyl-1,3-dioxolan-2-yl)pentanamino]-1,4-
benzoquinone (348) 
Similar treatment of the phenol (346) (36.5 mg, 0.095 mmol) with 
Fremy's salt under the same reaction conditions as for the phenol 
(311a) above yielded 6-methyl-2-(3(2--methyl-1 ,3-dioxolan-2-
yl)pentanamino]-1,4-benzoquinone (348) (4.2 mg, 17%). (Found: M, 
265.1314; C1 4H19 N0 4 requires 265.1315). 
1H NMR: & 1.32 (s, 3H, 
terminal CH
3
), 1.75 (m, 4H, NHCH 2 CB 2 CB 2 ), 2.01 (s, 3H, 6-CH 3 ), 3.09 
(m, 2H, NCH
2
), 3.97 (m, 4H, -OCH 2CH20-), 5.42 (m, lH, 83), 5.86 (bs, 
lH, NH), 6.46 (m, lH, HS). MS: m/z 265 (M, 8.0%), 250 (M-CH 3 , 
10.5), 205 (24.0) , 178 (M-C 4H702 , 7.1), 163 (178-CH 3 , 18.0), 150 
(178-CO, 25.1), 122 (150-CO, 4.4), 87 (C 4 H702 , 100), 71 (24.9), 43 
(40.9). 
2-(N-benzyloxycarbonyl)amino-6-methylphenol (352) 
198. 
The aminophenol (257) (104 mg, 0.85 mmol) was dissolved in THF 
(8.5 ml) and cooled in an ice-bath. Benzyl chloroformate (173 mg, 
145 µl, 1.01 mmol) was added followed by pyridine (80 mg, 82 µl, 1.01 
mmol). After stirring for 2 h, the reaction was worked-up in the 
usual manner to give a crude mixture which was purified on silica gel 
to give 2-(N-benzyloxycarbonyl)amino-6-methylphenol (352), (203 mg, 
93%), mp 74°-74.5° C (~-hexane). (Found: C, 70.04; H, 5.90; N, 5.35; 
C15H15N0 3 requires C, 70.02; H, 5.88; N, 5.44%). IR: \J 3310 (OH), max 
1715 (CO), 1480 , 1412, 1308 cm- 1 • 1 H NMR: o 2.28 (s, 3H, CH 3 ), 
5.23 (s, 2H, CH 2C6H5 ), 6.78 (t, lH, ~ 8.0 and 8.0 Hz, H4), 6.94 (d, 
lH, ~ 8.0 Hz, 83 or HS), 7.05 (d, lH, ~ 8.0 Hz, HS or H3), 7.40 (m, 
SH, CH 2C6H5 ). MS: m/z 257 (M, 20.5%), 213 (M-C02, 10.1), 149 (M-
C7H70, 20.8), 122 (M-C7H80, 12.2), 122 (213-C7H7, 12.2), 108 (C7H80, 
7.3), 107 (C7H70, 6.5), 91 (C7H7, 100). 
2-(N-benzyloxycarbonyl)amino-6-methyl-1,4-benzoquinone (353) 
The phenol (352) (47 mg, 0.183 mmol) was dissolved in methanol (4 
ml) and aqueous buffer pH 6.8 (2.9 ml). Fremy's salt (123 mg, 0.458 
mmol) was then added and the reaction mixture was stirred at room 
temperature for 0.5 hand then worked-up as usual. Recrystallization 
then gave 2-(N-benzyloxycarbonyl)amino-6-methyl-1,4-benzoquinone 
(353) (48 mg, 95%), mp 124° C (ethyl acetate/~-hexane). (Found: C, 
66.43; H, 4.69; N, 5.06; C15 H13 N0 4 requires C, 66.41; H, 4.83; N, 
5 .16%). UV: A 389, 272 nm. 
max 
IR: \J (CC14) 3380 (NH), 1754 
max 
(carbamate CO), 1658 (quinone CO), 1650 (C=C) cm- 1 • 1 8 NMR: o 2.06 
(d, 38, ~ 1.5 Hz, 6-CH 3 ) , 5.22 (s, 28, CH 2C6H5 ), 6.52 (m, lH, HS), 
7.21 (d, 18, ~ 2.7 Hz, H3), 7.39 (m, SH, C6H5 ), 7.65 (bs, lH, NH). 
MS: m/z 272 (M+l, 0.6%), 271 (M, 0.8), 227 (M-C0 2, 2.9), 226 (M+l-
C02, 3.3), 211 (226-CH
3
, 0.4), 210 (M+2-H-C0 2-H20, 2.8), 198 (226-CO, 
199. 
0.4), 182 (210-CO, 0.4), 165 (H+l-OCH CH, 39 .7) 163 (M-BOCH CH 
2 6 s ' 2 6 s' 
18.3), 135 (163-CO, 8.0), 108 (HOCH 2C6 85 , 18.5), 107 (OCB 2C6 H5 , 
19.1), 91 (C7 H7 , 100). 
S,6-dioxo-7-methyl-3-(4-oxo-pentyl)-2-benzoxazolone (358) 
The quinone (338) (30 mg, 0.085 mmol), dissolved in dry THF (2 
ml) was added to LDA (0.186 mmol) at -78° C. A green colour 
developed. After stirring at -78° C for 2.5 h, the crude reaction 
mixture was oxidized with Fremy's salt to give 5,6-dioxo-7-methyl-3-
(4-oxo-pentyl)-2-benzoxazolone (358) (4 mg, 18%). (Found: M, 
263.0794; C13 H13 N0 5 requires 263.0792). UV: A 293 nm. max IR: \J max 
1826 (oxazolone CO), 1715 (ketone CO), 1670 <~,a---unsaturated CO), 
1634 (C=C), 1420 cm- 1 • 
(s, 3H, quinone CH 3 ), 2. 17 (s, 3H, COC8 3 ), 2.59 (t, 2H, ~ 6.3 Hz, 
CH 2COCH 3 ), 3.70 (t, 2H, ~ 7.1 Hz, NCH 2 ), 5.85 (s, lH, H3). MS: m/z 
265 (M, 23%), 263 (22), 236 (31), 235 (263-CO, 100), 220 (M-C 2830, 
4), 207 (235-CO, 11.0), 165 (20), 
2-[N-(benzyloxycarbonyl)-4-oxo-pentanamino]-6-methyl-hydroquinone 
(354) 
The quinone (338) (57 mg, 0.16 mmol), dissolved in THF (6 ml), 
was added dropwise to a solution of LTMP (0.385 mmol) at -60° C. A 
green colour developed. The reaction mixture was stirred for 1.75 h 
and 1% acetic acid was then added to quench the reaction. It was 
then extracted with chloroform and the chloroform extracts was dried 
(Na SO) and evaporated under reduced pressure to give a crude 
2 4 
product mixture which was then purified by on silica gel to give 
starting material (4 mg, 7%) and 2-[N-(benzyloxycarbonyl)-4-oxo-
200. 
pentanamino]-6-methyl-hydroquinone (354) (30 mg, 53%). (Found: M, 
357.1576; C20 H23 N0 5 requires 357.1578). UV: Nllax 295 nm. 1 H NHR: o 
1.79 (m, 2H, CH 2CH2CH 2 ), 2.09 (bs, 3H, C0CH 3 ), 2.22 (s, 38, 6-CH 3 ), 
2.48 (m, 2H, CH 2C0CH 3 ), 3.68 (m, 2H, NCH 2 ), 5.11 (bs, 2H, CH 2C6H5 ), 
6.39 (m, lH, H3 or HS), 6.57 (m, lH, HS or H3), 7.29 (m, SH, C6H5 ). 
HS: m/z 358 (H+l, 21%), 357 (M, 16), 250 (358-C7H60, 6), 249 (H-
C7H60, 6), 223 (H+l-C7H602 , 41), 91 (C7H7, 100), 86 (21), 85 (22). 
201. 
4. Chapter 4 
furfuryl chloride (~-furfuryl chloride) 
Freshly distilled furfuryl alcohol (0.981 g, 0.86 ml, 0.01 mol) 
was dissolved in dry ether. Pyridine (0.95 g, 0.97 ml, 0.012 mol) 
was then added and the reaction mixture was cooled in an ice-bath. 
Thionyl chloride (1.309 g, 0.78 ml, 0.011 mol), dissolved in dry 
ether (1.0 ml) was then added dropwise using an equalizing dropping 
funnel. Formation of a brown-black precipitate hindered stirring. 
Dry ether was added to the solid mass and decanted off. The lumps 
were broken up with a bent glass rod and dry ether was added and 
stirred for 5 min. Then the ethereal solution was again decanted 
off. This extraction procedure was repeated three times. The 
combined ether extracts was washed with cold 30% potassium hydroxide. 
. . 
The ether layer was then dried over anhydrous sodium carbonate and 
distilled using a short-path distillation apparatus to give furfuryl 
chloride (0.58 g, 50%), bp 49° C/26 mm (lit. 191 49.6° _-S0.0° C/27 
mm), 1 H NMR: o 4.60 (s, 2H, CH 2Cl), 6.36 (m, 2H, H3 , 84), 7.42 (m, 
lH, HS). MS: m/z 116 (M, 34%), 91 (16), 81 (100). 
2-furylacetic acid (454) 
A solution of sodium carbonate (10.6 g, 0 .1 mol) and potassium 
cyanide (3.5 g, 0.054 mol) in water (50.0 ml) was stirred at room 
temperature, glyoxal bisulfite (8.8 g, 0.033 mol), 2-furaldehyde (2.1 
g, 0.021 mol) , dioxan (5.0 ml), and water (100.0 ml) were added 
rapidly. The solution was stirred at room temperature for 2 h during 
which time the colour deepened from yellow to reddish brown. The 
reaction mixture was then acidified to pH 2 with sulfuric acid(~ 
202. 
100 ml of 1 M solution) and extracted with chloroform (5 x 75 ml). 
The combined chloroform extracts was washed with brine (50 ml), dried 
(MgS0 4 ), and evaporated to give a yellow oil ( 3.0 g) which slowly 
solidified. Recrystallization from pet roleum ether gave 2-
furylacetic acid (1.05 g, 40%), mp 67° C (li t. 260 mp 68°-69° C). IR 
: \Jmax (nujol) 1705 cm- 1 (CO). 1 H NMR: o 3.72 (s, 2H, CH 2 ), 6.25, 
6.35 (m, 2H, 3H, 4H), 6.60 (br, lH, C0 2H), 7. 40 (m, lH, HS). MS: m/z 
126 (M, 26 . 0%), 81 (100), 53 (45.0). 
methyl 2-furylacetate (442) 
a. from 2-furylacetic acid (454) and diazomethane 
2-Furylacetic acid (454) (0.9 g, 7.0 mmol) was dissolved in THF 
and cooled in an ice-bath. Freshly prepared diazomethane was added 
dropwise until effervescence stopped. The reaction mixture was then 
allowed to warm to room temperature and stirred for 0.5 h. The 
solvent was evaporated off to give a crude product (0.9 g) which was 
distilled to give pure methyl 2-furylacetate (0 . 82 g , 84%) 
colourless oil, bp 80° C/20 mm (lit. 260 87°-88° C/21 mm). 
as a 
IR: \J 
max 
(NaCl) 1770 cm- 1 (CO). 1 H NMR: o 3.70 (s, 2H, CH 2 ). 3.73 (s, 3H, 
CH 3 ), 6.22 (m, lH, H3), 6.34 (m, 18, H4), 7.38 (m, lH, HS). MS: m/z 
140 (M, 27.7%), 108 (M-CH 3 0H, 0.6), 81 (M-C0 2 CH 3 , 100), 53 (19.5). 
b. from 2-furaldehyde, glyoxal bisulfite, potassium cyanide in 
methanol/water mi x ture 
2-furaldehyde (0.96 g, 0.83 ml, 0.01 mol), glyoxal bisulfite (4.0 
g, 0.015 mol) and potassium cyanide (1.63 g, 0.025 mol) were stirred 
in a mixture of methanol /water (1:1) (240 ml) at room temperature for 
203. 
16 h. The solution was acidified to pH 3.5 with sulfuric acid and 
extracted with chloroform (3 x 100 ml). The combined chloroform 
extract was washed with brine (2 x 50 ml) and dried (MgS0 4 ). 
Evaporation of solvent gave methyl 2-furylacetate (442) (1.04 g, 
74%), bp 95°-100° C/16 mm (Kugelrohr). 
cis- and trans-isomeric mixture of methyl 2-(2,5-dihydro-2,5-
dimethoxy)furylacetate (443) 
a. Methyl 2-furylacetate (442) (0.794 g, 5.67 mmol) was dissolved in 
10 ml of 0.03 M methanolic solution of sodium triflate (NaCF 3 S0 3 MeOH) 
and electrolyzed at -50° Con platinum electrodes at a current of 
0.1-0.3 A. The mixture was adjusted to pH 8 by addition of sodium 
methoxide in methanol at -40°. Methanol was evaporated in vacuo and 
the residue partition between ether and 1.5% solution of sodium 
hydrogen carbonate. The ethereal layer was dried (MgS0 4 ) and the 
solvent removed to give a crude green liquid which was distilled at 
94° C/0.8 mm to give a mixture of ci~- and trans-isomers of methyl 2-
(2,5-dihydro-2,5-dimethoxy)furylacetate (443) (0.630 g, 55%). IR: 
~ 1740, 1630 cm- 1 • MS: m/z 202 (M, 0.7%), 171 (M-OCH 3 , 100), 143 max 
(M-C
2
H
3
0
2
, 8.2), 129 (M-C 3H502 , 75.5), 111 (143-CH 308, 42.9), 101 
(50.9), 59 (23.4). 1 H NMR: & 2.85 (m, CH 2 ), 3.15 and 3.22 (s, OCH 3 , 
2 isomers), 3.45 and 3.53 (s, OCH 3 , 2 isomers), 3.69 (s, C0 2Me), 5.49 
and 5.75 (s, HS, 2 isomers), 6.15 (m, H3, H4, 2 isomers). 13 C NMR: & 
44.54, 45.6 (CH CO CH), 50.06, 50.40, 51.68, 51.71 (OCH 3 ), 55.35, 2 2 3 
56.35 (CO CH), 107.12, 107.93 (CS), 111.12, 112.17 (C2), 131.21, 
2 3 
132.47 (C4), 133.26, 133.28 (C3), 169.67, 169.69 (CO). 
b. To methyl 2-furylacetate (442) (0.540 g, 3.86 mmol) in an 
electrolytic cell under argon was added 2% lithium perchlorate (5.0 
204. 
ml) and 0.5% sodium acetate (5.0 ml) in anhydrous methanol. The 
solution was cooled to -50° and electrolyzed on platinum electrodes 
while keeping the current at 0 . 1-0.3 A. The solvent was removed 
under reduced pressure and dry ether (50 ml) was then added to 
dissolve the residue and the ethereal solut ion was washed with dilute 
sodium hydrogen carbonate (2%, 2 x 10 ml) and dried (Na SO). 2 4 
Removal of solvent under reduced pressure and distillation gave a 
colourless liquid (0.5 g, 66%), bp 85°-90° C/0.03 mm (Kugelrohr), (bp 
lit. 186 b 117°-119° C/0.76 mm). 
methyl (E)- and (Z)-5-methoxy-2,5-dihydrofuran-2-ylideneacetate (459) 
and (460) 
a. Distillation of the crude dihydrofuran (443) at 135°-140° C/20 mm 
afforded methyl (E)- and (Z)-5-methoxy-2,5-dihydrofuran-2-
ylideneacetate (459) and (460) (9:1). The crude product solidified 
on standing and were separated by flash column chromatography (Rt (~) 
0.56, (~) 0.34, ethyl acetate/~-hexane/dichloromethane, 2:4:4). 
Methyl (E)-5-methoxy-2,5-dihydrofuran-2-ylideneacetate (459), mp 33° 
C (lit. 186 b 32°-35° C). UV: A (MeOH) 278 (€ 12000), 221, 206 nm. 
max 
IR: ~ 1712, 1648, 1134, 1105 cm- 1 • 1H NMR: o 3.46 (s, 3H, OCH 3 ), max 
3.71 (s, 3H, C0
2
CH
3
), 5.39 (s, lH, CHC0 2CH 3 ), 6.03 (m, lH, HS), 6.50 
(m, lH, H4), 7.51 (m, lH, H3). MS: m/z 170 (M, 30.7%), 155 (M-CH 3 , 
9.7), 139 (M-OCH
3
, 36.3), 123 (155-CH 30H, 18.1), 111 (M-C 2H302 , 100), 
108 (139-0CH
3
, 11.0), 69 (17.0), 59 (C 2H302 , 15.4). Methyl (Z)-5-
methoxy-2,5-dihydrofuran-2-ylideneacetate (460) UV: Amax (MeOH) 278 
(€ 6800) nm. IR: ~ 1712 (CO), 1650 (C=C), 1224, 1138, 1108 cm- 1 • 
max 
1H NMR: o 3.55 (s, 3H, OCH 3 ), 3.73 (s, 3H, C0 2CH 3 ), 5.05 (s, lH, 
CHCO CH) 6.21 (m, lH, HS), 6.38 (dd, lH, J 5.9, 1.0 Hz, 83), 6.47 
2 3 ' -
(m, lH, J 5.9 Hz, 84). MS: m/z 170 (M, 34.5%), 155 (M-CH 3 , 10.4), 
205. 
139 (M-OC8 3 , 54.1), 129 (14.5), 123 (155-C8 308, 21.4), 111 (M-C 8 O, 2 3 2 
b. The pure ~-isomer (459) was heated with a small crystal of KHSO 4 
at 100° C/10 mm for 30 min. affording a mixture of E- and Z-isomers 
(~:~=5.5:1). 
E-2-(carbomethoxymethylidene)-4-(diphenylsulfilimino)-S-methoxy-2,S-
dihydrofuran (480) 
A solution of the ~-diene (459) (19 mg, 0.11 mmol) and 
diphenylsulfilimine (37 mg, 0.17 mmol) in dry dichloromethane (1.0 
ml) was heated under reflux for 5 h. The solvent was removed and the 
crude product mixture was purified by flash column chromatography on 
buffer-washed silica gel (ca. 7.3) to give starting material (2 mg, 
10% recovery) and E-2-(carbomethoxymethylidene)-4-
(diphenylsulfilimino)-5-methoxy-2,5-dihydrofuran (480) (31 mg, 85% 
based on reacted starting material). (Rf 0.35, 5% 
methanol/chloroform). (Found: C, 64.55; 8, 5.59; C20 H21 N0 4 S requires 
C, 64.67; H, 5.70%). (Found; M, 371.1191; C20 H21 N0 4S requires 
371.1190). 
(S=N), 1100 
IR: v 1710 (CO), 1650 (C=C), 1444, 1210, 1165, 1120 
max 
-1 cm 1H NMR: o 3.18 (dd, 2H, ~ 4.8, 1.7 Hz, 83), 3.21 
(s, 3H, OCH
3
), 3.64 (s, 38, C0
2
CH
3
), 3.80 (t, lH, ~ 4.8 Hz, 84), 4.63 
(m, lH, HS), 5.36 (t, lH, ~ 1.7 Hz, CHC0 2CH 3 ), 7.40-7.62 (m, lOH, 2 x 
C
6
H
5
). MS : m/z 371 (M, 9.2), 356 (M-CH 3 , 9.3), 340 (M-OCH 3 , 11.1), 
201 (16.3), 187 (37.9), 186 [(C6 H5 ) 2 S, 100), 185 (61.5), 184 (28.7), 
170 (24.1), 125 (15.8), 111 (15.9), 109 (25.2), 98 (17.4), 93 (15.0). 
attempted reactions of 2(58)-furanone (440) with diphenylsulfilimine 
206. 
A solution of 2(58)-furanone (25 mg, 0.30 mmol) and 
diphenylsulfilimine (98 mg, 0.45 mmol) in dry benzene (3.0 ml) was 
heated under reflux for two days. Removal of solvent gave a crude 
mixture which was flash chromatographed (ethyl acetate/~-
hexane/dichloromethane, 4:3:3) to give diphenysulfilimine (10 mg) and 
starting material (20 mg, 80%). Similar result was obtained using 
dichloromethane as solvent. 
attempted reactions with nitrene generated from ethyl p-
nitrobenzenesulfonoxycarbamate 
a. The E-diene (459) (51 mg, 0.3 mmol) was dissolved in acid-free 
dichloromethane (10 ml). A solution of triethylbenzylammonium 
chloride (10 mg, 0.045 mmol) in aqueous sodium hydrogen carbonate 
(lM, 10 ml) was then added. Ethyl £-nitrobenzenesulfonoxycarbamate 
(487 mg, 1.68 mmol) was then added in four portions at 45 min 
interval. After the last addition, the reaction mixture was allowed 
to stir for another 45 min before diluting with acid-free ethyl 
acetate (10 ml) and the two phases were separated. The organic phase 
was washed with saturated sodium hydrogen carbonate (3 x 5 ml), brine 
(5 ml) and dried (Na 2S0 4 ). The solvent was evaporated under reduced 
pressure and the residue was purified by flash column chromatography 
on buffer-washed silica (ca. pH 7.3) to give starting material (4.2 
mg, 8%), 6-carbethoxy-2-(carbomethoxymethylidene)-4-methoxy-3-oxa-6-
azabicyclo[3.1.0]hexane (465) (4.3 mg, 6%), and 66 ' 7 -1-carbethoxy-2-
carbomethoxy-5-methoxy-4-oxa-1-azaspiro[2.4]heptane (466) (2.4 mg, 
3%). 
6-carbethoxy-2-(carbomethoxymethylidene)-4-methoxy-3-oxa-6-
azabicyclo[3.1.0]hexane (465) (Found: M-0CH 3 , 226.0715; C10 H12 05N 
requires 226.0716). 1H NMR: & 1.24 (t, 3H, CH 2CH 3 ), 3.47 (d , lH, ~ 
207. 
3. 2 8z, 83), 3.51 (s, 38, 0C83), 3.75 (s, 38, C0 2CH 3, 4 . 17 (m, 2H, 
CH 2CH3), 4.65 (d, lH, J 3.2 Hz, 84), 5 . 35 (s, lH, C8C0 2CH 3), 5.61 (s, 
lH, HS) . MS: m/z 258 (M+l, 14.1%), 227 (11.3), 226 (M-0CH, 98.4), 3 
198 (M-C2H302, 29.6), 182 (11.0), 180 (226-CH3CH 20H, 10.9), 170 (M-
NC02CH2CH3, 4.2) , 154 (52.9), 153 (12.5), 129 (16. 6), 126 (20.2), 110 
(21. 8 ), 84 (33.2). MS: (CI) 275 (M+NH +) 
4 
~
6
•
7
-1-carbethoxy-2-carbomethoxy-5-methoxy-4-oxa-1-
azaspiro[2.4]heptane (466) (Found: M, 257.0899; C11H1506N requires 
257.0899). 18 NMR: o 1.28 (t, 3H, { 7.0 Hz, CH 2CH 3), 3.48 (s, 38, 
0CH 3 ), 3.78 (s, 3H, C0 2CH 3), 4.17 (q, 2H, CH 2CH 3), 5.81 (m, lH, HS), 
6.09 (s, lH, CHC0
2
CH 3), 6.42 (m, lH, 84), 7.38 (m, lH, 83). MS: m/z 
257 (M, 9.2%), 226 (M-0CH3, 15.0), 211 (M-CH3CH 20H, 10.7), 198 (M-
C2H302, 7.9), 180 (226-CH3CH 20H, 17.1), 170 (M-NC0 2CH 2CH3, 2.4), 154 
(54.8), 152 (27.8), 108 (25.6), 98 (37.4), 94 (70.6), 59 (26.8), 42 
(23.9). 
b. The dihydrofuran (443) (30 mg, 0.149 mmol) was dissolved in acid-
free dry dichlo r omethane (1.0 ml) under argon. Triethylamine (66 mg, 
0.653 mmol) was then added, followed by E-
nitrobenzenesulfonoxycarbamate (172 mg, 0.594 mmol) in 
dichloromethane (4 ml) in two portions at 1 h interval. After 
stirring for a further 4 h, the reaction mixture was diluted with 
acid-free ethyl acetate (5.0 ml), washed with saturated sodium 
hydrogen carbonate ( 3 x 3 ml) , brine (3 ml) and dried (Na 2 S0 4 ). The 
solvent was evaporated under reduced pressure to gi ve a crude mi xture 
(81 mg) which consisted of starting material and the E- and Z- dienes 
( 459) and ( 460) . 
c. The dihydrofuran (443) (40 mg, 0.20 mmol) was dissolved in acid-
free dichloromethane (6.6 ml) under argon. Triethylbenzylammonium 
208. 
chloride (6.4 mg, 0.03 mmol) dissolved in aqueous sodium hydrogen 
carbonate (1 M, 6.6 ml) was then added. Benzyl 2-
nitrobenzenesulfonoxycarbamate (0.42 g, 1.2 mmol) was added in four 
equal portions. After the last addition, the reaction mixture was 
allowed to stir overnight. Ethyl acetate (20 ml) was then added and 
the two phases were separated. The organic phase was washed with 
saturated NaHC0 3 (3 x 10 ml), brine (1 x 10 ml) and dried (Na SO). 2 4 
Removal of solvent gave a residue (237 mg) which on TLC showed the 
presence of starting material mainly. The 1H NMR spectrum showed 
starting material and byproducts from decomposition of benzyl 2-
nitrobenzenesulfonoxycarbamate. 
d. 2(5~)-Furanone (440) (12.6 mg, 0.15 mmol) was dissolved in acid-
free dichloromethane (5 ml) under argon. A solution of 
triethylbenzylammonium chloride (48 mg, 0.023 mmol) in aqueous sodium 
hydrogen carbonate (1 M, 5 ml) was then added. Ethyl 2-
nitrobenzenesulfonoxycarbamate (244 mg, 0.84 mmol) was then added in 
four por t ions at 45 min intervals. After the final addition, the 
reaction mixture was stirred for another 1 h before the usual work-
up. The solvent was removed under reduced pressure and the crude 
product was purified by flash chromatography to give starting 
material (8 mg, 64%) and a fraction (8.9 mg) which by 1H NMR was 
shown to be deri ved from the ni trene precursor. 
7-carbethoxy-7-azabicyclo[4.1.0]heptane ( 464) 
a. Cyclohexene (10 mg , 0. 12 mmol) was dissolved in acid-free 
dichloromethane (2.4 ml) under argon. A solution of 
triethylbenzylammonium chloride (3.8 mg, 0.018 mmol) in aqueous 
sodium hydrogen carbonate (1 M, 2.4 ml) was then added. Ethyl 2-
209. 
nitrobenzenesulfonoxycarbamate (195 mg, 0.672 mmol) was then added in 
four portions at 45 min interval. After the final addition, the 
reaction mixture was allowed to stir for another 45 min before the 
usual work-up. Removal of solvent gave a crude mixture (17 mg) which 
matched the TLC of a sample prepared according to a literature 
method. 197 
b. A solution of triethylbenzylammonium chloride (2.8 mg, 0.013 
mmol) in aqueous sodium hydrogen carbonate (1 H, 0.6 ml) was added to 
a solution of cyclohexene (20 mg, 0.244 mmol) and ethyl E-
nitrobenzenesulfonoxycarbamate (30 mg, 0.103 mmol) in dichloromethane 
(0.6 ml). The reaction mixture was stirred at room temperature for 2 
h. Ethyl acetate (10 ml) was then added to the reaction mixture and 
the two phases were separated. The organic phase was washed with 
saturated sodium hydrogen carbonate (3 x 5 ml), brine (5 ml) and 
dried (Na 2S0 4 ). Evaporation of solvent gave a yellow oil (6.4 mg, 
37%) whose 1H NHR spectrum was consistent with the literature 
data. 197 1H NMR: o 1.28 (t, 3H, CH 2CH 3 ), 1.2-1.5 (m, 4H, H3, H4), 
1.7-2.0 (m, 4H, HZ, HS), 2.62 (m, 2H, Hl, 86). 
ethyl azidoformate (467) 
To an ice-cooled solution of sodium azide (7.0 g, 0.108 mol) in 
distilled water (38 ml) was added a solution of ethyl chloroformate 
(10.0 g, 0.09 mol) in ether (10 ml). The mixture was stirred 
vigorously with constant cooling (ice-bath) for 2.5 h. The two 
phases were separated, the aqueous layer was extracted with ether (2 
x 25 ml), and the combined ether solutions was dried thoroughly over 
sodium sulfate. The ether was removed by distillation at atmospheric 
pressure and the residue was then distilled under reduced pressure 
210. 
through a short Vigreux column to give ethyl azidoformate (467) (8.8 
g, 85%), bp 45° C/35 mm (lit. 197 b 40° C/30.5 mm). UV: A (MeOH) 
ffl4X 
208 nm; (cyclohexene) 253 nm. IR: v 2416, 2185 and 2137 (azide), 
ffl4X 
1759 and 1730 (CO) cm- 1 • 1H NMR: o 1.33 (t , 38, J 7.1 Hz, CH
2
C8
3
), 
4.28 (q, 2H, J 7.1 Hz, CH
2
CH
3
) 
attempted photolysis 
a. A mixture of the §-diene (459) (18.0 mg, 0.106 mmol) and ethyl 
azidoformate (467) (36 mg, 0.32 mmol) in a quartz tube, with external 
cooling, was subjected to irradiation with a Hanovia medium pressure 
mercury lamp (250 W) fitted with a quartz window. After 3 h, a check 
of t.l.c. showed some starting material and the Z-isomer (460). The 
reaction was irradiated for 31 h. Evaporation under reduced pressure 
left a residue which by t.l.c. and 1H NMR showed a mixture of E- and 
Z-dienes (459) and (460) (§:~=1:8.5). 
b. A solution of the dihydrofuran (443) (54 mg, 0.267 mmol) and 
ethyl azidoformate (107 mg, 0.936 mmol) in dry THF (1.3 ml) was 
irradiated in a photophysics photochemical reactor for 4 h. Removal 
of solvent under reduced pressure left a residue (111 mg) whose 1H 
NMR and t.l.c. showed starting material and azide byproducts. 
Irradiation for 19 h yielded starting material, a mixture of the 
E- and Z-dienes (459) and (460) and azide byproducts by t.l.c. and 
1 H NMR. 
c. A solution of the dihydrofuran (443) (26 mg, 0.13 mmol) and ethyl 
azidoformate (467) (74 mg, 0.64 mmol) inn-hexane (120 ml) was 
irradiated with a Hanovia medium pressure mercury lamp (100 W) for 
4.5 h. Only starting material was recovered after evaporation of 
solvent. 
211. 
d. A solution of the dihydrofuran (443) (50.5 mg, 0.25 mmol) and 
ethyl azidoformate (467) (29 mg, 0.25 mmol) inn-hexane (2.5 ml) in a 
quartz tube was irradiated with a Hanovia medium pressure mercury 
lamp (100 ~). The course of the reaction was followed by the 
disappearance of the azide absorptions (2185 and 2137 cm- 1 ) in the IR 
spectrum. Two thirds of azide was consumed after 2 h by measuring 
the peak height of the azide absorption. After 4 h, no azide was 
left. Evaporation of solvent under reduced pressure left a residue 
(80 mg) whose t.l.c. and 1H NMR showed starting material and azide 
byproducts. 
e. A solution of the ~-diene (459) (20 mg, 0.118 mmol) and ethyl 
azidoformate (41 mg, 0.353 mmol) in acid-free dichloromethane (11 ml) 
was deoxygenated by bubbling nitrogen through. The degassed solution 
was then irradiated at 253.7 nm in a Clemco photochemical reactor for 
29 h. Removal of solvent left a residue (45 mg), the t.l.c. and 
1
H NMR of which showed a mixture of E- and Z-dienes (459) and (460) 
(~!~=1:10). 
f. A 0.1 M solution of ethyl azidoformate (29 mg 0.25 mmol) in 
cyclohexene (2.03 g, 2.5 ml, 0 . 025 mmol) in a quartz tube fitted wit h 
a reflux condenser was irradiated for 3 h in a Clemco photochemical 
reactor. Evaporation of the excess cyclohexene under reduced 
pressure gave a crude product (42 mg, 100%) whose 1H NMR was 
consistent with that expected for the addition product, 7-carbethoxy-
7-azabicyclo[4.1.0]heptane (464). 197 
212. 
g. A 0 . 1 M solution of ethyl azidoformate (29 mg, 0 . 25 mmol) in 
cyclohexene (2.03 g, 2.5 ml, 0.025 mmol) in a quartz tube was 
irradiated for 3 h with a Hanovia medium pressure mercury lamp (100 
W) with external cooling. Evaporation of excess cyclohexene under 
reduced pressure gave a crude product, 7-carbethoxy-7-
azabicyclo[4.l.0]heptane (464) 197 (34 mg, 80%). 
thermal reaction 
a. A solution of the dihydrofuran (443) (55 mg, 0.27 mmol) and ethyl 
azidoformate (60 mg, 0.52 mmol) in dry benzene (5.0 ml) was heated 
under reflux overnight. Acid-free ethyl acetate (10 ml) was added to 
dilute the reaction mixture and then washed with water (2 x 5 ml) and 
dried (Na 2 S0 4 ). Removal of solvent under reduced pressure left a 
residue (109 mg) whose 1H NMR spectrum and t.l.c. showed starting 
material and azide byproducts. 
Repeating the reaction in neat azidoformate in a sealed tube at 
100° C for 16 h gave only starting material and the E- and Z-dienes 
(459) and (460) in addition to azide byproducts. 
~-aminophthalimide (471) 
96% Hydrazine hydrate (4.4 g, 0 . 088 mol) in 96% ethanol (80 ml) 
was treated with powdered phthalimide (12.0 g, 0.08 mol). The 
mixture was shaken for 2 min at room temperature, and then heated in 
an oil-bath and refluxed for 5 min. Water (50 ml) was then added 
quickly and the whole solution was poured into water (200 ml). N-
Aminophthalimide (471) crystallized out. The crude product was 
recrystallized from ethanol to give colourless needles (3.7 g, 28%) , 
213. 
mp 201°-204° C (lit. 204 mp 200°-202° C). 1 H NHR: o (C0
3
COC0
3
) 4.7 
(bs, 2H, NH 2 ), 7.85 (m, 4H, C6H4 ). HS: m/z 162 (H, 100%), 147 (H-NH, 
0.5), 132 (H-N2H2 , 10 . 5), 104 (H-N H CO, 77.4), 91 (CH, 3.2), 76 2 2 7 7 
(26.4). From the mother liqour, 2,3-dihydro-1,4-phthalazinedione 
(472) (1.20 g, 10%) was also isolated, mp> 300° C (lit. 204 mp> 
300° C). MS: m/z 162 (H, 100%), 163 (H+l, 26.8), 132 (H-N H, 37.2), 
2 2 
105 (41.2), 104 (M-N
2
H
2
CO, 100). 
attempted reactions with nitrene generated from N-aminophthalimide 
a. A mixture of the dihydrofuran (443) (101 mg, 0.5 mmol) and~-
aminophthalimide (471) (16.2 mg, 0.1 mmol) in dichloromethane (0.3 
ml) was stirred at room temperature under argon. Lead tetraacetate 
(53 mg, 0.12 mmol) was then added slowly. The reaction mixture was 
allowed to stir at room temperature for 0.5 hand then filtered. The 
residue was washed with dichloromethane and the combined filtrate and 
washings was evaporated under reduced pressure. The crude product 
was purified by flash column chromatography to give starting material 
(98 mg, 97% recovery). 
b. A mixture of the ~-diene (459) (37 mg, 0.022 mmol) and~-
aminophthalimide (471) (7 mg, 0.04 mmol) in dichloromethane (0.1 ml) 
was stirred at room temperature under argon. Lead tetraacetate (18 
mg, 0.04 mmol) was then added slowly. After stirring for 0 .5 h, the 
reaction mixture was filtered, the residue was washed with 
dichloromethane and the combined filtrate and washings was evaporated 
under reduced pressure to gi ve a crude mixture (50 mg) which by 1 H 
NMR showed mainly starting material. Purification by flash column 
chromatography gave starting material (27 mg, 73 % recovery). 
214. 
c. A mixture of 2(5g)-furanone (440) (130 mg, 1.5 mmol) and N-
aminophthalimide (471) (50 mg, 0.30 mmol) in dichloromethane (1 ml) 
was stirred at room temperature under argon. Lead tetraacetate (179 
mg, 0.40 mmol) was added slowly via a solid addition device. After 
stirring for a further 20 min, the reaction mixture was filtered. 
The residue was washed with dichloromethane and the combined filtrate 
and washings was evaporated under reduced pressure to give a crude 
mixture (180 mg) which by t.l.c. and 1H NMR showed mainly starting 
material. 
In another experiment, the reaction mixture was allowed to stir 
overnight, similar result was obtained. 
Lead tetraacetate was purified by washing with anhydrous acetic 
acid and dry ether im~~diately before the reaction in another 
experiment. Similarly, starting material was obtained. 
7-phthalimido-7-azabicyclo[4,l,0]heptane 
A mixture of ~-aminophthalimide (50 mg, 0.3 mmol) and cyclohexene 
(123 mg, 152 µl, 1.5 mmol) was stirred in dry dichloromethane (1.0 
ml) under argon. Lead tetraacetate (160 mg, 0.36 mmol) was then 
added slowly. After stirring at room temperature for 0.5 h , the 
mixture was filtered. The residue was washed with dichloromethane 
and the combined filtrate and washings was evaporated to give the 
titled compound (52 mg, 72 %) . 1H NMR: o 1.34 (m, 4H), 1.98 (m, 2H), 
2.25 (m , 2H), 2.72 (m, 2H) , 7.71 (m, 4H). MS: m/z 242 (M, 46.4%), 
214 (M-28, 12.3), 201 (36.2), 188 (29.8), 162 (C8 H6N207., 18.7), 148 
(33.5), 132 (C 8H402 , 10.9), 130 (31.3), 105 (45.7), 104 (C7H40, 100), 
96 (C6H10 N, 80.5), 95 (40.6), 81 (26.3). 
215. 
attempted reaction with trimethylsilyl azide 
A solution of the dihydrofuran (443) (50 mg, 0 . 247 mmol) and 
trimethylsilyl azide (81 mg, 93 µl, 0.704 mmol) in benzene (5 ml) was 
heated under reflux overnight. A t.l.c. examination only showed 
starting material. The reaction was allowed to stir for another 48 
h. No appreciable change was observed on the t.l.c. Chloroform (10 
ml) was then added and the solution washed with water (2 X 5 ml) and 
dried (Na 2 S0 4 ). Removal of solvent under reduced pressure gave a 
residue (69 mg) which contained mainly starting material. 
This general procedure was applied to 2(5~)-furanone (440) and 
the E-diene (459). In both cases, starting materials were recovered. 
~-ethoxycarbonyldiphenylsulfilimine (481) 
Diphenylsulfilimine (102 mg, 0.51 mmol) was dissolved in dry THF 
(5 ml) and cooled to 0° C. Triethylamine (62 mg, 85 µl, 0.61 mmol) 
was then added, followed by ethyl chloroformate (66 mg, 58 µl, 0.61 
mmol). After stirring for 2 hat 0° C, water (3 ml) was added and 
the reaction mixture was extracted with ethyl acetate (3 x5 ml). The 
combined ethyl acetate extracts was washed with water (2 x 5 ml), 
brine (5 ml) and dried (Na 2 S0 4 ). Removal of solvent gave a crude 
product (132 mg, 95%) which was recrystallized to gi ve pure~-
ethoxycarbonyldiphenylsulfilimine (481) (115 mg, 85%) mp 87.5°-
88.50 C (ethyl acetate / ~-hexane) [lit. 21 4 mp 88.5°-89° C 
(ethanol / ether)]. IR: v 3065, 2980, 1635 (CO), 1489, 1445, 1365, max 
1260 cm- 1 • 1 H NMR: & 1.29 (t, 3H, { 7.0 Hz, CH 2CH 3 ), 4.18 (q, 2H, { 
7.0 Hz, CH CH), 7.4-7.8 (m, lOH, Ph 2S). MS: m/z 273 (M, 8%), 228 2 3 
216. 
attempted reaction of N-ethoxycarbonyldiphenylsulfilimine (481) with 
the E-diene (459) and 2(5H)-furanone (440) 
The E-diene (459) (17 mg, 0.1 mmol) was dissolved in dry 
dichloromethane (1 ml). ~-Ethoxycarbonyldiphenylsulfilimine (481) 
(29 mg, 0.11 mmol) was then added and the reaction mixture was 
refluxed for 3 h. A t.l.c. examination showed only starting 
material. The reaction mixture was allowed to stir at room 
temperature for 2 days. Evaporation of solvent returned only 
starting material (15mg, 88%). 
The reaction was repeated using benzene as a solvent and refluxed 
for 5 h. Only starting material was recovered after evaporation. 
Similar treatment of 2(5~)-furanone (440) also returned only 
starting material quantitatively. 
attempted reactions with iodine azide 
To a stirred slurry of sodium azide (162 mg, 2.5 mmol) in 
acetonitrile (1 ml) cooled in a methanol-ice bath (-15° C) was added 
iodine monochloride (183 mg, 1.1 mmol). The reaction mixture was 
stirred for 10 min and 2(5~)-furanone (440) (84 mg, 1.0 ml) was then 
added. The reaction mixture was allowed to warm to room temperature 
and stirred for a further 18 h. Vater (4 ml) was then added and the 
mixture was extracted with ether (3 x 5 ml). The combined ether 
extracts was washed with 5% sodium thiosulfate solution, water, brine 
-
and dried (MgS0 4 ). Removal of solvent yielded starting material (30 
mg, 36%). The aqueous layer was then saturated with sodium chloride 
and re- extracted with ethyl acetate (5 x 10 ml). Removal of solvent 
gave more starting material (52mg, 62%). 
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This general procedure was employed in the reaction with the E-
diene (459) and the dihydrofuran (443). The adducts in the former 
case could not be characterized and attempts to convert the crude 
adducts into an aziridine were not successful. No reaction occurred 
with the latter substrate, starting material being recovered. 
trans-1-azido-2-iodocyclohexane (485) 
To a stirred slurry of sodium azide (162 mg, 2.49 mmol) in 
acetonitrile (1.0 ml) cooled in methanol-ice-bath (-15° C) was added 
iodine monochloride (183 mg, 1.13 mmol) and the mixture was stirred 
for 10 min. Cyclohexene (82 mg, 101 µl, 1.0 mmol) was then added. 
The reaction mixture was then stirred a room temperature for 18 h. 
Vater (2.5 ml) was added and the mixtur~ was extracted with ether (3 
x 3 ml). The combined ether extracts was washed with 5% sodium 
thiosulfate solution until colourless. The ethereal solution was 
then washed with water (2 x3 ml), brine (3 ml) and dried (MgS0
4
). 
R 1 f 1 1 'd 2 . d 1 h (485) 218 (235 emova o so vent gave trans- -az1 o- -10 ocyc o exane 
mg, 94%). 1H NMR: & 1.2-1.65 (m, 4H, H3, H4), 1.8-2.52 (m, 4H, H2, 
HS), 3.52 (m, lH, Hl or H6), 3.98 (m, lH, Hl or 86). MS: m/z 251 (M, 
61.0%), 209 (M-N3 , 7.3), 154 (34.0), 127 (28.5), 124 (M-I, 100), 82 
(M-N3-I, 26.5), 81 (M-HN 3-I, 98.7), 80 (16.2), 79 (38.9), 77 (21.0) 
1-butyl hypochlorite 
A solution of sodium hydroxide (8 .0 g, 0.2 mol) in water (50 ml) 
in a three-necked round-bottomed flask was placed in a water-bath at 
15°-20° c. I-Butyl alcohol (7.4 g, 9.6 ml, 0.1 mol) was added 
together with enough water (about 50.0 ml) to form a homogeneous 
solution. Vith constant stirring, chlorine was passed into the 
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mixture for 0.5 h. The two layers were separated. The upper oily 
layer was washed with 10% sodium carbonate solution until the 
washings were no longer acidic to Congo red. It is further washed 
four times with an equal volume of water and dried (CaC1
2
). The 
crude product was distilled to give pure !-butyl hypochlorite (8.1 g, 
75%), bp 74°-77° C /760 mm (lit. 235 77°-78° C/760 mm). 
cis- and trans- methyl 2,5-dimethoxy-3(4)-chloro-4(3)-
hydroxytetrahydro-2-furylacetate (492) 
!-Butyl hypochlorite (59 mg, 0.54 mmol) in acetone (0.1 ml) was 
added to the dihydrofuran (443) (107 mg, 0.53 mmol) in aqueous 
acetone (50% water, 0.5 ml). After stirring for 7 h, a t.l.c. 
examination showed that all starting material was consumed. Acetone 
was removed under reduced pressure, and water was added to the 
residue. It was then extracted with chloroform (3 x 5 ml). The 
combined chloroform extracts was washed with brine (3 ml) and dried 
(Na 2 S0 4 ). Removal of solvent gave a crude mixture (142 mg) which was 
purified on silica gel to give cis- and trans- methyl 2,5-dimethoxy-
3(4)-chloro-4(3)-hydroxytetrahydro-2-furylacetate (492) (26 mg, 19%). 
(Found: C, 42.38; H, 5.59; Cl, 13.51; C9H1506Cl requires C, 42.45; H, 
5.94; Cl, 13.92%). (Found: M-OCH3, 223.0373; C8H12 05Cl requires 
223.0373). IR: v 3560 (OH), 2950 (C-H), 1750 (CO), 1440. ma x 18 NMR: 
o 3.03 (s), 3.14 (m ), 3.35 (s, 3H, OCH 3), 3.38 (s, 38, OCH 3), 3.47 
(s, 3 H, OCH3), 3 . 59 (s, 3 H, OCH 3), 3.72 (s, CH 2C0 2CB3), 3.73 (s, 
CH 2 C0 2 CH3), 4.38 (m), 4.42 (m), 4.96 (m), 5.19 (m). MS: m/z 225 (M-
OCH3, 3.5%), 223 (M-OCH3, 9.9), 207 (225-8 20, 3.3), 205 (223-8 20, 
9.4), 193 (225-CH3 0H, 5.6), 191 (223-CH30H, 14.0), 187 (223-HCl, 
19.0), 181 (M-C3H5 02 , 4.8), 159 (191-CH 3 0H, 93.3), 145 (181-HCl, 
23 . 0), 133 (32.0), 127 (159-CH 30H, 100), 101 (57.7), 95 (26.8). 
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3,4-epoxy-y-lactone (500) 
2(5~)-Furanone (440) (0.89 g, 0.11 mol) was dissolved in ether (8 
ml) and cooled in ice-bath. Freshly prepared sodium hypochlorite (18 
ml of 11% solution, 0.026 mol) was then added dropwise. The mixture 
was stirred at 0° C for 2.5 hand the t.l.c. showed all starting 
material was consumed. Dilute aqueous hydrochloric acid was then 
added to acidify the reaction mixture to pH 2.5. Sodium chloride was 
added to saturate the reaction mixture and the aqueous layer was 
extracted with ethyl acetate (4 x 25 ml) to give a crude product 
(0.68 g) which by 1H NMR was a mixture of 3,4-epoxy-y-lactone (500) 
and the open-chained 2,3-epoxy-4-hydroxybutyric acid. The crude 
mixture was dissolved in dry ether (29 ml) and stirred with Amberlyst 
15 and 4 A molecular sieves overnight. Removal of solvent and 
purification by flash column chromatography on buffer-washed silica 
gel (ca. pH 7.3) gave 3,4-epoxy-y-lactone (500) (0.61 g, 55%). 
(Found: C, 48.15; H, 4.01; C4 H403 requires C, 48.01; H, 4.03%). 
(Found: M, 100.0160; CH 03 requires 100.0160). IR: v (NaCl) 1780 4 4 max 
(CO), 1180 , 1050, 852. 18 NMR: o 3.81 (dd, 18, ~ 2.7 and 0.7 Hz, 
H3), 4.25 (dd, lH, J 1.5 and 2.7 Hz, 84), 4.33 (dd, lH, ~ 1.5 and 
11.5 Hz, HS), 4.47 (dd, lH, ~ 0.7 and 11.5 Hz, HS). 13 C NMR: o 59.41 
(C3), 54.90 (C4), 68.24 (CS), 170.76 (CO). MS: m/z 100 (M, 93.4 %) 
69 (13.9), 55 (70.5), 44 (57.5), 43 (63.5), 42 (45.9). 
2,3-epoxy-4-hydroxybutyric acid 1H NMR: o (CD
3
COCD
3
) 3.34 (dt, lH, ~ 
4.9 and 4.6 Hz, 83), 3.56 (d, lH , J 4.6 Hz , 82), 3.75 (d, 28 , J 4.9 
cis- and trans-3-azido-4-hydroxy-2(38)-dihydrofuranone (503) and 
(502) 
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A solution of the 3,4-epoxy-y-lactone (500) (190 mg, 1.9 mmol), 
trimethylsilyl azide (382 mg, 440 µl, 3.33 mmol), methanol (106 mg, 
135 µl, 3.33 mmol) in ~.~-dimethylformamide (9.5 ml) was stirred · at 
65° Cina constant temperature bath. The course of the reaction was 
followed by GC. Dilute aqueous hydrochloric acid (1 M, 4.7 ml) was 
then added and the reaction mixture was stirred a room temperature 
for 1.5 h. Ethyl acetate (15 ml) was then added and the two phases 
separated. The aqueous layer was extracted with ethyl acetate (2 x 
15 ml). The combined ethyl acetate extracts was dried (Na
2 S0 4 ) and 
evaporated under reduced pressure. ~.~-Dimethylformamide was removed 
on a high vacuum pump and the residue was purified by flash 
chromatography (ethyl acetate/~-hexane/dichloromethane, 4:3:3) to 
give a major component, cis-3-azido-4-hydroxy-2(38)-dihydrofuranone 
(503), (140 mg, 52%) and a minor component, trans-3-azido-4-hydroxy-
2(38)-dihydrofuranone (502),(64 mg, 24%). 
cis-3-Azido-4-hydroxy-2(38)-dihydrofuranone (503) (Found: C, 33.35, 
H, 3.63: C
4H5N303 requires C, 33.57, H, 3.52 %). (Found: M, 
IR: v 3357 (hydrogen-max 
bonded OH), 2115 (N
3
), 1799 (CO), 1602 cm- 1 • 1 H NMR: & 2.82 (d, 18, 
~ 3.0 Hz, OH), 4.10 (dd, lH, ~ 8.7, 6.5 Hz, HS), 4.24 (d, 18, J 6.8 
Hz, 83), 4.45 (m, 18, ~ 6.9, 6.5, 6.8, 3.0 Bz, 84), 4.51 (dd, 18, ~ 
8.8, 6.8 Hz, HS'). 13C NMR: & 63.74 (C4), 70.93 (CS), 71.66 (C3), 
171.90 (CO). MS: m/z 143 (M, 6.8%), 115 (M-N 2 , 1.5), 101 (M-N 3 , 
0.6), 97 (M-N
2
- H
2
0, 0.9), 60 (C 2H402 , 3.9), 57 (C 3H50, 13.5), 44 
(CO
2
, 88.1), 43 (HN3 , 100). 
trans-3-Azido-4-hydroxy-2(3H) -dihydrofuranone (502) (Found: C, 33.31; 
H, 3.35; C
4
H
5
N
3
0
3 
requires C, 33 .57; H, 3.52%). (Found: M, 143.0331; 
CH NO requires 143.0330). 4 5 3 3 IR: v 3357 (hydrogen-bonded OH), max 
2124 (N ), 1791 (CO), 1602 cm- 1 • 3 1H NMR: & 2.66 (t, ~ 1.5, 1.6 Hz, 
OH), 4.28 (d, lH, ~ 4.8 Hz, H3), 4.38 (ddd, lH , J 10.6, 3.0, 1.5 Hz, 
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HS), 4.43 (dd, 18, ~ 10.6, 0.8 Hz, HS'), 4.58 (m, lH, ~ 4.8, 3.0, 
0.8, 1.5 Hz, H4). 13 C NMR: cS 60.44 (C4), 68.71 (CS), 72.39 (CJ), 
171.84 (CO). MS: m/z 143 (M, 2.9%), 125 (M-H O, 0.05), 115 (M-N, 
2 2 
1.1), 101 (M-N3 , 0.2), 85 (C 2H3N30, 4.4), 60 (C 2H402 , 2.6), 57 
(C3H50, 11.9), 44 (CO 2 , 91.8), 43 (HN 3 , 100). 
3-azido-2(5B)-furanone (505) 
To a solution of cis-3-azido-4-hydroxy-2(38)-dihydrofuranone 
(503) (79 mg, 0.55 mmol) in dichloromethane (3.0 ml) at -10° C was 
added triethylamine (83 mg, 115 µl, 0.825 mmol). 
Methanesulfonylchloride (70 mg, 47 µl, 0.608 mmol) was then added 
slowly. The reaction mixture was diluted with dichloromethane, 
washed with ice-cold water, followed by dilute aqueous hydrochloric 
acid (lM), distilled water, saturated sodium hydrogen carbonate 
solution, brine and dried (Na2 S0 4 ). The solvent was removed under 
reduced pressure and the crude product was purified by flash column 
chromatography to give pure 3-azido-2(5H)-furanone (505) (39 mg, 
57%). 
IR: \I 
max 
(CCl) 2118 (N ), 1780 (CO), 1645 (C=C), 1340, 1270 (C-0), 1150, 4 3 
1070, 1050 cm- 1 • 1 H NMR: cS 4.86 (d, 2H, J 2.2 Hz, HS), 6.69 (t, lH, 
J 2.2 Hz, H4). 13C NMR: cS 68.77 (CS), 127.46 (C4), 129.32 (CJ), 
167.98 (CO). MS: m/z 125 (M , 8.5%), 97 (M-N
2
, 0.1), 83 (M-N
3
, 0.1), 
67 (M-C0 2-N, 2.1), 54 (11.1), 53 (M-C0 2-N2 , 100), 52 (42.8), 44 (CO 2 , 
12.1). 
trans-3-Azido-4-hydroxy-2(3H)-dihydrofuranone (502) gave the same 
product, 3-azido-2(58)-furanone (505) under similar reaction 
conditions. 
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3-amino-2(5H)-furanone (504) 
A solution of 3-azido-2(58)-furanone (505) (2.5 mg, 0.02 mmol) 
and 5% palladium on carbon (0.6 mg) was sus pended in dry ethyl 
acetate (1.3 ml) at room temperature under hydrogen atmosphere. The 
reaction was followed by t.l.c., a new component (Rt 0.20, ethyl 
acetate/dichloromethane/~-hexane, 2:4:4) was observed. After 6 h, no 
starting material was left. The catalyst was filtered off and washed 
with ethyl acetate. Removal of solvent under reduced pressure gave 
3-amino-2(58)-furanone (504) (2 mg, 100 %) which was purified by 
preparative t.l.c., mp 86.5°-87° C (lit. 244 87° C). (Found: M, 
\) 
max 
UV: A 256 ( e: 74130) nm . max 
3500 and 3400 (NH) , 1760 (CO), 1675 (C=C) , 1595 (o NH) cm- 1 • 
IR: 
NMR: o 3.74 (bs , 2H, NH 2 ) , 4.74 (d, 2H, ~ 2.2 Hz, HS), 5.94 (t, lH, J 
2. 2 Hz, 84). MS: m/z 99 (M, 66.8%), 85 (5.9), 83 (M-NH
2
, 5 . 9), 71 
(M-C), 58.4) , 55 (M-C0 2 , 19.9), 54 (26.3), 44 (CO 2 , 100). 
APPENDIX 
1. Selected Physical Data of Some Naturally Occurring Hitomycins 
~N 
0 
0 
M,,o 
Me 
0 
MeO 
Me 
0 
0 
~N 
Me 
0 
mitomycin C 
C1sH1sN4Os 
Blue-violet crystals 
mp> 360°C 
LD50 (mice): 5 mg/kg 
mitomycin A 
C1~1¢13O6 
red-violet crystals 
mp 159°-161° C (dee.) 
LD50 (mice): 2 mg/kg 
mitomycin B 
C1~1¢13O6 
violet crystals 
mp 182° -184° C (dee.) 
LD50 (mice): 10 mg/kg 
porfiromycin 
C1JiwN40s 
dark purple crystals 
mp 201 °-201.5° C (dee.) 
LDso= Lethal Dose; LDso - a dose which is lethal to 50% of the animals tested 
___ :~ 
5.0 4.0 3.0 
100 MHz 1H n.m.r. spectrum of mitomycin C in pyridine-d 5 • 
(Lown, J.V. and Begleiter, A., Can. J. Chem. 1974, 52, 2331). 
223. 
2. No tes on Nomenclature 
There are a number of nomenclature systems for naming the 
mitomycin antibiotics. 
mitosane 
mitosane 
0 
224. 
The semi-synthetic name 'mitosane' was proposed 5 • for the 
structure I, common to the mitomycins. The numbering system used in 
this nomenclature is as shown above. 
The trivial names, mitomycins A, B, C, ...... are based on 
allocating a letter to each of the mitomycins in order of 
isolation. 2 4 c The numbering system is the same as in the semi-
synthetic nomenclature. 
In the systematic nomenclature, the mitomycin skeleton I is 
numbered and named differently, as indicated below. 
Me 
0 
8-( aminocarbonyloxymethyl)-1 , l a,2,8,8a,8b-
hexahydro-5-methylazirino(2' ,3 ': 3,4 ]pyrrolo-
[ 1,2-~] indole-4, 7-dione 
The semi-synthetic and trivial names occur commonly in the 
literature whereas the systematic names are only used in Chemical 
Abstracts. Once the generic name 'mitosane' is understood, the semi-
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synthetic names allow for the ready identification of individual 
mitomycins. On the other hand, the trivial names are only clear to 
readers who are familiar with the mitomycin structures. Both the 
trivial names and the semi-synthetic names are used in this thesis. 
All of the naturally occurring mitomycins isolated so far have 
the same chirality at C-1, C-2 and C-9a (lS, 2S, 9aR). The only 
ambigu ity lies in the chirality at C-9. Therefore, only the 
chirality at C-9 (9S or 9R) needs to be specified in describing the 
absolute configuration of a mitomycin. 
Below are some examples of the trivial and semi-systematic naming 
of the mitomycins and their derivatives:-
0 
0 
McO 
Me 
0 
9~-7 ,9a-dimethoxymitosane 
or mitomycin A 
9~-7-hyclroxy-9a-methoxymitosane 
9B.-9a-hyclroxy-7-methoxy- la-methylmitosane 
or mitomycin B 
226. 
mitosene 
10 
mitosene 
0 
II 
'Mitosene' 5 a is the semi-synthetic name given to the formula II 
above. It refers to a mitomycin derivative which has a double bond 
across C-9 and C-9a. A trivial nomenclature system does not exist 
for this class of compounds. Two examples of the semi-synthetic 
naming are given below. 
7-methoxymitosene 
0 
7-methoxy-1,2-~-methylaziridino )mitosene 
0 
227. 
3. Selected 1 H NMR Data for Protons on Aziridines 
0 0 
MO M.o 
Me Me 
0 6 2.85 0 63.25 
! 4.5 Hz 
( 5 )· ( 9 )· 
Ma:> 
Me 
~~Me 
.. A>-0~ 
6 4.0-4.55 
(401) C 
Me 
0 64.16 
J 4.2 Hz 
(107) • 
a. Auerbach, J. and Franck, R.V., J. Chem. Soc., Chem. Commun. 1969, 
991. 
b. Morton, G.0., van Lear, G.E., and Fulmor, V., J. Am. Chem . Soc. 
1970, 92, 2588. 
c. Hirata, T., Yamada, Y., and Matsui, M., Tetrahedron Lett. 1969, 
4107. 
d. Siuta, G.J., Franck, R.V., and Kempton, R.J., J. 0rg. Chem. 1974, 
39, 3739. 
e. Chew, S., Rickards, R.V., and Vagner, A., unpublished results. 
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